Shibing的个人主页 - 老虎社区

Shibing

Shibing

暂无个人介绍

IP属地：未知

147关注

9粉丝

0主题

0勋章

2021-09-13

OK

抱歉，原内容已删除

2021-07-31

Hi

抱歉，原内容已删除

2021-08-27

Ok

抱歉，原内容已删除

2021-09-27

F

Debt ceiling debates in Congress, consumer confidence: What to know this week<blockquote>国会债务上限辩论、消费者信心：本周需要了解什么</blockquote>

2021-09-24

Ok

抱歉，原内容已删除

2021-09-22

Ok

抱歉，原内容已删除

2021-09-16

Ok

3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>

2021-09-07

Ok

Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?<blockquote>策略师表示，今年秋天股市可能会陷入困境。现在买什么？</blockquote>

2021-08-25

Ok

抱歉，原内容已删除

2021-09-11

Hi

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3554626415127931","uuid":"3554626415127931","gmtCreate":1591534679686,"gmtModify":1614133891012,"name":"Shibing","pinyin":"shibing","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":147,"tweetSize":71,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.69%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":601708276,"gmtCreate":1638554457990,"gmtModify":1638554458061,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/601708276","repostId":"1158981658","repostType":4,"isVote":1,"tweetType":1,"viewCount":3818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857424193,"gmtCreate":1635556846115,"gmtModify":1635556846183,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857424193","repostId":"1185142327","repostType":4,"repost":{"id":"1185142327","kind":"news","pubTimestamp":1635554397,"share":"https://www.laohu8.com/m/news/1185142327?lang=zh_CN&edition=full","pubTime":"2021-10-30 08:39","market":"sh","language":"en","title":"Amazon and Apple warn of supply chain issues<blockquote>亚马逊和苹果警告供应链问题</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1185142327","media":"CNN","summary":"(CNN Business)Even Amazon and Apple are grappling with the global supply chain crunch.\nBoth companie","content":"<p>(CNN Business)Even Amazon and Apple are grappling with the global supply chain crunch.</p><p><blockquote>（CNN商业）就连亚马逊和苹果也在努力应对全球供应链紧缩。</blockquote></p><p> Both companies reported revenue results on Thursday that fell short of Wall Street analysts' expectations and warned that supply chain issues could weigh on business in the December quarter.</p><p><blockquote>两家公司周四公布的营收业绩均低于华尔街分析师的预期，并警告称，供应链问题可能会给12月季度的业务带来压力。</blockquote></p><p> Amazon missed Wall Street projections for both sales and profit for the three months ended September 30 — a rare miss for the internet giant. It posted net sales of $110.8 billion, up 15% from the same period a year earlier, but below analyst projections of $111.6 billion. Net income for the quarter decreased from the prior year to $3.2 billion, well short of the $4.6 billion analysts expected.</p><p><blockquote>截至9月30日的三个月，亚马逊的销售额和利润均未达到华尔街的预期，这对于这家互联网巨头来说是罕见的。该公司公布的净销售额为1108亿美元，比去年同期增长15%，但低于分析师预测的1116亿美元。该季度净利润较上年同期下降至32亿美元，远低于分析师预期的46亿美元。</blockquote></p><p> Amazon CEO Andy Jassy warned in a statement that, in the upcoming fourth quarter, the company's consumer business expects to incur several billion dollars of additional costs. Those costs, he said, come \"as we manage through labor supply shortages, increased wage costs, global supply chain issues, and increased freight and shipping costs — all while doing whatever it takes to minimize the impact on customers and selling partners this holiday season.\"</p><p><blockquote>亚马逊首席执行官安迪·贾西在一份声明中警告称，在即将到来的第四季度，该公司的消费者业务预计将产生数十亿美元的额外成本。他说，这些成本是“当我们应对劳动力供应短缺、工资成本增加、全球供应链问题以及运费和运输成本增加时产生的，同时尽一切努力最大限度地减少这个假期对客户和销售合作伙伴的影响。”</blockquote></p><p> Apple posted quarterly sales of $83.4 billion, slightly lower than analysts had anticipated. iPhone sales were lower than analyst forecasts, too, coming in at $38.9 billion.</p><p><blockquote>苹果公布季度销售额为834亿美元，略低于分析师预期。iPhone销售额也低于分析师预期，为389亿美元。</blockquote></p><p> In a conference call with analysts after reporting the results, CEO Tim Cook focused on the fact that Apple managed to post a quarterly sales record despite the supply constraints. \"Demand was very robust,\" he said, but he also noted that \"larger-than-expected supply constraints,\" including silicon shortages and a \"related manufacturing disruption,\" had a $6 billion negative impact on the business.</p><p><blockquote>在公布业绩后与分析师举行的电话会议中，首席执行官蒂姆·库克重点谈到了这样一个事实：尽管供应受到限制，苹果仍设法创下了季度销售记录。“需求非常强劲，”他说，但他也指出，“超出预期的供应限制”，包括硅短缺和“相关的制造中断”，对该业务产生了60亿美元的负面影响。</blockquote></p><p> Amazon's (AMZN) stock fell as much as 5% and Apple (AAPL) shares fell more than 4% in after-hours trading Thursday.</p><p><blockquote>周四盘后交易中，亚马逊(AMZN)股价下跌5%，苹果(AAPL)股价下跌超过4%。</blockquote></p><p> Supply chain disruptions and staffing issues caused by the pandemic have escalated in recent months, hitting a wide range of industries. Several retailers, manufacturers and economists have warned that global supply chain constraints will lead to not only fewer discounts during the holidays this year but also result in a potential dearth of products on store shelves.</p><p><blockquote>近几个月来，疫情造成的供应链中断和人员配备问题不断升级，影响了广泛的行业。多家零售商、制造商和经济学家警告称，全球供应链限制不仅会导致今年假期折扣减少，还可能导致商店货架上的产品短缺。</blockquote></p><p> Apple has built up a sophisticated supply chain over the years for its various hardware products, and Amazon has developed an advanced logistics operation for deliveries. The supply concerns are also dragging into important periods for both companies: for Amazon, the all-important holiday shopping season, and for Apple, the launch of several new products, including its iPhone 13 lineup.</p><p><blockquote>多年来，苹果为其各种硬件产品建立了复杂的供应链，亚马逊也开发了先进的送货物流业务。供应担忧也将两家公司拖入了重要时期：对于亚马逊来说，这是最重要的假日购物季；对于苹果来说，这是几款新产品的推出，包括iPhone 13系列。</blockquote></p><p> Amazon previously warned that the second half of 2021 could bring slower growth compared to last year because more people were returning to in-person shopping versus online ordering as vaccines rolled out. And things don't appear to be looking up just yet. Amazon is now projecting much slower-than-usual growth for the final three months of the year.</p><p><blockquote>亚马逊此前警告称，与去年相比，2021年下半年的增长可能会放缓，因为随着疫苗的推出，越来越多的人回归面对面购物而不是在线订购。事情似乎还没有好转。亚马逊目前预计今年最后三个月的增长将比平时慢得多。</blockquote></p><p> Apple declined to provide revenue guidance for the December quarter, \"given the continued uncertainty around the world in the near term,\" CFO Luca Maestri said during the company's earnings call Thursday. \"We estimate the impact from supply constraints will be larger during the December quarter. Despite this challenge, we are seeing high demand for our products,\" he said.</p><p><blockquote>苹果首席财务官卢卡·马埃斯特里(Luca Maestri)在周四的公司财报看涨期权上表示，“鉴于短期内全球持续存在不确定性”，拒绝提供12月份季度的收入指引。“我们估计，在12月季度，供应限制的影响将会更大。尽管面临这一挑战，但我们看到对我们产品的需求很高，”他说。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon and Apple warn of supply chain issues<blockquote>亚马逊和苹果警告供应链问题</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon and Apple warn of supply chain issues<blockquote>亚马逊和苹果警告供应链问题</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">CNN</strong><span class=\"h-time small\">2021-10-30 08:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(CNN Business)Even Amazon and Apple are grappling with the global supply chain crunch.</p><p><blockquote>（CNN商业）就连亚马逊和苹果也在努力应对全球供应链紧缩。</blockquote></p><p> Both companies reported revenue results on Thursday that fell short of Wall Street analysts' expectations and warned that supply chain issues could weigh on business in the December quarter.</p><p><blockquote>两家公司周四公布的营收业绩均低于华尔街分析师的预期，并警告称，供应链问题可能会给12月季度的业务带来压力。</blockquote></p><p> Amazon missed Wall Street projections for both sales and profit for the three months ended September 30 — a rare miss for the internet giant. It posted net sales of $110.8 billion, up 15% from the same period a year earlier, but below analyst projections of $111.6 billion. Net income for the quarter decreased from the prior year to $3.2 billion, well short of the $4.6 billion analysts expected.</p><p><blockquote>截至9月30日的三个月，亚马逊的销售额和利润均未达到华尔街的预期，这对于这家互联网巨头来说是罕见的。该公司公布的净销售额为1108亿美元，比去年同期增长15%，但低于分析师预测的1116亿美元。该季度净利润较上年同期下降至32亿美元，远低于分析师预期的46亿美元。</blockquote></p><p> Amazon CEO Andy Jassy warned in a statement that, in the upcoming fourth quarter, the company's consumer business expects to incur several billion dollars of additional costs. Those costs, he said, come \"as we manage through labor supply shortages, increased wage costs, global supply chain issues, and increased freight and shipping costs — all while doing whatever it takes to minimize the impact on customers and selling partners this holiday season.\"</p><p><blockquote>亚马逊首席执行官安迪·贾西在一份声明中警告称，在即将到来的第四季度，该公司的消费者业务预计将产生数十亿美元的额外成本。他说，这些成本是“当我们应对劳动力供应短缺、工资成本增加、全球供应链问题以及运费和运输成本增加时产生的，同时尽一切努力最大限度地减少这个假期对客户和销售合作伙伴的影响。”</blockquote></p><p> Apple posted quarterly sales of $83.4 billion, slightly lower than analysts had anticipated. iPhone sales were lower than analyst forecasts, too, coming in at $38.9 billion.</p><p><blockquote>苹果公布季度销售额为834亿美元，略低于分析师预期。iPhone销售额也低于分析师预期，为389亿美元。</blockquote></p><p> In a conference call with analysts after reporting the results, CEO Tim Cook focused on the fact that Apple managed to post a quarterly sales record despite the supply constraints. \"Demand was very robust,\" he said, but he also noted that \"larger-than-expected supply constraints,\" including silicon shortages and a \"related manufacturing disruption,\" had a $6 billion negative impact on the business.</p><p><blockquote>在公布业绩后与分析师举行的电话会议中，首席执行官蒂姆·库克重点谈到了这样一个事实：尽管供应受到限制，苹果仍设法创下了季度销售记录。“需求非常强劲，”他说，但他也指出，“超出预期的供应限制”，包括硅短缺和“相关的制造中断”，对该业务产生了60亿美元的负面影响。</blockquote></p><p> Amazon's (AMZN) stock fell as much as 5% and Apple (AAPL) shares fell more than 4% in after-hours trading Thursday.</p><p><blockquote>周四盘后交易中，亚马逊(AMZN)股价下跌5%，苹果(AAPL)股价下跌超过4%。</blockquote></p><p> Supply chain disruptions and staffing issues caused by the pandemic have escalated in recent months, hitting a wide range of industries. Several retailers, manufacturers and economists have warned that global supply chain constraints will lead to not only fewer discounts during the holidays this year but also result in a potential dearth of products on store shelves.</p><p><blockquote>近几个月来，疫情造成的供应链中断和人员配备问题不断升级，影响了广泛的行业。多家零售商、制造商和经济学家警告称，全球供应链限制不仅会导致今年假期折扣减少，还可能导致商店货架上的产品短缺。</blockquote></p><p> Apple has built up a sophisticated supply chain over the years for its various hardware products, and Amazon has developed an advanced logistics operation for deliveries. The supply concerns are also dragging into important periods for both companies: for Amazon, the all-important holiday shopping season, and for Apple, the launch of several new products, including its iPhone 13 lineup.</p><p><blockquote>多年来，苹果为其各种硬件产品建立了复杂的供应链，亚马逊也开发了先进的送货物流业务。供应担忧也将两家公司拖入了重要时期：对于亚马逊来说，这是最重要的假日购物季；对于苹果来说，这是几款新产品的推出，包括iPhone 13系列。</blockquote></p><p> Amazon previously warned that the second half of 2021 could bring slower growth compared to last year because more people were returning to in-person shopping versus online ordering as vaccines rolled out. And things don't appear to be looking up just yet. Amazon is now projecting much slower-than-usual growth for the final three months of the year.</p><p><blockquote>亚马逊此前警告称，与去年相比，2021年下半年的增长可能会放缓，因为随着疫苗的推出，越来越多的人回归面对面购物而不是在线订购。事情似乎还没有好转。亚马逊目前预计今年最后三个月的增长将比平时慢得多。</blockquote></p><p> Apple declined to provide revenue guidance for the December quarter, \"given the continued uncertainty around the world in the near term,\" CFO Luca Maestri said during the company's earnings call Thursday. \"We estimate the impact from supply constraints will be larger during the December quarter. Despite this challenge, we are seeing high demand for our products,\" he said.</p><p><blockquote>苹果首席财务官卢卡·马埃斯特里(Luca Maestri)在周四的公司财报看涨期权上表示，“鉴于短期内全球持续存在不确定性”，拒绝提供12月份季度的收入指引。“我们估计，在12月季度，供应限制的影响将会更大。尽管面临这一挑战，但我们看到对我们产品的需求很高，”他说。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://edition.cnn.com/2021/10/28/tech/amazon-apple-earnings-supply-chain/index.html\">CNN</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","AMZN":"亚马逊"},"source_url":"https://edition.cnn.com/2021/10/28/tech/amazon-apple-earnings-supply-chain/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185142327","content_text":"(CNN Business)Even Amazon and Apple are grappling with the global supply chain crunch.\nBoth companies reported revenue results on Thursday that fell short of Wall Street analysts' expectations and warned that supply chain issues could weigh on business in the December quarter.\nAmazon missed Wall Street projections for both sales and profit for the three months ended September 30 — a rare miss for the internet giant. It posted net sales of $110.8 billion, up 15% from the same period a year earlier, but below analyst projections of $111.6 billion. Net income for the quarter decreased from the prior year to $3.2 billion, well short of the $4.6 billion analysts expected.\nAmazon CEO Andy Jassy warned in a statement that, in the upcoming fourth quarter, the company's consumer business expects to incur several billion dollars of additional costs. Those costs, he said, come \"as we manage through labor supply shortages, increased wage costs, global supply chain issues, and increased freight and shipping costs — all while doing whatever it takes to minimize the impact on customers and selling partners this holiday season.\"\nApple posted quarterly sales of $83.4 billion, slightly lower than analysts had anticipated. iPhone sales were lower than analyst forecasts, too, coming in at $38.9 billion.\nIn a conference call with analysts after reporting the results, CEO Tim Cook focused on the fact that Apple managed to post a quarterly sales record despite the supply constraints. \"Demand was very robust,\" he said, but he also noted that \"larger-than-expected supply constraints,\" including silicon shortages and a \"related manufacturing disruption,\" had a $6 billion negative impact on the business.\nAmazon's (AMZN) stock fell as much as 5% and Apple (AAPL) shares fell more than 4% in after-hours trading Thursday.\nSupply chain disruptions and staffing issues caused by the pandemic have escalated in recent months, hitting a wide range of industries. Several retailers, manufacturers and economists have warned that global supply chain constraints will lead to not only fewer discounts during the holidays this year but also result in a potential dearth of products on store shelves.\nApple has built up a sophisticated supply chain over the years for its various hardware products, and Amazon has developed an advanced logistics operation for deliveries. The supply concerns are also dragging into important periods for both companies: for Amazon, the all-important holiday shopping season, and for Apple, the launch of several new products, including its iPhone 13 lineup.\nAmazon previously warned that the second half of 2021 could bring slower growth compared to last year because more people were returning to in-person shopping versus online ordering as vaccines rolled out. And things don't appear to be looking up just yet. Amazon is now projecting much slower-than-usual growth for the final three months of the year.\nApple declined to provide revenue guidance for the December quarter, \"given the continued uncertainty around the world in the near term,\" CFO Luca Maestri said during the company's earnings call Thursday. \"We estimate the impact from supply constraints will be larger during the December quarter. Despite this challenge, we are seeing high demand for our products,\" he said.","news_type":1,"symbols_score_info":{"AAPL":0.9,"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":3250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862089975,"gmtCreate":1632817548197,"gmtModify":1632817548385,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862089975","repostId":"2170624172","repostType":4,"isVote":1,"tweetType":1,"viewCount":2539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866995549,"gmtCreate":1632719027981,"gmtModify":1632798313176,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"F","listText":"F","text":"F","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/866995549","repostId":"2170488786","repostType":4,"repost":{"id":"2170488786","kind":"news","pubTimestamp":1632685409,"share":"https://www.laohu8.com/m/news/2170488786?lang=zh_CN&edition=full","pubTime":"2021-09-27 03:43","market":"other","language":"en","title":"Debt ceiling debates in Congress, consumer confidence: What to know this week<blockquote>国会债务上限辩论、消费者信心：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2170488786","media":"Yahoo Finance","summary":"Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race t","content":"<p><div> Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race to pass legislation to avoid a government shutdown by the end of the month and debate raising the ...</p><p><blockquote><div>投资者本周将密切关注华盛顿特区的事态发展，因为议员们竞相通过立法，以避免政府在本月底关闭，并就提高...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页连接</a></blockquote></p><p></p>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Debt ceiling debates in Congress, consumer confidence: What to know this week<blockquote>国会债务上限辩论、消费者信心：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDebt ceiling debates in Congress, consumer confidence: What to know this week<blockquote>国会债务上限辩论、消费者信心：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2021-09-27 03:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race to pass legislation to avoid a government shutdown by the end of the month and debate raising the ...</p><p><blockquote><div>投资者本周将密切关注华盛顿特区的事态发展，因为议员们竞相通过立法，以避免政府在本月底关闭，并就提高...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e7e749e88d2580d292ffc6ae18d03b65","relate_stocks":{"SPY.AU":"SPDR® S&P 500® ETF Trust"},"source_url":"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170488786","content_text":"Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race to pass legislation to avoid a government shutdown by the end of the month and debate raising the debt ceiling. Elsewhere, economic data on consumer confidence is also due for release.\nThe Senate is expected to vote Monday on a procedural motion over the legislation passed by the House of Representatives last week. That bill included a plan to temporarily fund the government through early December, and came alongside a measure to raise the government debt ceiling through December 2022.\nThe latter point has been an area of contention for Senate Republicans, who are only narrowly outnumbered by Democratic lawmakers in both chambers and who have threatened to block the bill in its current form.\nSenate Republicans including Minority Leader Mitch McConnell have suggested that Democratic lawmakers should use the budget reconciliation process to raise the debt ceiling without Republican support. McConnell has, however, supported a short-term government funding bill that excludes a debt ceiling suspension.\n\"If they [the Democrats] want to tax, borrow and spend historic sums of money without our input, they’ll have to raise the debt limit without our help. This is the reality,” McConnell said on the Senate floor last week.\nDemocratic lawmakers, for their part, have called for the move to raise the debt limit be bipartisan to prevent the government from defaulting on its obligations. The Treasury Department has warned that the U.S. could default on its debts as soon as October in absence of congressional action.\n\"The U.S. has always paid its bills on time, but the overwhelming consensus among economists and Treasury officials of both parties is that failing to raise the debt limit would produce widespread economic catastrophe,\" Treasury Secretary Janet Yellen wrote in an op-ed in the Wall Street Journal last week.\nFederal Reserve Chair Jerome Powell also warned of the consequences of a failure to raise the debt ceiling during his post-FOMC meeting press conference last week.\n\"It's just very important that the debt ceiling be raised in a timely fashion so that the United States can pay its bills when and as they come due. That's a critically important thing,\" he said. \"The failure to do that is something that could result in severe reactions, severe damage to the economy and to the financial markets ... no one should assume that the Fed or anyone else can protect the markets or the economy in the event of a failure.\"\nA dead Elm tree is removed on the West Front of the Capitol in Washington, Friday, Sept. 10, 2021. (AP Photo/J. Scott Applewhite)ASSOCIATED PRESS\nAmid the standoff, the Office of Management and Budget began warning federal agencies last week to prepare for a potential government shutdown. The reminder served as a standard warning one week out from Congress's deadline to reach an agreement to at least temporarily continue funding the government.\nThough leaders of both political parties have agreed that a continuing resolution to avoid the shutdown at the end of the month is needed, the ongoing tension over raising the debt limit has served as a potential roadblock in this effort.\n\"We still expect Congress to avert a partial government shutdown at the start of October. Republicans won’t vote for the current continuing resolution being touted by the Democratic leadership, which also includes a new debt ceiling suspension,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note Friday. \"But we expect a Plan B to emerge next week with the latter stripped out, which Republicans will support.\"\n\"The bigger issue is that there doesn’t appear to be an easy path to raising the debt ceiling by mid-October, which is when estimates suggest the Treasury’s will exhaust the 'extraordinary measures it is currently using to keep the lights on,\" he added.\nInvestors have also grown jittery as the debates wore on, with stocks posting their worst day since May last week amid a confluence of concerns that also included debt concerns with China Evergrande.\nMany strategists, however, have suggested market participants need not be overly concerned about the impacts of a potential government shutdown.\n\"Historically, we've seen that government shutdowns tend to be short-lived,\" Jordan Jackson, JPMorgan Asset Management global market strategist, told Yahoo Finance Live on Friday. \"We also know that for those non-essential federal employees, they do get furlough pay as well.\"\n\"If it lasts more than 30 days, it's certainly going to have a bigger impact on the economy. But generally speaking, these shutdowns tend to be short-lived and markets — while they may correct in the short-term — they do sort of continue to grind higher,\" he added. \"I think it's certainly a risk in terms of a short-term mini correction there. But again, with all the liquidity out there, I think any sort of blip in the markets will be short-lived.\"\nHistorical equity performance during and immediately following a government shutdown has also tended to point to a muted market impact.\n\"In the 14 government shutdowns since 1980, the S&P 500 generated median returns of -0.1% on the dates of budget authority expiration, 0.1% during the shutdown periods, and 0.3% on the dates of resolution,\" David Kostin, Goldman Sachs chief equity strategist, wrote in a note published on Sept. 21.\n\"One notable exception was the most recent federal shutdown in December 2018, when the S&P 500 fell 2% on the spending authority expiration date,\" he added. \"However, this decline was likely driven primarily by investor concerns about Fed tightening.\"\nKostin also noted that the typical government shutdown since 1980 has only lasted three days before ultimately being resolved. More recent shutdowns have lasted several times longer, however, with the duration of the four most recent federal shutdowns averaging 18 days, Kostin said.\nConsumer confidence\nOn the economic data front, one of the most closely watched new pieces of data will be on consumer confidence.\nThe Conference Board is set to release its September consumer confidence index Tuesday morning. Economists expect the index to tick up only slightly compared to August, with consumers' views on the coronavirus and rising prices stabilizing near the lowest level since February.\nSpecifically, consensus economists are looking for the index to rise to 115.0 in September after dropping to 113.8 in August. During the last monthly report, consumers' assessments of current business and labor market conditions both eased, and expectations for the next six months out also deteriorated.\n\"Consumer confidence fell to a six-month low in August, due to concerns around the Delta variant and inflation,\" wrote Bank of America economist Michelle Meyer in a note on Friday. \"We think these concerns largely remained in September.\"\nAt the time, Lynn Franco, senior director of economic indicators at the Conference Board, said it was still \"too soon to conclude\" whether decline in consumer confidence would \"result in consumers significantly curtailing their spending in the months ahead.\"\nThe latest spending data has also been equivocal. The Commerce Department's latest report showed retail sales rose 0.7% in August after declining in July. However, the categories posting the biggest declines were areas like e-commerce shops and grocery stores, suggesting consumer behavior was shifting back toward stay-in-place trends and away from in-person events like restaurant dining amid the latest wave of the coronavirus.\nEconomic calendar\n\nMonday: Durable goods orders, August preliminary (0.6% expected, -0.1% in July); Durable goods excluding transportation, August preliminary (0.5% expected, 0.8% in July); Non-defense capital goods orders excluding aircraft, August preliminary (0.3% expected, 0.1% in July); Non-defense capital goods orders excluding aircraft, August preliminary (0.9% in July); Dallas Fed Manufacturing Activity Index, September (11.0 expected, 9.0 in July)\nTuesday: Advance goods trade balance, August (-$87.0 billion expected, -$86.4 billion in July); Wholesale inventories, month-over-month, August preliminary (0.6% in July); Retail inventories, month-over-month, August (0.4% in July); FHFA House Price Index, month-over-month, July (1.5% expected, 1.6% in July); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, July (1.62% expected, 1.77% in June); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, July (20.1% expected, 19.08% in June); Conference Board Consumer Confidence Index, September (114.2 expected, 113.8 in August); Richmond Fed Manufacturing Index, September (9 in August)\nWednesday: MBA Mortgage Applications, week ended September 24 (4.9% during prior month); Pending home sales, month-over-month, August (1.0% expected, -1.8% in July)\nThursday: Initial jobless claims, week ended September 25 (320,000 expected, 351,000 during prior week); Continuing claims, week ended September 18 (2.845 million during prior week); GDP annualized, quarter-over-quarter, second-quarter third estimate (6.7% expected, 6.6% in prior estimate); Personal consumption, second-quarter third estimate (11.9% in prior estimate); Core personal consumption expenditures, second quarter third estimate (6.1% in prior estimate); MNI Chicago PMI, September (65.0 expected, 66.8 in August)\nFriday: Personal income, August (0.2% expected, 1.1% in July); Personal spending, August (0.7% expected, 0.3% in July); Personal consumption expenditures core deflator, month-over-over, August (0.2% expected, 0.3% in July); Personal consumption expenditures core deflator, year-over-year, August (3.6% expected, 3.6% in July); Markit manufacturing PMI, September final (60.5 in prior estimate); Construction spending, month-over-month, August (0.3% expected, 0.3% in July); University of Michigan sentiment, September final (71.0 expected, 71.0 in prior print); ISM Manufacturing, September (59.5 expected, 59.9 in August)\n\nEarnings calendar\n\nMonday: Aurora Cannabis (ACB) after market close\nTuesday: Micron Technology (MU) after market close.\nWednesday: No notable reports scheduled for release\nThursday: CarMax (KMX), Bed Bath & Beyond (BBBY) before market open; Jefferies (JEF) after market close\nFriday: No notable reports scheduled for releas","news_type":1,"symbols_score_info":{"SPY.AU":0.9}},"isVote":1,"tweetType":1,"viewCount":2139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861380860,"gmtCreate":1632457098750,"gmtModify":1632465444190,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/861380860","repostId":"2169240695","repostType":4,"isVote":1,"tweetType":1,"viewCount":2407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":863484850,"gmtCreate":1632412498970,"gmtModify":1632729778079,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/863484850","repostId":"1159478468","repostType":4,"repost":{"id":"1159478468","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632411695,"share":"https://www.laohu8.com/m/news/1159478468?lang=zh_CN&edition=full","pubTime":"2021-09-23 23:41","market":"other","language":"en","title":"EngageSmart opens for trading at $37, up about 43.6% from IPO price<blockquote>EngageSmart开盘价为37美元，较IPO价格上涨约43.6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1159478468","media":"Tiger Newspress","summary":"(Sept 23) EngageSmart Inc. opens for trading at $37, up about 43.6% from IPO price.\n\nCompany\nBraintr","content":"<p>(Sept 23)&nbsp;<a href=\"https://laohu8.com/S/ESMT\">EngageSmart Inc.</a> opens for trading at $37, up about 43.6% from IPO price.</p><p><blockquote>（9月23日）<a href=\"https://laohu8.com/S/ESMT\">EngageSmart公司。</a>开盘价为37美元，较IPO价格上涨约43.6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/835bc9b4ff09e761852f27f75743b887\" tg-width=\"898\" tg-height=\"550\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Company</b></p><p><blockquote><b>公司</b></blockquote></p><p> Braintree, Massachusetts-based EngageSmart was founded to develop a platform that improves customer engagement tailored for certain industry verticals.</p><p><blockquote>总部位于马萨诸塞州布伦特里的EngageSmart成立的目的是开发一个平台，提高针对某些垂直行业的客户参与度。</blockquote></p><p> Management is headed by founder and CEO Robert P. Bennett, who has been with the firm since inception and was previously president of Sage Payment Solutions.</p><p><blockquote>管理层由创始人兼首席执行官Robert P.Bennett领导，他自公司成立以来一直在公司工作，此前曾担任Sage Payment Solutions总裁。</blockquote></p><p> The company's primary offerings include:</p><p><blockquote>该公司的主要产品包括：</blockquote></p><p> <ul>  <li>SimplePractice - Wellness</li>  <li>InvoiceCloud - Government, Utilities and Financial Services</li>  <li>HealthPay24 - Healthcare</li>  <li>DonorDrive - Non-profit and Corporate Fundraising</li> </ul> EngageSmart has received at least $451 million in equity investment from investors including General Atlantic and Summit Partners.</p><p><blockquote><ul><li>简单实践-健康</li><li>InvoiceCloud–政府、公用事业和金融服务</li><li>HealthPay24-医疗保健</li><li>DonorDrive-非营利和企业筹款</li></ul>EngageSmart已从General Atlantic和Summit Partners等投资者那里获得了至少4.51亿美元的股权投资。</blockquote></p><p> <b>Customer Acquisition</b></p><p><blockquote><b>客户获取</b></blockquote></p><p> The firm pursues both large enterprise customers and SMB customers via its direct sales force and online service.</p><p><blockquote>该公司通过其直销队伍和在线服务追求大型企业客户和中小型企业客户。</blockquote></p><p> As of June 30, 2021, the firm had served over 68,000 clients in the SMB market and more than 3,000 customers in its Enterprise Solutions segment.</p><p><blockquote>截至2021年6月30日，该公司已为中小企业市场的68,000多家客户和企业解决方案领域的3,000多家客户提供服务。</blockquote></p><p> Selling and Marketing expenses as a percentage of total revenue have dropped as revenues have increased, as the figures below indicate:</p><p><blockquote>销售和营销费用占总收入的百分比随着收入的增加而下降，如下图所示：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Selling and Marketing</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Expenses vs. Revenue</b></p><p><blockquote><td><b>费用与收入</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Percentage</p><p><blockquote><td>百分比</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>32.4%</p><p><blockquote><td>32.4%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>33.1%</p><p><blockquote><td>33.1%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>43.1%</p><p><blockquote><td>43.1%</td></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> The Selling and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling and Marketing spend, dropped slightly to 1.1x in the most recent reporting period, as shown in the table below:</p><p><blockquote>销售和营销效率率（定义为每美元的销售和营销支出产生多少美元的额外新收入）在最近的报告期略有下降至1.1倍，如下表所示：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Selling and Marketing</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Efficiency Rate</b></p><p><blockquote><td><b>效率率</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Multiple</p><p><blockquote><td>多个的</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>1.1</p><p><blockquote><td>1.1</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>1.3</p><p><blockquote><td>1.3</td></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> The Rule of 40 is a software industry rule of thumb that says that as long as the combined revenue growth rate and EBITDA percentage rate equal or exceed 40%, the firm is on an acceptable growth/EBITDA trajectory.</p><p><blockquote>40法则是软件行业的经验法则，只要收入增长率和EBITDA百分比等于或超过40%，公司就处于可接受的增长/EBITDA轨迹上。</blockquote></p><p> ESMT's most recent calculation was 64% as of June 30, 2021, so the firm is performing well in this regard, per the table below:</p><p><blockquote>截至2021年6月30日，ESMT的最新计算结果为64%，因此该公司在这方面表现良好，如下表所示：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Rule of 40</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>40法则</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Calculation</b></p><p><blockquote><td><b>计算</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Recent Rev. Growth %</p><p><blockquote><tr><td>近期收入增长%</td></tr></blockquote></p><p></td>    <td>59%</p><p><blockquote><td>59%</td></blockquote></p><p></td>   </tr>   <tr>    <td>EBITDA %</p><p><blockquote><tr><td>EBITDA%</td></tr></blockquote></p><p></td>    <td>5%</p><p><blockquote><td>5%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Total</p><p><blockquote><tr><td>总的</td></tr></blockquote></p><p></td>    <td>64%</p><p><blockquote><td>64%</td></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> The firm's dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p><p><blockquote>截至2020年12月31日，该公司以美元计算的净收入保留率为124%，这是一个强劲的业绩。</blockquote></p><p> The dollar-based net revenue retention rate metric measures how much additional revenue is generated over time from each cohort of customers, so that a figure over 100% means that the company is generating more revenue from the same customer cohort over time, indicating good product/market fit and efficient sales and marketing efforts.</p><p><blockquote>基于美元的净收入保留率指标衡量随着时间的推移，每个客户群产生了多少额外收入，因此超过100%的数字意味着公司随着时间的推移从同一客户群产生了更多收入，表明良好的产品/市场契合度以及高效的销售和营销工作。</blockquote></p><p> <b>Market &amp; Competition</b></p><p><blockquote><b>市场与竞争</b></blockquote></p><p> According to a 2021 marketresearch reportby Mordor Intelligence, the global market for customer engagement solutions was an estimated $15.5 billion in 2020 and is forecast to reach $30.9 billion by 2026.</p><p><blockquote>根据Mordor Intelligence的2021年市场研究报告，2020年全球客户参与解决方案市场规模估计为155亿美元，预计到2026年将达到309亿美元。</blockquote></p><p> This represents a forecast CAGR of 12.65% from 2021 to 2026.</p><p><blockquote>这意味着2021年至2026年的预测复合年增长率为12.65%。</blockquote></p><p> The main drivers for this expected growth are a growth in technology solutions to improve the customer journey via any device they use to connect with businesses.</p><p><blockquote>这一预期增长的主要驱动力是技术解决方案的增长，以改善客户通过他们用来与企业联系的任何设备的旅程。</blockquote></p><p> Also, a desire to reduce customer churn rate results in improved business financials and growing valuation.</p><p><blockquote>此外，降低客户流失率的愿望会导致企业财务状况的改善和估值的增长。</blockquote></p><p> Below is a chart showing the variation in customer churn rates in different industries in the U.S. in 2018:</p><p><blockquote>下图显示了2018年美国不同行业客户流失率的变化：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1066adb602d05e4e99630aacf61e1c5\" tg-width=\"1060\" tg-height=\"922\" referrerpolicy=\"no-referrer\">Major competitive or other industry participants include:</p><p><blockquote>主要竞争对手或其他行业参与者包括：</blockquote></p><p> <ul>  <li>IBM(NYSE:IBM)</p><p><blockquote><ul><li>IBM（纽约证券交易所代码：IBM）</li></ul></blockquote></p><p></li>  <li>Microsoft(NASDAQ:MSFT)</p><p><blockquote><li>微软（纳斯达克：MSFT）</li></blockquote></p><p></li>  <li>Nuance(NASDAQ:NUAN)</p><p><blockquote><li>细微差别（纳斯达克：暖）</li></blockquote></p><p></li>  <li>Oracle(NYSE:ORCL)</p><p><blockquote><li>甲骨文（纽约证券交易所代码：ORCL）</li></blockquote></p><p></li>  <li>Salesforce(NYSE:CRM)</p><p><blockquote><li>Salesforce（纽约证券交易所代码：CRM）</li></blockquote></p><p></li>  <li>Avaya(NYSE:AVYA)</p><p><blockquote><li>Avaya（纽约证券交易所代码：AVYA）</li></blockquote></p><p></li>  <li>Calabrio</p><p><blockquote><li>卡拉布里奥</li></blockquote></p><p></li>  <li>Aspect Software</p><p><blockquote><li>Aspect软件</li></blockquote></p><p></li>  <li>Genesys</p><p><blockquote><li>创世纪</li></blockquote></p><p></li>  <li>Verint Systems(NASDAQ:VRNT)</p><p><blockquote><li>Verint Systems（纳斯达克：VRNT）</li></blockquote></p><p></li>  <li>NICE Ltd.(NASDAQ:NICE)</p><p><blockquote><li>尼斯有限公司（纳斯达克：NICE）</li></blockquote></p><p></li>  <li>OpenText</p><p><blockquote><li>OpenText</li></blockquote></p><p></li>  <li>Pegasystems(NASDAQ:PEGA)</p><p><blockquote><li>飞马系统（纳斯达克：PEGA）</li></blockquote></p><p></li>  <li>Others</p><p><blockquote><li>其他</li></blockquote></p><p></p><p></li> </ul> <b>Financial Performance</b></p><p><blockquote><b>财务表现</b></blockquote></p><p> EngageSmart's recent financial results can be summarized as follows:</p><p><blockquote>EngageSmart最近的财务业绩可总结如下：</blockquote></p><p> <ul>  <li>Growing topline revenue</p><p><blockquote><ul><li>营收不断增长</li></ul></blockquote></p><p></li>  <li>Increasing gross profit and high gross margin</p><p><blockquote><li>毛利增加，毛利率高</li></blockquote></p><p></li>  <li>Growing operating profit and net income</p><p><blockquote><li>营业利润和净利润不断增长</li></blockquote></p><p></li>  <li>Increasing cash flow from operations</p><p><blockquote><li>增加经营现金流</li></blockquote></p><p></li> </ul> Below are relevant financial results derived from the firm's registration statement:</p><p><blockquote>以下是来自公司注册声明的相关财务业绩：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Total Revenue</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>收入总额</b></td></tr></tbody></table></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Total Revenue</p><p><blockquote><td>收入总额</td></blockquote></p><p></td>    <td>% Variance vs. Prior</p><p><blockquote><td>与既往相比的%差异</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 99,171,000</p><p><blockquote><td>$99,171,000</td></blockquote></p><p></td>    <td>58.6%</p><p><blockquote><td>58.6%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 146,557,000</p><p><blockquote><td>$146,557,000</td></blockquote></p><p></td>    <td>77.8%</p><p><blockquote><td>77.8%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ 82,432,000</p><p><blockquote><td>$82,432,000</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Gross Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>毛利（亏损）</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Gross Profit (Loss)</p><p><blockquote><td>毛利（亏损）</td></blockquote></p><p></td>    <td>% Variance vs. Prior</p><p><blockquote><td>与既往差异%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 73,673,000</p><p><blockquote><td>$73,673,000</td></blockquote></p><p></td>    <td>61.4%</p><p><blockquote><td>61.4%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 108,964,000</p><p><blockquote><td>$108,964,000</td></blockquote></p><p></td>    <td>89.2%</p><p><blockquote><td>89.2%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ 57,591,000</p><p><blockquote><td>$57,591,000</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Gross Margin</b></p><p><blockquote><tr></tr><tr><td><b>毛利率</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Gross Margin</p><p><blockquote><td>毛利率</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>74.29%</p><p><blockquote><td>74.29%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>74.35%</p><p><blockquote><td>74.35%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>69.86%</p><p><blockquote><td>69.86%</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Operating Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>经营溢利（亏损）</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Operating Profit (Loss)</p><p><blockquote><td>经营溢利（亏损）</td></blockquote></p><p></td>    <td>Operating Margin</p><p><blockquote><td>营业利润率</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 5,001,000</p><p><blockquote><td>$5,001,000</td></blockquote></p><p></td>    <td>5.0%</p><p><blockquote><td>5.0%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 648,000</p><p><blockquote><td>$648,000</td></blockquote></p><p></td>    <td>0.4%</p><p><blockquote><td>0.4%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ (50,398,000)</p><p><blockquote><td>$(50,398,000)</td></blockquote></p><p></td>    <td>-61.1%</p><p><blockquote><td>-61.1%</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Net Income (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>净利润（亏损）</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Net Income (Loss)</p><p><blockquote><td>净利润（亏损）</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 274,000</p><p><blockquote><td>$274,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ (6,678,000)</p><p><blockquote><td>$(6,678,000)</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ (53,598,000)</p><p><blockquote><td>$(53,598,000)</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Cash Flow From Operations</b></p><p><blockquote><tr></tr><tr><td><b>经营所得现金流量</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Cash Flow From Operations</p><p><blockquote><td>经营所得现金流量</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 12,044,000</p><p><blockquote><td>$12,044,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 19,645,000</p><p><blockquote><td>$19,645,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ (1,427,000)</p><p><blockquote><td>$(1,427,000)</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td>(Glossary Of Terms)</p><p><blockquote><tr></tr><tr><td>（术语表）</td></tr></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> As of June 30, 2021, EngageSmart had $31.8 million in cash and $151.8 million in total liabilities.</p><p><blockquote>截至2021年6月30日，EngageSmart拥有现金3180万美元，总负债1.518亿美元。</blockquote></p><p> Free cash flow during the twelve months ended June 30, 2021, was $25.2 million.</p><p><blockquote>截至2021年6月30日的12个月内的自由现金流为2520万美元。</blockquote></p><p> <b>IPO Details</b></p><p><blockquote><b>IPO详情</b></blockquote></p><p> ESMT intends to sell 13 million shares and selling shareholders will offer 1.55 million shares of common stock at a proposed midpoint price of $24.00 per share for gross proceeds of approximately $349 million, not including the sale of customary underwriter options.</p><p><blockquote>ESMT打算出售1300万股股票，出售股东将以每股24.00美元的拟议中中间价发行155万股普通股，总收益约为3.49亿美元，不包括出售惯常承销商期权。</blockquote></p><p> New potential investor Dragoneer Investment Group has indicated an interest to purchase 2.1 million shares of the offering or about $50.4 million at the proposed midpoint price.</p><p><blockquote>新的潜在投资者Dragoneer Investment Group已表示有兴趣购买此次发行的210万股股票，即按拟议中的中点价格购买约5040万美元。</blockquote></p><p> Assuming a successful IPO at the midpoint of the proposed price range, the company's enterprise value at IPO (ex- underwriter options) would approximate $3.7 billion.</p><p><blockquote>假设在拟议价格范围的中点成功IPO，该公司IPO时的企业价值（前承销商期权）将约为37亿美元。</blockquote></p><p> Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 9.04%. A figure under 10% is generally considered a 'low float' stock which can be subject to significant price volatility.</p><p><blockquote>排除承销商期权和私募股份或限制性股票（如有）的影响，流通股与流通股的比率约为9.04%。低于10%的数字通常被认为是“低流通量”股票，可能会受到价格大幅波动的影响。</blockquote></p><p> Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:</p><p><blockquote>根据该公司最新的监管文件，它计划使用净收益如下：</blockquote></p><p>   We expect to use the net proceeds of this offering to repay in full the outstanding borrowings of approximately $114.2 million under our Credit Facilities. We currently intend to use the remaining net proceeds from this offering for general corporate purposes, including to fund our growth, acquire complementary businesses, products, services, or technologies, working capital, operating expenses, and capital expenditures.    Source: SEC  Management's presentation of the company roadshow isavailable here.</p><p><blockquote>我们预计将使用本次发行的净收益全额偿还我们信贷安排下约1.142亿美元的未偿借款。我们目前打算将本次发行的剩余净收益用于一般公司目的，包括为我们的增长提供资金、收购互补业务、产品、服务或技术、营运资金、运营费用和资本支出。资料来源：SEC管理层对公司路演的介绍可在此处获得。</blockquote></p><p> Regarding outstanding legal proceedings, management did not disclose any legal claims against the firm as of the regulatory filing date.</p><p><blockquote>关于未决法律诉讼，截至监管备案日，管理层未披露针对该公司的任何法律索赔。</blockquote></p><p> Listed underwriters of the IPO are JPMorgan, Goldman Sachs, BofA Securities, and other investment banks.</p><p><blockquote>此次IPO的上市承销商包括摩根大通、高盛、美银证券和其他投资银行。</blockquote></p><p> <b>Valuation Metrics</b></p><p><blockquote><b>估值指标</b></blockquote></p><p></p><p> Below is a table of the firm's relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:</p><p><blockquote>下表列出了该公司IPO时的相关资本化和估值指标，不包括承销商期权的影响：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Measure [TTM]</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>测量[TTM]</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Amount</b></p><p><blockquote><td><b>数量</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Market Capitalization at IPO</p><p><blockquote><tr><td>IPO时的市值</td></tr></blockquote></p><p></td>    <td>$3,862,956,720</p><p><blockquote><td>$3,862,956,720</td></blockquote></p><p></td>   </tr>   <tr>    <td>Enterprise Value</p><p><blockquote><tr><td>企业价值</td></tr></blockquote></p><p></td>    <td>$3,656,695,720</p><p><blockquote><td>$3,656,695,720</td></blockquote></p><p></td>   </tr>   <tr>    <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td>    <td>21.09</p><p><blockquote><td>21.09</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td>    <td>19.96</p><p><blockquote><td>19.96</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td>    <td>377.37</p><p><blockquote><td>377.37</td></blockquote></p><p></td>   </tr>   <tr>    <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td>    <td>$0.00</p><p><blockquote><td>$0.00</td></blockquote></p><p></td>   </tr>   <tr>    <td>Float To Outstanding Shares Ratio</p><p><blockquote><tr><td>流通股与流通股比率</td></tr></blockquote></p><p></td>    <td>9.04%</p><p><blockquote><td>9.04%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Proposed IPO Midpoint Price per Share</p><p><blockquote><tr><td>建议IPO每股中点价格</td></tr></blockquote></p><p></td>    <td>$24.00</p><p><blockquote><td>$24.00</td></blockquote></p><p></td>   </tr>   <tr>    <td>Net Free Cash Flow</p><p><blockquote><tr><td>净自由现金流</td></tr></blockquote></p><p></td>    <td>$25,236,000</p><p><blockquote><td>$25,236,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>Free Cash Flow Yield Per Share</p><p><blockquote><tr><td>每股自由现金流收益率</td></tr></blockquote></p><p></td>    <td>0.65%</p><p><blockquote><td>0.65%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td>    <td>58.59%</p><p><blockquote><td>58.59%</td></blockquote></p><p></td>   </tr>   <tr></tr>  </tbody> </table> Source: SEC</p><p><blockquote><tr></tr>资料来源：SEC</blockquote></p><p> As a reference, a potential public comparable would be NICE Ltd.; shown below is a comparison of their primary valuation metrics:</p><p><blockquote>作为参考，潜在的公共可比公司是NICE Ltd.；下图是其主要估值指标的比较：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Metric</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>公制</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Nice Ltd.</b></p><p><blockquote><td><b>尼斯有限公司。</b></td></blockquote></p><p></td>    <td><b>EngageSmart</b></p><p><blockquote><td><b>参与智能</b></td></blockquote></p><p></td>    <td><b>Variance</b></p><p><blockquote><td><b>差异</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td>    <td>11.01</p><p><blockquote><td>11.01</td></blockquote></p><p></td>    <td>21.09</p><p><blockquote><td>21.09</td></blockquote></p><p></td>    <td>91.5%</p><p><blockquote><td>91.5%</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td>    <td>10.67</p><p><blockquote><td>10.67</td></blockquote></p><p></td>    <td>19.96</p><p><blockquote><td>19.96</td></blockquote></p><p></td>    <td>87.1%</p><p><blockquote><td>87.1%</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td>    <td>41.73</p><p><blockquote><td>41.73</td></blockquote></p><p></td>    <td>377.37</p><p><blockquote><td>377.37</td></blockquote></p><p></td>    <td>804.3%</p><p><blockquote><td>804.3%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td>    <td>$3.05</p><p><blockquote><td>$3.05</td></blockquote></p><p></td>    <td>$0.00</p><p><blockquote><td>$0.00</td></blockquote></p><p></td>    <td>-100.0%</p><p><blockquote><td>-100.0%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td>    <td>5.3%</p><p><blockquote><td>5.3%</td></blockquote></p><p></td>    <td>58.59%</p><p><blockquote><td>58.59%</td></blockquote></p><p></td>    <td>1003.34%</p><p><blockquote><td>1003.34%</td></blockquote></p><p></td>   </tr>   <tr></tr>  </tbody> </table> (S-1/A andSeeking Alpha)</p><p><blockquote><tr></tr>（S-1/A和Seeking Alpha）</blockquote></p><p> <b>Commentary</b></p><p><blockquote><b>评论</b></blockquote></p><p> ESMT is seeking public investment to pay down debt and for its general unspecified corporate growth plans.</p><p><blockquote>ESMT正在寻求公共投资来偿还债务及其未具体说明的总体企业增长计划。</blockquote></p><p> The firm's financials show strong topline revenue growth and gross profit growth, operating profit and a swing to slight net profit along with growing cash flow from operations.</p><p><blockquote>该公司的财务数据显示，随着运营现金流的增长，营业利润和小幅净利润增长强劲。</blockquote></p><p> Free cash flow for the twelve months ended June 30, 2021, was a solid $25.2 million.</p><p><blockquote>截至2021年6月30日的12个月的自由现金流为2520万美元。</blockquote></p><p> Selling and Marketing expenses as a percentage of total revenue have dropped as revenue has increased and its Selling and Marketing efficiency rate dropped to 1.1x in the most recent six-month reporting period.</p><p><blockquote>随着收入的增加，销售和营销费用占总收入的百分比有所下降，其销售和营销效率在最近六个月的报告期内降至1.1倍。</blockquote></p><p> The company's Rule of 40 performance was excellent and its dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p><p><blockquote>该公司的40法则表现出色，截至2020年12月31日止年度以美元计算的净收入保留率为124%，这是一个强劲的业绩。</blockquote></p><p> The market opportunity for providing customer engagement software to businesses is large and expected to double in size by the end of 2026, so the company will be helped by strong industry growth dynamics.</p><p><blockquote>为企业提供客户参与软件的市场机会很大，预计到2026年底规模将翻一番，因此该公司将受益于强劲的行业增长动力。</blockquote></p><p> JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 20.4% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p><p><blockquote>摩根大通是主要承销商，该公司在过去12个月内牵头的IPO自IPO以来的平均回报率为20.4%。这是期内所有主要承销商的中等表现。</blockquote></p><p> The primary risk to the company's outlook is the ability for larger firms to bundle some of their services into their existing offerings, resulting in downward pricing pressure and greater competition.</p><p><blockquote>该公司前景的主要风险是大型公司有能力将其部分服务捆绑到现有产品中，从而导致价格下行压力和竞争加剧。</blockquote></p><p> As for valuation, compared to partial competitor NICE, ESMT is growing revenue much faster and so its much higher revenue multiples would appear to be justified.</p><p><blockquote>至于估值，与部分竞争对手NICE相比，ESMT的收入增长速度要快得多，因此其更高的收入倍数似乎是合理的。</blockquote></p><p> Also, the company is growing much faster than competitor Pegasystems, so seems to be taking market share from these and other companies in the customer engagement market.</p><p><blockquote>此外，该公司的增长速度远快于竞争对手Pegasystems，因此似乎正在从这些公司和其他公司手中夺取客户参与市场的市场份额。</blockquote></p><p> Given the firm's strong growth and operating metrics versus its competitors, while the IPO isn't cheap, it is worth consideration.</p><p><blockquote>鉴于该公司相对于竞争对手的强劲增长和运营指标，虽然IPO并不便宜，但值得考虑。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EngageSmart opens for trading at $37, up about 43.6% from IPO price<blockquote>EngageSmart开盘价为37美元，较IPO价格上涨约43.6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEngageSmart opens for trading at $37, up about 43.6% from IPO price<blockquote>EngageSmart开盘价为37美元，较IPO价格上涨约43.6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-23 23:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Sept 23)&nbsp;<a href=\"https://laohu8.com/S/ESMT\">EngageSmart Inc.</a> opens for trading at $37, up about 43.6% from IPO price.</p><p><blockquote>（9月23日）<a href=\"https://laohu8.com/S/ESMT\">EngageSmart公司。</a>开盘价为37美元，较IPO价格上涨约43.6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/835bc9b4ff09e761852f27f75743b887\" tg-width=\"898\" tg-height=\"550\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Company</b></p><p><blockquote><b>公司</b></blockquote></p><p> Braintree, Massachusetts-based EngageSmart was founded to develop a platform that improves customer engagement tailored for certain industry verticals.</p><p><blockquote>总部位于马萨诸塞州布伦特里的EngageSmart成立的目的是开发一个平台，提高针对某些垂直行业的客户参与度。</blockquote></p><p> Management is headed by founder and CEO Robert P. Bennett, who has been with the firm since inception and was previously president of Sage Payment Solutions.</p><p><blockquote>管理层由创始人兼首席执行官Robert P.Bennett领导，他自公司成立以来一直在公司工作，此前曾担任Sage Payment Solutions总裁。</blockquote></p><p> The company's primary offerings include:</p><p><blockquote>该公司的主要产品包括：</blockquote></p><p> <ul>  <li>SimplePractice - Wellness</li>  <li>InvoiceCloud - Government, Utilities and Financial Services</li>  <li>HealthPay24 - Healthcare</li>  <li>DonorDrive - Non-profit and Corporate Fundraising</li> </ul> EngageSmart has received at least $451 million in equity investment from investors including General Atlantic and Summit Partners.</p><p><blockquote><ul><li>简单实践-健康</li><li>InvoiceCloud–政府、公用事业和金融服务</li><li>HealthPay24-医疗保健</li><li>DonorDrive-非营利和企业筹款</li></ul>EngageSmart已从General Atlantic和Summit Partners等投资者那里获得了至少4.51亿美元的股权投资。</blockquote></p><p> <b>Customer Acquisition</b></p><p><blockquote><b>客户获取</b></blockquote></p><p> The firm pursues both large enterprise customers and SMB customers via its direct sales force and online service.</p><p><blockquote>该公司通过其直销队伍和在线服务追求大型企业客户和中小型企业客户。</blockquote></p><p> As of June 30, 2021, the firm had served over 68,000 clients in the SMB market and more than 3,000 customers in its Enterprise Solutions segment.</p><p><blockquote>截至2021年6月30日，该公司已为中小企业市场的68,000多家客户和企业解决方案领域的3,000多家客户提供服务。</blockquote></p><p> Selling and Marketing expenses as a percentage of total revenue have dropped as revenues have increased, as the figures below indicate:</p><p><blockquote>销售和营销费用占总收入的百分比随着收入的增加而下降，如下图所示：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Selling and Marketing</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Expenses vs. Revenue</b></p><p><blockquote><td><b>费用与收入</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Percentage</p><p><blockquote><td>百分比</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>32.4%</p><p><blockquote><td>32.4%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>33.1%</p><p><blockquote><td>33.1%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>43.1%</p><p><blockquote><td>43.1%</td></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> The Selling and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling and Marketing spend, dropped slightly to 1.1x in the most recent reporting period, as shown in the table below:</p><p><blockquote>销售和营销效率率（定义为每美元的销售和营销支出产生多少美元的额外新收入）在最近的报告期略有下降至1.1倍，如下表所示：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Selling and Marketing</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Efficiency Rate</b></p><p><blockquote><td><b>效率率</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Multiple</p><p><blockquote><td>多个的</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>1.1</p><p><blockquote><td>1.1</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>1.3</p><p><blockquote><td>1.3</td></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> The Rule of 40 is a software industry rule of thumb that says that as long as the combined revenue growth rate and EBITDA percentage rate equal or exceed 40%, the firm is on an acceptable growth/EBITDA trajectory.</p><p><blockquote>40法则是软件行业的经验法则，只要收入增长率和EBITDA百分比等于或超过40%，公司就处于可接受的增长/EBITDA轨迹上。</blockquote></p><p> ESMT's most recent calculation was 64% as of June 30, 2021, so the firm is performing well in this regard, per the table below:</p><p><blockquote>截至2021年6月30日，ESMT的最新计算结果为64%，因此该公司在这方面表现良好，如下表所示：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Rule of 40</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>40法则</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Calculation</b></p><p><blockquote><td><b>计算</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Recent Rev. Growth %</p><p><blockquote><tr><td>近期收入增长%</td></tr></blockquote></p><p></td>    <td>59%</p><p><blockquote><td>59%</td></blockquote></p><p></td>   </tr>   <tr>    <td>EBITDA %</p><p><blockquote><tr><td>EBITDA%</td></tr></blockquote></p><p></td>    <td>5%</p><p><blockquote><td>5%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Total</p><p><blockquote><tr><td>总的</td></tr></blockquote></p><p></td>    <td>64%</p><p><blockquote><td>64%</td></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> The firm's dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p><p><blockquote>截至2020年12月31日，该公司以美元计算的净收入保留率为124%，这是一个强劲的业绩。</blockquote></p><p> The dollar-based net revenue retention rate metric measures how much additional revenue is generated over time from each cohort of customers, so that a figure over 100% means that the company is generating more revenue from the same customer cohort over time, indicating good product/market fit and efficient sales and marketing efforts.</p><p><blockquote>基于美元的净收入保留率指标衡量随着时间的推移，每个客户群产生了多少额外收入，因此超过100%的数字意味着公司随着时间的推移从同一客户群产生了更多收入，表明良好的产品/市场契合度以及高效的销售和营销工作。</blockquote></p><p> <b>Market &amp; Competition</b></p><p><blockquote><b>市场与竞争</b></blockquote></p><p> According to a 2021 marketresearch reportby Mordor Intelligence, the global market for customer engagement solutions was an estimated $15.5 billion in 2020 and is forecast to reach $30.9 billion by 2026.</p><p><blockquote>根据Mordor Intelligence的2021年市场研究报告，2020年全球客户参与解决方案市场规模估计为155亿美元，预计到2026年将达到309亿美元。</blockquote></p><p> This represents a forecast CAGR of 12.65% from 2021 to 2026.</p><p><blockquote>这意味着2021年至2026年的预测复合年增长率为12.65%。</blockquote></p><p> The main drivers for this expected growth are a growth in technology solutions to improve the customer journey via any device they use to connect with businesses.</p><p><blockquote>这一预期增长的主要驱动力是技术解决方案的增长，以改善客户通过他们用来与企业联系的任何设备的旅程。</blockquote></p><p> Also, a desire to reduce customer churn rate results in improved business financials and growing valuation.</p><p><blockquote>此外，降低客户流失率的愿望会导致企业财务状况的改善和估值的增长。</blockquote></p><p> Below is a chart showing the variation in customer churn rates in different industries in the U.S. in 2018:</p><p><blockquote>下图显示了2018年美国不同行业客户流失率的变化：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1066adb602d05e4e99630aacf61e1c5\" tg-width=\"1060\" tg-height=\"922\" referrerpolicy=\"no-referrer\">Major competitive or other industry participants include:</p><p><blockquote>主要竞争对手或其他行业参与者包括：</blockquote></p><p> <ul>  <li>IBM(NYSE:IBM)</p><p><blockquote><ul><li>IBM（纽约证券交易所代码：IBM）</li></ul></blockquote></p><p></li>  <li>Microsoft(NASDAQ:MSFT)</p><p><blockquote><li>微软（纳斯达克：MSFT）</li></blockquote></p><p></li>  <li>Nuance(NASDAQ:NUAN)</p><p><blockquote><li>细微差别（纳斯达克：暖）</li></blockquote></p><p></li>  <li>Oracle(NYSE:ORCL)</p><p><blockquote><li>甲骨文（纽约证券交易所代码：ORCL）</li></blockquote></p><p></li>  <li>Salesforce(NYSE:CRM)</p><p><blockquote><li>Salesforce（纽约证券交易所代码：CRM）</li></blockquote></p><p></li>  <li>Avaya(NYSE:AVYA)</p><p><blockquote><li>Avaya（纽约证券交易所代码：AVYA）</li></blockquote></p><p></li>  <li>Calabrio</p><p><blockquote><li>卡拉布里奥</li></blockquote></p><p></li>  <li>Aspect Software</p><p><blockquote><li>Aspect软件</li></blockquote></p><p></li>  <li>Genesys</p><p><blockquote><li>创世纪</li></blockquote></p><p></li>  <li>Verint Systems(NASDAQ:VRNT)</p><p><blockquote><li>Verint Systems（纳斯达克：VRNT）</li></blockquote></p><p></li>  <li>NICE Ltd.(NASDAQ:NICE)</p><p><blockquote><li>尼斯有限公司（纳斯达克：NICE）</li></blockquote></p><p></li>  <li>OpenText</p><p><blockquote><li>OpenText</li></blockquote></p><p></li>  <li>Pegasystems(NASDAQ:PEGA)</p><p><blockquote><li>飞马系统（纳斯达克：PEGA）</li></blockquote></p><p></li>  <li>Others</p><p><blockquote><li>其他</li></blockquote></p><p></p><p></li> </ul> <b>Financial Performance</b></p><p><blockquote><b>财务表现</b></blockquote></p><p> EngageSmart's recent financial results can be summarized as follows:</p><p><blockquote>EngageSmart最近的财务业绩可总结如下：</blockquote></p><p> <ul>  <li>Growing topline revenue</p><p><blockquote><ul><li>营收不断增长</li></ul></blockquote></p><p></li>  <li>Increasing gross profit and high gross margin</p><p><blockquote><li>毛利增加，毛利率高</li></blockquote></p><p></li>  <li>Growing operating profit and net income</p><p><blockquote><li>营业利润和净利润不断增长</li></blockquote></p><p></li>  <li>Increasing cash flow from operations</p><p><blockquote><li>增加经营现金流</li></blockquote></p><p></li> </ul> Below are relevant financial results derived from the firm's registration statement:</p><p><blockquote>以下是来自公司注册声明的相关财务业绩：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Total Revenue</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>收入总额</b></td></tr></tbody></table></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Total Revenue</p><p><blockquote><td>收入总额</td></blockquote></p><p></td>    <td>% Variance vs. Prior</p><p><blockquote><td>与既往相比的%差异</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 99,171,000</p><p><blockquote><td>$99,171,000</td></blockquote></p><p></td>    <td>58.6%</p><p><blockquote><td>58.6%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 146,557,000</p><p><blockquote><td>$146,557,000</td></blockquote></p><p></td>    <td>77.8%</p><p><blockquote><td>77.8%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ 82,432,000</p><p><blockquote><td>$82,432,000</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Gross Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>毛利（亏损）</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Gross Profit (Loss)</p><p><blockquote><td>毛利（亏损）</td></blockquote></p><p></td>    <td>% Variance vs. Prior</p><p><blockquote><td>与既往差异%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 73,673,000</p><p><blockquote><td>$73,673,000</td></blockquote></p><p></td>    <td>61.4%</p><p><blockquote><td>61.4%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 108,964,000</p><p><blockquote><td>$108,964,000</td></blockquote></p><p></td>    <td>89.2%</p><p><blockquote><td>89.2%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ 57,591,000</p><p><blockquote><td>$57,591,000</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Gross Margin</b></p><p><blockquote><tr></tr><tr><td><b>毛利率</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Gross Margin</p><p><blockquote><td>毛利率</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>74.29%</p><p><blockquote><td>74.29%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>74.35%</p><p><blockquote><td>74.35%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>69.86%</p><p><blockquote><td>69.86%</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Operating Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>经营溢利（亏损）</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Operating Profit (Loss)</p><p><blockquote><td>经营溢利（亏损）</td></blockquote></p><p></td>    <td>Operating Margin</p><p><blockquote><td>营业利润率</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 5,001,000</p><p><blockquote><td>$5,001,000</td></blockquote></p><p></td>    <td>5.0%</p><p><blockquote><td>5.0%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 648,000</p><p><blockquote><td>$648,000</td></blockquote></p><p></td>    <td>0.4%</p><p><blockquote><td>0.4%</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ (50,398,000)</p><p><blockquote><td>$(50,398,000)</td></blockquote></p><p></td>    <td>-61.1%</p><p><blockquote><td>-61.1%</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Net Income (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>净利润（亏损）</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Net Income (Loss)</p><p><blockquote><td>净利润（亏损）</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 274,000</p><p><blockquote><td>$274,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ (6,678,000)</p><p><blockquote><td>$(6,678,000)</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ (53,598,000)</p><p><blockquote><td>$(53,598,000)</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td><b>Cash Flow From Operations</b></p><p><blockquote><tr></tr><tr><td><b>经营所得现金流量</b></td></tr></blockquote></p><p></td>   </tr>   <tr>    <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td>    <td>Cash Flow From Operations</p><p><blockquote><td>经营所得现金流量</td></blockquote></p><p></td>   </tr>   <tr>    <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td>    <td>$ 12,044,000</p><p><blockquote><td>$12,044,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td>    <td>$ 19,645,000</p><p><blockquote><td>$19,645,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td>    <td>$ (1,427,000)</p><p><blockquote><td>$(1,427,000)</td></blockquote></p><p></td>   </tr>   <tr></tr>   <tr>    <td>(Glossary Of Terms)</p><p><blockquote><tr></tr><tr><td>（术语表）</td></tr></blockquote></p><p></td>   </tr>  </tbody> </table> Source: SEC</p><p><blockquote>资料来源：SEC</blockquote></p><p> As of June 30, 2021, EngageSmart had $31.8 million in cash and $151.8 million in total liabilities.</p><p><blockquote>截至2021年6月30日，EngageSmart拥有现金3180万美元，总负债1.518亿美元。</blockquote></p><p> Free cash flow during the twelve months ended June 30, 2021, was $25.2 million.</p><p><blockquote>截至2021年6月30日的12个月内的自由现金流为2520万美元。</blockquote></p><p> <b>IPO Details</b></p><p><blockquote><b>IPO详情</b></blockquote></p><p> ESMT intends to sell 13 million shares and selling shareholders will offer 1.55 million shares of common stock at a proposed midpoint price of $24.00 per share for gross proceeds of approximately $349 million, not including the sale of customary underwriter options.</p><p><blockquote>ESMT打算出售1300万股股票，出售股东将以每股24.00美元的拟议中中间价发行155万股普通股，总收益约为3.49亿美元，不包括出售惯常承销商期权。</blockquote></p><p> New potential investor Dragoneer Investment Group has indicated an interest to purchase 2.1 million shares of the offering or about $50.4 million at the proposed midpoint price.</p><p><blockquote>新的潜在投资者Dragoneer Investment Group已表示有兴趣购买此次发行的210万股股票，即按拟议中的中点价格购买约5040万美元。</blockquote></p><p> Assuming a successful IPO at the midpoint of the proposed price range, the company's enterprise value at IPO (ex- underwriter options) would approximate $3.7 billion.</p><p><blockquote>假设在拟议价格范围的中点成功IPO，该公司IPO时的企业价值（前承销商期权）将约为37亿美元。</blockquote></p><p> Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 9.04%. A figure under 10% is generally considered a 'low float' stock which can be subject to significant price volatility.</p><p><blockquote>排除承销商期权和私募股份或限制性股票（如有）的影响，流通股与流通股的比率约为9.04%。低于10%的数字通常被认为是“低流通量”股票，可能会受到价格大幅波动的影响。</blockquote></p><p> Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:</p><p><blockquote>根据该公司最新的监管文件，它计划使用净收益如下：</blockquote></p><p>   We expect to use the net proceeds of this offering to repay in full the outstanding borrowings of approximately $114.2 million under our Credit Facilities. We currently intend to use the remaining net proceeds from this offering for general corporate purposes, including to fund our growth, acquire complementary businesses, products, services, or technologies, working capital, operating expenses, and capital expenditures.    Source: SEC  Management's presentation of the company roadshow isavailable here.</p><p><blockquote>我们预计将使用本次发行的净收益全额偿还我们信贷安排下约1.142亿美元的未偿借款。我们目前打算将本次发行的剩余净收益用于一般公司目的，包括为我们的增长提供资金、收购互补业务、产品、服务或技术、营运资金、运营费用和资本支出。资料来源：SEC管理层对公司路演的介绍可在此处获得。</blockquote></p><p> Regarding outstanding legal proceedings, management did not disclose any legal claims against the firm as of the regulatory filing date.</p><p><blockquote>关于未决法律诉讼，截至监管备案日，管理层未披露针对该公司的任何法律索赔。</blockquote></p><p> Listed underwriters of the IPO are JPMorgan, Goldman Sachs, BofA Securities, and other investment banks.</p><p><blockquote>此次IPO的上市承销商包括摩根大通、高盛、美银证券和其他投资银行。</blockquote></p><p> <b>Valuation Metrics</b></p><p><blockquote><b>估值指标</b></blockquote></p><p></p><p> Below is a table of the firm's relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:</p><p><blockquote>下表列出了该公司IPO时的相关资本化和估值指标，不包括承销商期权的影响：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Measure [TTM]</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>测量[TTM]</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Amount</b></p><p><blockquote><td><b>数量</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Market Capitalization at IPO</p><p><blockquote><tr><td>IPO时的市值</td></tr></blockquote></p><p></td>    <td>$3,862,956,720</p><p><blockquote><td>$3,862,956,720</td></blockquote></p><p></td>   </tr>   <tr>    <td>Enterprise Value</p><p><blockquote><tr><td>企业价值</td></tr></blockquote></p><p></td>    <td>$3,656,695,720</p><p><blockquote><td>$3,656,695,720</td></blockquote></p><p></td>   </tr>   <tr>    <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td>    <td>21.09</p><p><blockquote><td>21.09</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td>    <td>19.96</p><p><blockquote><td>19.96</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td>    <td>377.37</p><p><blockquote><td>377.37</td></blockquote></p><p></td>   </tr>   <tr>    <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td>    <td>$0.00</p><p><blockquote><td>$0.00</td></blockquote></p><p></td>   </tr>   <tr>    <td>Float To Outstanding Shares Ratio</p><p><blockquote><tr><td>流通股与流通股比率</td></tr></blockquote></p><p></td>    <td>9.04%</p><p><blockquote><td>9.04%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Proposed IPO Midpoint Price per Share</p><p><blockquote><tr><td>建议IPO每股中点价格</td></tr></blockquote></p><p></td>    <td>$24.00</p><p><blockquote><td>$24.00</td></blockquote></p><p></td>   </tr>   <tr>    <td>Net Free Cash Flow</p><p><blockquote><tr><td>净自由现金流</td></tr></blockquote></p><p></td>    <td>$25,236,000</p><p><blockquote><td>$25,236,000</td></blockquote></p><p></td>   </tr>   <tr>    <td>Free Cash Flow Yield Per Share</p><p><blockquote><tr><td>每股自由现金流收益率</td></tr></blockquote></p><p></td>    <td>0.65%</p><p><blockquote><td>0.65%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td>    <td>58.59%</p><p><blockquote><td>58.59%</td></blockquote></p><p></td>   </tr>   <tr></tr>  </tbody> </table> Source: SEC</p><p><blockquote><tr></tr>资料来源：SEC</blockquote></p><p> As a reference, a potential public comparable would be NICE Ltd.; shown below is a comparison of their primary valuation metrics:</p><p><blockquote>作为参考，潜在的公共可比公司是NICE Ltd.；下图是其主要估值指标的比较：</blockquote></p><p> <table>  <colgroup></colgroup>  <tbody>   <tr>    <td><b>Metric</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>公制</b></td></tr></tbody></table></blockquote></p><p></td>    <td><b>Nice Ltd.</b></p><p><blockquote><td><b>尼斯有限公司。</b></td></blockquote></p><p></td>    <td><b>EngageSmart</b></p><p><blockquote><td><b>参与智能</b></td></blockquote></p><p></td>    <td><b>Variance</b></p><p><blockquote><td><b>差异</b></td></blockquote></p><p></td>   </tr>   <tr>    <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td>    <td>11.01</p><p><blockquote><td>11.01</td></blockquote></p><p></td>    <td>21.09</p><p><blockquote><td>21.09</td></blockquote></p><p></td>    <td>91.5%</p><p><blockquote><td>91.5%</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td>    <td>10.67</p><p><blockquote><td>10.67</td></blockquote></p><p></td>    <td>19.96</p><p><blockquote><td>19.96</td></blockquote></p><p></td>    <td>87.1%</p><p><blockquote><td>87.1%</td></blockquote></p><p></td>   </tr>   <tr>    <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td>    <td>41.73</p><p><blockquote><td>41.73</td></blockquote></p><p></td>    <td>377.37</p><p><blockquote><td>377.37</td></blockquote></p><p></td>    <td>804.3%</p><p><blockquote><td>804.3%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td>    <td>$3.05</p><p><blockquote><td>$3.05</td></blockquote></p><p></td>    <td>$0.00</p><p><blockquote><td>$0.00</td></blockquote></p><p></td>    <td>-100.0%</p><p><blockquote><td>-100.0%</td></blockquote></p><p></td>   </tr>   <tr>    <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td>    <td>5.3%</p><p><blockquote><td>5.3%</td></blockquote></p><p></td>    <td>58.59%</p><p><blockquote><td>58.59%</td></blockquote></p><p></td>    <td>1003.34%</p><p><blockquote><td>1003.34%</td></blockquote></p><p></td>   </tr>   <tr></tr>  </tbody> </table> (S-1/A andSeeking Alpha)</p><p><blockquote><tr></tr>（S-1/A和Seeking Alpha）</blockquote></p><p> <b>Commentary</b></p><p><blockquote><b>评论</b></blockquote></p><p> ESMT is seeking public investment to pay down debt and for its general unspecified corporate growth plans.</p><p><blockquote>ESMT正在寻求公共投资来偿还债务及其未具体说明的总体企业增长计划。</blockquote></p><p> The firm's financials show strong topline revenue growth and gross profit growth, operating profit and a swing to slight net profit along with growing cash flow from operations.</p><p><blockquote>该公司的财务数据显示，随着运营现金流的增长，营业利润和小幅净利润增长强劲。</blockquote></p><p> Free cash flow for the twelve months ended June 30, 2021, was a solid $25.2 million.</p><p><blockquote>截至2021年6月30日的12个月的自由现金流为2520万美元。</blockquote></p><p> Selling and Marketing expenses as a percentage of total revenue have dropped as revenue has increased and its Selling and Marketing efficiency rate dropped to 1.1x in the most recent six-month reporting period.</p><p><blockquote>随着收入的增加，销售和营销费用占总收入的百分比有所下降，其销售和营销效率在最近六个月的报告期内降至1.1倍。</blockquote></p><p> The company's Rule of 40 performance was excellent and its dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p><p><blockquote>该公司的40法则表现出色，截至2020年12月31日止年度以美元计算的净收入保留率为124%，这是一个强劲的业绩。</blockquote></p><p> The market opportunity for providing customer engagement software to businesses is large and expected to double in size by the end of 2026, so the company will be helped by strong industry growth dynamics.</p><p><blockquote>为企业提供客户参与软件的市场机会很大，预计到2026年底规模将翻一番，因此该公司将受益于强劲的行业增长动力。</blockquote></p><p> JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 20.4% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p><p><blockquote>摩根大通是主要承销商，该公司在过去12个月内牵头的IPO自IPO以来的平均回报率为20.4%。这是期内所有主要承销商的中等表现。</blockquote></p><p> The primary risk to the company's outlook is the ability for larger firms to bundle some of their services into their existing offerings, resulting in downward pricing pressure and greater competition.</p><p><blockquote>该公司前景的主要风险是大型公司有能力将其部分服务捆绑到现有产品中，从而导致价格下行压力和竞争加剧。</blockquote></p><p> As for valuation, compared to partial competitor NICE, ESMT is growing revenue much faster and so its much higher revenue multiples would appear to be justified.</p><p><blockquote>至于估值，与部分竞争对手NICE相比，ESMT的收入增长速度要快得多，因此其更高的收入倍数似乎是合理的。</blockquote></p><p> Also, the company is growing much faster than competitor Pegasystems, so seems to be taking market share from these and other companies in the customer engagement market.</p><p><blockquote>此外，该公司的增长速度远快于竞争对手Pegasystems，因此似乎正在从这些公司和其他公司手中夺取客户参与市场的市场份额。</blockquote></p><p> Given the firm's strong growth and operating metrics versus its competitors, while the IPO isn't cheap, it is worth consideration.</p><p><blockquote>鉴于该公司相对于竞争对手的强劲增长和运营指标，虽然IPO并不便宜，但值得考虑。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ESMT":"EngageSmart Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159478468","content_text":"(Sept 23) EngageSmart Inc. opens for trading at $37, up about 43.6% from IPO price.\n\nCompany\nBraintree, Massachusetts-based EngageSmart was founded to develop a platform that improves customer engagement tailored for certain industry verticals.\nManagement is headed by founder and CEO Robert P. Bennett, who has been with the firm since inception and was previously president of Sage Payment Solutions.\nThe company's primary offerings include:\n\nSimplePractice - Wellness\nInvoiceCloud - Government, Utilities and Financial Services\nHealthPay24 - Healthcare\nDonorDrive - Non-profit and Corporate Fundraising\n\nEngageSmart has received at least $451 million in equity investment from investors including General Atlantic and Summit Partners.\nCustomer Acquisition\nThe firm pursues both large enterprise customers and SMB customers via its direct sales force and online service.\nAs of June 30, 2021, the firm had served over 68,000 clients in the SMB market and more than 3,000 customers in its Enterprise Solutions segment.\nSelling and Marketing expenses as a percentage of total revenue have dropped as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling and Marketing\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n32.4%\n\n\n2020\n33.1%\n\n\n2019\n43.1%\n\n\n\nSource: SEC\nThe Selling and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling and Marketing spend, dropped slightly to 1.1x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling and Marketing\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n1.1\n\n\n2020\n1.3\n\n\n\nSource: SEC\nThe Rule of 40 is a software industry rule of thumb that says that as long as the combined revenue growth rate and EBITDA percentage rate equal or exceed 40%, the firm is on an acceptable growth/EBITDA trajectory.\nESMT's most recent calculation was 64% as of June 30, 2021, so the firm is performing well in this regard, per the table below:\n\n\n\n\nRule of 40\nCalculation\n\n\nRecent Rev. Growth %\n59%\n\n\nEBITDA %\n5%\n\n\nTotal\n64%\n\n\n\nSource: SEC\nThe firm's dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.\nThe dollar-based net revenue retention rate metric measures how much additional revenue is generated over time from each cohort of customers, so that a figure over 100% means that the company is generating more revenue from the same customer cohort over time, indicating good product/market fit and efficient sales and marketing efforts.\nMarket & Competition\nAccording to a 2021 marketresearch reportby Mordor Intelligence, the global market for customer engagement solutions was an estimated $15.5 billion in 2020 and is forecast to reach $30.9 billion by 2026.\nThis represents a forecast CAGR of 12.65% from 2021 to 2026.\nThe main drivers for this expected growth are a growth in technology solutions to improve the customer journey via any device they use to connect with businesses.\nAlso, a desire to reduce customer churn rate results in improved business financials and growing valuation.\nBelow is a chart showing the variation in customer churn rates in different industries in the U.S. in 2018:\nMajor competitive or other industry participants include:\n\nIBM(NYSE:IBM)\nMicrosoft(NASDAQ:MSFT)\nNuance(NASDAQ:NUAN)\nOracle(NYSE:ORCL)\nSalesforce(NYSE:CRM)\nAvaya(NYSE:AVYA)\nCalabrio\nAspect Software\nGenesys\nVerint Systems(NASDAQ:VRNT)\nNICE Ltd.(NASDAQ:NICE)\nOpenText\nPegasystems(NASDAQ:PEGA)\nOthers\n\nFinancial Performance\nEngageSmart's recent financial results can be summarized as follows:\n\nGrowing topline revenue\nIncreasing gross profit and high gross margin\nGrowing operating profit and net income\nIncreasing cash flow from operations\n\nBelow are relevant financial results derived from the firm's registration statement:\n\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 99,171,000\n58.6%\n\n\n2020\n$ 146,557,000\n77.8%\n\n\n2019\n$ 82,432,000\n\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 73,673,000\n61.4%\n\n\n2020\n$ 108,964,000\n89.2%\n\n\n2019\n$ 57,591,000\n\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nSix Mos. Ended June 30, 2021\n74.29%\n\n\n2020\n74.35%\n\n\n2019\n69.86%\n\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nSix Mos. Ended June 30, 2021\n$ 5,001,000\n5.0%\n\n\n2020\n$ 648,000\n0.4%\n\n\n2019\n$ (50,398,000)\n-61.1%\n\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nSix Mos. Ended June 30, 2021\n$ 274,000\n\n\n2020\n$ (6,678,000)\n\n\n2019\n$ (53,598,000)\n\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nSix Mos. Ended June 30, 2021\n$ 12,044,000\n\n\n2020\n$ 19,645,000\n\n\n2019\n$ (1,427,000)\n\n\n\n(Glossary Of Terms)\n\n\n\nSource: SEC\nAs of June 30, 2021, EngageSmart had $31.8 million in cash and $151.8 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was $25.2 million.\nIPO Details\nESMT intends to sell 13 million shares and selling shareholders will offer 1.55 million shares of common stock at a proposed midpoint price of $24.00 per share for gross proceeds of approximately $349 million, not including the sale of customary underwriter options.\nNew potential investor Dragoneer Investment Group has indicated an interest to purchase 2.1 million shares of the offering or about $50.4 million at the proposed midpoint price.\nAssuming a successful IPO at the midpoint of the proposed price range, the company's enterprise value at IPO (ex- underwriter options) would approximate $3.7 billion.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 9.04%. A figure under 10% is generally considered a 'low float' stock which can be subject to significant price volatility.\nPer the firm's most recent regulatory filing, it plans to use the net proceeds as follows:\n\n We expect to use the net proceeds of this offering to repay in full the outstanding borrowings of approximately $114.2 million under our Credit Facilities. We currently intend to use the remaining net proceeds from this offering for general corporate purposes, including to fund our growth, acquire complementary businesses, products, services, or technologies, working capital, operating expenses, and capital expenditures.\n\n\n Source: SEC\n\nManagement's presentation of the company roadshow isavailable here.\nRegarding outstanding legal proceedings, management did not disclose any legal claims against the firm as of the regulatory filing date.\nListed underwriters of the IPO are JPMorgan, Goldman Sachs, BofA Securities, and other investment banks.\nValuation Metrics\nBelow is a table of the firm's relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:\n\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$3,862,956,720\n\n\nEnterprise Value\n$3,656,695,720\n\n\nPrice / Sales\n21.09\n\n\nEV / Revenue\n19.96\n\n\nEV / EBITDA\n377.37\n\n\nEarnings Per Share\n$0.00\n\n\nFloat To Outstanding Shares Ratio\n9.04%\n\n\nProposed IPO Midpoint Price per Share\n$24.00\n\n\nNet Free Cash Flow\n$25,236,000\n\n\nFree Cash Flow Yield Per Share\n0.65%\n\n\nRevenue Growth Rate\n58.59%\n\n\n\n\nSource: SEC\nAs a reference, a potential public comparable would be NICE Ltd.; shown below is a comparison of their primary valuation metrics:\n\n\n\n\nMetric\nNice Ltd.\nEngageSmart\nVariance\n\n\nPrice / Sales\n11.01\n21.09\n91.5%\n\n\nEV / Revenue\n10.67\n19.96\n87.1%\n\n\nEV / EBITDA\n41.73\n377.37\n804.3%\n\n\nEarnings Per Share\n$3.05\n$0.00\n-100.0%\n\n\nRevenue Growth Rate\n5.3%\n58.59%\n1003.34%\n\n\n\n\n(S-1/A andSeeking Alpha)\nCommentary\nESMT is seeking public investment to pay down debt and for its general unspecified corporate growth plans.\nThe firm's financials show strong topline revenue growth and gross profit growth, operating profit and a swing to slight net profit along with growing cash flow from operations.\nFree cash flow for the twelve months ended June 30, 2021, was a solid $25.2 million.\nSelling and Marketing expenses as a percentage of total revenue have dropped as revenue has increased and its Selling and Marketing efficiency rate dropped to 1.1x in the most recent six-month reporting period.\nThe company's Rule of 40 performance was excellent and its dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.\nThe market opportunity for providing customer engagement software to businesses is large and expected to double in size by the end of 2026, so the company will be helped by strong industry growth dynamics.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 20.4% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company's outlook is the ability for larger firms to bundle some of their services into their existing offerings, resulting in downward pricing pressure and greater competition.\nAs for valuation, compared to partial competitor NICE, ESMT is growing revenue much faster and so its much higher revenue multiples would appear to be justified.\nAlso, the company is growing much faster than competitor Pegasystems, so seems to be taking market share from these and other companies in the customer engagement market.\nGiven the firm's strong growth and operating metrics versus its competitors, while the IPO isn't cheap, it is worth consideration.","news_type":1,"symbols_score_info":{"ESMT":0.9}},"isVote":1,"tweetType":1,"viewCount":1453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869578979,"gmtCreate":1632311053491,"gmtModify":1632801348195,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/869578979","repostId":"1146187405","repostType":4,"isVote":1,"tweetType":1,"viewCount":1734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860766891,"gmtCreate":1632215333613,"gmtModify":1632802023673,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860766891","repostId":"1160840483","repostType":4,"repost":{"id":"1160840483","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632214161,"share":"https://www.laohu8.com/m/news/1160840483?lang=zh_CN&edition=full","pubTime":"2021-09-21 16:49","market":"us","language":"en","title":"U.S. Stock Futures Advance, Airline shares, Carnival stocks rally<blockquote>美国股指期货上涨，航空股、嘉年华股上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160840483","media":"Tiger Newspress","summary":"(Update: Sept 20, 2021 at 04:49 a.m. ET)\n(Sept 21) U.S. Stock Futures Advance, Airline shares, Carni","content":"<p><i><b>(Update: Sept 20, 2021 at 04:49 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月20日凌晨04:49）</b></i></blockquote></p><p> (Sept 21)&nbsp;U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.</p><p><blockquote>（九月二十一日）美国。股票期货上涨，航空公司股票，嘉年华股票上涨。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9607d4b938bceb5794ca0672738db43c\" tg-width=\"1230\" tg-height=\"507\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <img src=\"https://static.tigerbbs.com/492800aae703e8bd5f15daf33c8c038e\" tg-width=\"274\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stock Futures Advance, Airline shares, Carnival stocks rally<blockquote>美国股指期货上涨，航空股、嘉年华股上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stock Futures Advance, Airline shares, Carnival stocks rally<blockquote>美国股指期货上涨，航空股、嘉年华股上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-21 16:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><i><b>(Update: Sept 20, 2021 at 04:49 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月20日凌晨04:49）</b></i></blockquote></p><p> (Sept 21)&nbsp;U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.</p><p><blockquote>（九月二十一日）美国。股票期货上涨，航空公司股票，嘉年华股票上涨。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9607d4b938bceb5794ca0672738db43c\" tg-width=\"1230\" tg-height=\"507\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <img src=\"https://static.tigerbbs.com/492800aae703e8bd5f15daf33c8c038e\" tg-width=\"274\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160840483","content_text":"(Update: Sept 20, 2021 at 04:49 a.m. ET)\n(Sept 21) U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":1377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860928763,"gmtCreate":1632125011152,"gmtModify":1632802688040,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860928763","repostId":"1195990706","repostType":2,"repost":{"id":"1195990706","kind":"news","pubTimestamp":1631781148,"share":"https://www.laohu8.com/m/news/1195990706?lang=zh_CN&edition=full","pubTime":"2021-09-16 16:32","market":"us","language":"en","title":"3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195990706","media":"Motley Fool","summary":"Here are three healthcare stocks as nominees for a quick double in 2021.","content":"<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p><p><blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote></p><p> Read more to find out why we think&nbsp;<b>Novavax</b>(NASDAQ:NVAX),&nbsp;<b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and&nbsp;<b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p><p><blockquote>阅读更多内容，了解我们为什么认为<b>Novavax</b>（纳斯达克：NVAX），<b>索伦托治疗公司</b>（纳斯达克：SRNE），以及<b>InMode</b>（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p><p><blockquote><b>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</b></blockquote></p><p> <b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote></p><p> Right now,<b>Moderna</b>&nbsp;enjoys a $169 billion market cap, and&nbsp;<b>BioNTech</b>&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p><p><blockquote>现在，<b>现代</b>市值为1690亿美元，<b>BioNTech</b>估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote></p><p> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p><p><blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote></p><p> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.</p><p><blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote></p><p> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p><p><blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和初始疫苗受到世界上大多数未接种疫苗的人的欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote></p><p> <b>2. Sorrento Therapeutics: Don't sleep on this name</b></p><p><blockquote><b>2.Sorrento Therapeutics：别睡在这个名字上</b></blockquote></p><p> <b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.</p><p><blockquote><b>George Budwell（索伦托治疗公司）：</b>由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote></p><p> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p><p><blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote></p><p> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p><p><blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote></p><p> <b>3. InMode stock will spike as the world reopens</b></p><p><blockquote><b>3.随着世界重新开放，InMode股票将飙升</b></blockquote></p><p></p><p> <b>Patrick Bafuma</b>&nbsp;<b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p><p><blockquote><b>帕特里克·巴富马</b> <b>（在模式中）：</b>随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote></p><p> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p><p><blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote></p><p> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p><p><blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote></p><p> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p><p><blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote></p><p> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p><p><blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote></p><p> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p><p><blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-16 16:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p><p><blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote></p><p> Read more to find out why we think&nbsp;<b>Novavax</b>(NASDAQ:NVAX),&nbsp;<b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and&nbsp;<b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p><p><blockquote>阅读更多内容，了解我们为什么认为<b>Novavax</b>（纳斯达克：NVAX），<b>索伦托治疗公司</b>（纳斯达克：SRNE），以及<b>InMode</b>（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p><p><blockquote><b>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</b></blockquote></p><p> <b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote></p><p> Right now,<b>Moderna</b>&nbsp;enjoys a $169 billion market cap, and&nbsp;<b>BioNTech</b>&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p><p><blockquote>现在，<b>现代</b>市值为1690亿美元，<b>BioNTech</b>估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote></p><p> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p><p><blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote></p><p> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.</p><p><blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote></p><p> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p><p><blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和初始疫苗受到世界上大多数未接种疫苗的人的欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote></p><p> <b>2. Sorrento Therapeutics: Don't sleep on this name</b></p><p><blockquote><b>2.Sorrento Therapeutics：别睡在这个名字上</b></blockquote></p><p> <b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.</p><p><blockquote><b>George Budwell（索伦托治疗公司）：</b>由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote></p><p> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p><p><blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote></p><p> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p><p><blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote></p><p> <b>3. InMode stock will spike as the world reopens</b></p><p><blockquote><b>3.随着世界重新开放，InMode股票将飙升</b></blockquote></p><p></p><p> <b>Patrick Bafuma</b>&nbsp;<b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p><p><blockquote><b>帕特里克·巴富马</b> <b>（在模式中）：</b>随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote></p><p> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p><p><blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote></p><p> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p><p><blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote></p><p> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p><p><blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote></p><p> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p><p><blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote></p><p> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p><p><blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SRNE":"索伦托医疗","NVAX":"诺瓦瓦克斯医药","INMD":"InMode Ltd."},"source_url":"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195990706","content_text":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.\nRead more to find out why we think Novavax(NASDAQ:NVAX), Sorrento Therapeutics(NASDAQ:SRNE), and InMode(NASDAQ:INMD)will close out 2021 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\n1. Multiple catalysts will make Novavax shares jump in 2021\nTaylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.\nRight now,Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.\nThe majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.\nThe U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.\nI'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.\n2. Sorrento Therapeutics: Don't sleep on this name\nGeorge Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.\nThe core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.\nIt is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.\n3. InMode stock will spike as the world reopens\nPatrick Bafuma (InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.\nUsing a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.\nAnd this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.\nAs the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"\nTheodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.\nWith many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.","news_type":1,"symbols_score_info":{"NVAX":0.9,"SRNE":0.9,"INMD":0.9}},"isVote":1,"tweetType":1,"viewCount":3044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885606281,"gmtCreate":1631781412643,"gmtModify":1631890460940,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/885606281","repostId":"1195990706","repostType":4,"repost":{"id":"1195990706","kind":"news","pubTimestamp":1631781148,"share":"https://www.laohu8.com/m/news/1195990706?lang=zh_CN&edition=full","pubTime":"2021-09-16 16:32","market":"us","language":"en","title":"3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195990706","media":"Motley Fool","summary":"Here are three healthcare stocks as nominees for a quick double in 2021.","content":"<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p><p><blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote></p><p> Read more to find out why we think&nbsp;<b>Novavax</b>(NASDAQ:NVAX),&nbsp;<b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and&nbsp;<b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p><p><blockquote>阅读更多内容，了解我们为什么认为<b>Novavax</b>（纳斯达克：NVAX），<b>索伦托治疗公司</b>（纳斯达克：SRNE），以及<b>InMode</b>（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p><p><blockquote><b>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</b></blockquote></p><p> <b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote></p><p> Right now,<b>Moderna</b>&nbsp;enjoys a $169 billion market cap, and&nbsp;<b>BioNTech</b>&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p><p><blockquote>现在，<b>现代</b>市值为1690亿美元，<b>BioNTech</b>估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote></p><p> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p><p><blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote></p><p> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.</p><p><blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote></p><p> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p><p><blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和初始疫苗受到世界上大多数未接种疫苗的人的欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote></p><p> <b>2. Sorrento Therapeutics: Don't sleep on this name</b></p><p><blockquote><b>2.Sorrento Therapeutics：别睡在这个名字上</b></blockquote></p><p> <b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.</p><p><blockquote><b>George Budwell（索伦托治疗公司）：</b>由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote></p><p> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p><p><blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote></p><p> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p><p><blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote></p><p> <b>3. InMode stock will spike as the world reopens</b></p><p><blockquote><b>3.随着世界重新开放，InMode股票将飙升</b></blockquote></p><p></p><p> <b>Patrick Bafuma</b>&nbsp;<b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p><p><blockquote><b>帕特里克·巴富马</b> <b>（在模式中）：</b>随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote></p><p> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p><p><blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote></p><p> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p><p><blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote></p><p> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p><p><blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote></p><p> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p><p><blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote></p><p> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p><p><blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-16 16:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p><p><blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote></p><p> Read more to find out why we think&nbsp;<b>Novavax</b>(NASDAQ:NVAX),&nbsp;<b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and&nbsp;<b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p><p><blockquote>阅读更多内容，了解我们为什么认为<b>Novavax</b>（纳斯达克：NVAX），<b>索伦托治疗公司</b>（纳斯达克：SRNE），以及<b>InMode</b>（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p><p><blockquote><b>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</b></blockquote></p><p> <b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote></p><p> Right now,<b>Moderna</b>&nbsp;enjoys a $169 billion market cap, and&nbsp;<b>BioNTech</b>&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p><p><blockquote>现在，<b>现代</b>市值为1690亿美元，<b>BioNTech</b>估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote></p><p> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p><p><blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote></p><p> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.</p><p><blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote></p><p> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p><p><blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和初始疫苗受到世界上大多数未接种疫苗的人的欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote></p><p> <b>2. Sorrento Therapeutics: Don't sleep on this name</b></p><p><blockquote><b>2.Sorrento Therapeutics：别睡在这个名字上</b></blockquote></p><p> <b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.</p><p><blockquote><b>George Budwell（索伦托治疗公司）：</b>由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote></p><p> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p><p><blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote></p><p> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p><p><blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote></p><p> <b>3. InMode stock will spike as the world reopens</b></p><p><blockquote><b>3.随着世界重新开放，InMode股票将飙升</b></blockquote></p><p></p><p> <b>Patrick Bafuma</b>&nbsp;<b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p><p><blockquote><b>帕特里克·巴富马</b> <b>（在模式中）：</b>随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote></p><p> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p><p><blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote></p><p> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p><p><blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote></p><p> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p><p><blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote></p><p> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p><p><blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote></p><p> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p><p><blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SRNE":"索伦托医疗","NVAX":"诺瓦瓦克斯医药","INMD":"InMode Ltd."},"source_url":"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195990706","content_text":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.\nRead more to find out why we think Novavax(NASDAQ:NVAX), Sorrento Therapeutics(NASDAQ:SRNE), and InMode(NASDAQ:INMD)will close out 2021 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\n1. Multiple catalysts will make Novavax shares jump in 2021\nTaylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.\nRight now,Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.\nThe majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.\nThe U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.\nI'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.\n2. Sorrento Therapeutics: Don't sleep on this name\nGeorge Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.\nThe core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.\nIt is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.\n3. InMode stock will spike as the world reopens\nPatrick Bafuma (InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.\nUsing a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.\nAnd this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.\nAs the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"\nTheodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.\nWith many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.","news_type":1,"symbols_score_info":{"NVAX":0.9,"SRNE":0.9,"INMD":0.9}},"isVote":1,"tweetType":1,"viewCount":1540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885606881,"gmtCreate":1631781367343,"gmtModify":1631890460953,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885606881","repostId":"1178217262","repostType":4,"repost":{"id":"1178217262","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631780500,"share":"https://www.laohu8.com/m/news/1178217262?lang=zh_CN&edition=full","pubTime":"2021-09-16 16:21","market":"us","language":"en","title":"EV Stocks slipped in premarket trading<blockquote>电动汽车股在盘前交易中下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178217262","media":"Tiger Newspress","summary":"EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto fell between 0.5% and 2.8%","content":"<p>EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;fell&nbsp;between 0.5% and 2.8%&nbsp;while&nbsp;Lucid&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;as&nbsp;BofA called Lucid&nbsp;the 'Tesla/Ferrari of New EV Automakers'.</p><p><blockquote>电动汽车股在盘前交易中下跌。特斯拉、蔚来、小鹏汽车和理想汽车下跌0.5%至2.8%，而Lucid上涨近2%，美国银行称Lucid为“新电动汽车制造商中的特斯拉/法拉利”。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/294b5ec452d391346819925d05588591\" tg-width=\"405\" tg-height=\"301\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cathie Wood’s exchange-traded funds sold more Tesla Inc. shares, taking the total value of the electric vehicle maker’s stock they’ve offloaded this month to about $266 million.</p><p><blockquote>Cathie Wood的交易所交易基金出售了更多特斯拉公司股票，使他们本月抛售的这家电动汽车制造商股票总价值达到约2.66亿美元。</blockquote></p><p> XPeng&nbsp;launched its third production model, the P5 sedan. A lidar-equipped EV that starts at less than 160,00 Chinese renminbi, or less than $25,000.There are lower-priced EVs on the market, but not with lidar-enabled, advanced driver assistance systems and not with range of the P5.The stock isn’t reacting too positively to the announcement.</p><p><blockquote>小鹏汽车推出了第三款量产车型P5轿车。一款配备激光雷达的电动汽车起价不到16万人民币，即不到25,000美元。市场上有价格较低的电动汽车，但没有配备激光雷达、先进的驾驶员辅助系统，也没有P5的续航里程。该股对这一消息的反应并不太积极。</blockquote></p><p> Bank of America predicts 50% gain in Lucid, compares EV maker to Tesla and Ferrari.</p><p><blockquote>美银预测Lucid将上涨50%，并将电动汽车制造商与特斯拉和Ferrari进行比较。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks slipped in premarket trading<blockquote>电动汽车股在盘前交易中下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks slipped in premarket trading<blockquote>电动汽车股在盘前交易中下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-16 16:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;fell&nbsp;between 0.5% and 2.8%&nbsp;while&nbsp;Lucid&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;as&nbsp;BofA called Lucid&nbsp;the 'Tesla/Ferrari of New EV Automakers'.</p><p><blockquote>电动汽车股在盘前交易中下跌。特斯拉、蔚来、小鹏汽车和理想汽车下跌0.5%至2.8%，而Lucid上涨近2%，美国银行称Lucid为“新电动汽车制造商中的特斯拉/法拉利”。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/294b5ec452d391346819925d05588591\" tg-width=\"405\" tg-height=\"301\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Cathie Wood’s exchange-traded funds sold more Tesla Inc. shares, taking the total value of the electric vehicle maker’s stock they’ve offloaded this month to about $266 million.</p><p><blockquote>Cathie Wood的交易所交易基金出售了更多特斯拉公司股票，使他们本月抛售的这家电动汽车制造商股票总价值达到约2.66亿美元。</blockquote></p><p> XPeng&nbsp;launched its third production model, the P5 sedan. A lidar-equipped EV that starts at less than 160,00 Chinese renminbi, or less than $25,000.There are lower-priced EVs on the market, but not with lidar-enabled, advanced driver assistance systems and not with range of the P5.The stock isn’t reacting too positively to the announcement.</p><p><blockquote>小鹏汽车推出了第三款量产车型P5轿车。一款配备激光雷达的电动汽车起价不到16万人民币，即不到25,000美元。市场上有价格较低的电动汽车，但没有配备激光雷达、先进的驾驶员辅助系统，也没有P5的续航里程。该股对这一消息的反应并不太积极。</blockquote></p><p> Bank of America predicts 50% gain in Lucid, compares EV maker to Tesla and Ferrari.</p><p><blockquote>美银预测Lucid将上涨50%，并将电动汽车制造商与特斯拉和Ferrari进行比较。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","LCID":"Lucid Group Inc","LI":"理想汽车","NIO":"蔚来","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178217262","content_text":"EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto fell between 0.5% and 2.8% while Lucid rose nearly 2% as BofA called Lucid the 'Tesla/Ferrari of New EV Automakers'.\n\nCathie Wood’s exchange-traded funds sold more Tesla Inc. shares, taking the total value of the electric vehicle maker’s stock they’ve offloaded this month to about $266 million.\nXPeng launched its third production model, the P5 sedan. A lidar-equipped EV that starts at less than 160,00 Chinese renminbi, or less than $25,000.There are lower-priced EVs on the market, but not with lidar-enabled, advanced driver assistance systems and not with range of the P5.The stock isn’t reacting too positively to the announcement.\nBank of America predicts 50% gain in Lucid, compares EV maker to Tesla and Ferrari.","news_type":1,"symbols_score_info":{"LCID":0.9,"XPEV":0.9,"TSLA":0.9,"NIO":0.9,"LI":0.9}},"isVote":1,"tweetType":1,"viewCount":527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885003623,"gmtCreate":1631736185462,"gmtModify":1631890460968,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885003623","repostId":"1148341685","repostType":4,"repost":{"id":"1148341685","kind":"news","pubTimestamp":1631660884,"share":"https://www.laohu8.com/m/news/1148341685?lang=zh_CN&edition=full","pubTime":"2021-09-15 07:08","market":"us","language":"en","title":"U.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148341685","media":"Reuters","summary":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing","content":"<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.</p><p><blockquote>路透纽约-华尔街周二下跌，原因是经济不确定性和企业税率上调的可能性越来越大，抑制了投资者情绪，并引发了广泛的抛售，尽管通胀有缓解的迹象。</blockquote></p><p> Optimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.</p><p><blockquote>整个交易日乐观情绪消退，扭转了劳工部消费者价格指数报告发布后最初的涨势。美国三大股指均收于负值，提醒人们9月份对于股市来说是历史上艰难的一个月。</blockquote></p><p> So far this month the S&amp;P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.</p><p><blockquote>本月迄今为止，标普500已下跌近1.8%，尽管基准指数自年初以来已上涨超过18%。</blockquote></p><p> “There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”</p><p><blockquote>纽约CFRA Research首席投资策略师Sam Stovall表示：“市场有可能只是准备好经历一次迟来的调整。”“从季节性来看，9月往往是基金经理的粉饰期。”</blockquote></p><p> The advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.</p><p><blockquote>高度传染性的Delta COVID变种的出现导致人们对从全球健康危机中复苏的看跌情绪增加，许多人现在预计股市将在今年年底前大幅调整。</blockquote></p><p> “We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”</p><p><blockquote>芝加哥Kingsview Asset Management投资组合经理保罗·诺尔特(Paul Nolte)表示：“我们仍处于人们几个月来一直呼吁的纠正模式。”“经济数据点一直低于预期，而这与德尔塔变异毒株的上升同时发生。”</blockquote></p><p> The CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.</p><p><blockquote>CPI报告公布的8月份读数低于市场普遍预期，这一减速支持了美联储主席杰罗姆·鲍威尔的说法，即通胀飙升是暂时的，并平息了市场对美联储将比预期更早开始收紧货币政策的担忧。</blockquote></p><p> U.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]</p><p><blockquote>美国国债收益率因数据而下跌，这给金融股带来压力，投资者的青睐转向增长，而牺牲了价值。[美国/]</blockquote></p><p> The long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.</p><p><blockquote>随着美国总统乔·拜登（Joe Biden）的3.5万亿美元预算计划逐渐接近通过，人们期待已久的公司税上调（如果民主党获胜，将从21%上调至26.5%）即将实现。</blockquote></p><p> The Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&amp;P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.</p><p><blockquote>道琼工业指数跌292.06点，或0.84%，报34577.57点；标普500跌25.68点，跌幅0.57%，报4,443.05点；纳斯达克综合指数下跌67.82点，跌幅0.45%，至15037.76点。</blockquote></p><p> All 11 major sectors in the S&amp;P 500 ended the session red, with energy and financials suffering the largest percentage drops.</p><p><blockquote>标普500 11大板块全部收红，能源和金融板块跌幅最大。</blockquote></p><p> Apple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&amp;P 500 and the Nasdaq.</p><p><blockquote>苹果公司在今年最大的产品发布会上推出了iPhone 13，并为其iPad和苹果手表设备添加了新功能，因为该公司面临着法院对其商业行为的更严格审查。其股价收盘下跌1.0%，对标普500和纳斯达克拖累最大。</blockquote></p><p> Intuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.</p><p><blockquote>TurboTax制造商Intuit Inc宣布将以120亿美元收购数字营销公司Mailchimp后，该公司股价上涨1.9%。</blockquote></p><p> CureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.</p><p><blockquote>德国生物技术公司CureVac取消其实验性COVID-19疫苗的生产交易后，股价下跌8.0%。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌股与上涨股的比例为2.25比1；在纳斯达克，2.40比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.</p><p><blockquote>标普500创下两个52周新高和两个新低；纳斯达克综合指数录得50个新高和107个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为100.7亿股，而过去20个交易日的平均成交量为93.8亿股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-09-15 07:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.</p><p><blockquote>路透纽约-华尔街周二下跌，原因是经济不确定性和企业税率上调的可能性越来越大，抑制了投资者情绪，并引发了广泛的抛售，尽管通胀有缓解的迹象。</blockquote></p><p> Optimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.</p><p><blockquote>整个交易日乐观情绪消退，扭转了劳工部消费者价格指数报告发布后最初的涨势。美国三大股指均收于负值，提醒人们9月份对于股市来说是历史上艰难的一个月。</blockquote></p><p> So far this month the S&amp;P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.</p><p><blockquote>本月迄今为止，标普500已下跌近1.8%，尽管基准指数自年初以来已上涨超过18%。</blockquote></p><p> “There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”</p><p><blockquote>纽约CFRA Research首席投资策略师Sam Stovall表示：“市场有可能只是准备好经历一次迟来的调整。”“从季节性来看，9月往往是基金经理的粉饰期。”</blockquote></p><p> The advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.</p><p><blockquote>高度传染性的Delta COVID变种的出现导致人们对从全球健康危机中复苏的看跌情绪增加，许多人现在预计股市将在今年年底前大幅调整。</blockquote></p><p> “We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”</p><p><blockquote>芝加哥Kingsview Asset Management投资组合经理保罗·诺尔特(Paul Nolte)表示：“我们仍处于人们几个月来一直呼吁的纠正模式。”“经济数据点一直低于预期，而这与德尔塔变异毒株的上升同时发生。”</blockquote></p><p> The CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.</p><p><blockquote>CPI报告公布的8月份读数低于市场普遍预期，这一减速支持了美联储主席杰罗姆·鲍威尔的说法，即通胀飙升是暂时的，并平息了市场对美联储将比预期更早开始收紧货币政策的担忧。</blockquote></p><p> U.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]</p><p><blockquote>美国国债收益率因数据而下跌，这给金融股带来压力，投资者的青睐转向增长，而牺牲了价值。[美国/]</blockquote></p><p> The long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.</p><p><blockquote>随着美国总统乔·拜登（Joe Biden）的3.5万亿美元预算计划逐渐接近通过，人们期待已久的公司税上调（如果民主党获胜，将从21%上调至26.5%）即将实现。</blockquote></p><p> The Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&amp;P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.</p><p><blockquote>道琼工业指数跌292.06点，或0.84%，报34577.57点；标普500跌25.68点，跌幅0.57%，报4,443.05点；纳斯达克综合指数下跌67.82点，跌幅0.45%，至15037.76点。</blockquote></p><p> All 11 major sectors in the S&amp;P 500 ended the session red, with energy and financials suffering the largest percentage drops.</p><p><blockquote>标普500 11大板块全部收红，能源和金融板块跌幅最大。</blockquote></p><p> Apple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&amp;P 500 and the Nasdaq.</p><p><blockquote>苹果公司在今年最大的产品发布会上推出了iPhone 13，并为其iPad和苹果手表设备添加了新功能，因为该公司面临着法院对其商业行为的更严格审查。其股价收盘下跌1.0%，对标普500和纳斯达克拖累最大。</blockquote></p><p> Intuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.</p><p><blockquote>TurboTax制造商Intuit Inc宣布将以120亿美元收购数字营销公司Mailchimp后，该公司股价上涨1.9%。</blockquote></p><p> CureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.</p><p><blockquote>德国生物技术公司CureVac取消其实验性COVID-19疫苗的生产交易后，股价下跌8.0%。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌股与上涨股的比例为2.25比1；在纳斯达克，2.40比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.</p><p><blockquote>标普500创下两个52周新高和两个新低；纳斯达克综合指数录得50个新高和107个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为100.7亿股，而过去20个交易日的平均成交量为93.8亿股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148341685","content_text":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.\nOptimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.\nSo far this month the S&P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.\n“There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”\nThe advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.\n“We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”\nThe CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.\nU.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]\nThe long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.\nThe Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.\nAll 11 major sectors in the S&P 500 ended the session red, with energy and financials suffering the largest percentage drops.\nApple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&P 500 and the Nasdaq.\nIntuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.\nCureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.\nThe S&P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.\nVolume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886588732,"gmtCreate":1631605678426,"gmtModify":1631890460984,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/886588732","repostId":"1133790240","repostType":4,"repost":{"id":"1133790240","kind":"news","pubTimestamp":1631605138,"share":"https://www.laohu8.com/m/news/1133790240?lang=zh_CN&edition=full","pubTime":"2021-09-14 15:38","market":"us","language":"en","title":"Here's Why Ocugen Is Skyrocketing On Monday<blockquote>这就是Ocugen周一飙升的原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133790240","media":"Motley Fool","summary":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(N","content":"<p>There's both good and bad news for this troubled coronavirus vaccine biotech.</p><p><blockquote>对于这种陷入困境的冠状病毒疫苗生物技术公司来说，既有好消息也有坏消息。</blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> <b>Ocugen</b>(NASDAQ:OCGN)&nbsp;shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.</p><p><blockquote><b>奥库根</b>（纳斯达克：OCGN）周一股价放量飙升15.8%，至每股8.28美元，消息人士告诉印度通讯社亚洲新闻国际，世界卫生组织可能会在本周批准印度冠状病毒疫苗Covaxin的紧急使用上市。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> An EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.</p><p><blockquote>世卫组织的EUL将为世界各地更多监管机构批准科瓦克辛提供可信度。在临床试验中，该疫苗对有症状的新冠肺炎（包括由变异毒株引起的病例）表现出77.8%的有效性。总部位于印度的Bharat Biotech拥有科瓦克辛的全球商业化权利，但在美国和加拿大除外，该公司将其授权给了Ocugen。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/303e002c71ec48a633f9aeed23a7c925\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> While the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.</p><p><blockquote>虽然世卫组织的进展是个好消息，但请记住，Ocugen是一家处于研究阶段的生物技术公司，没有后期候选产品，甚至不拥有科瓦克辛。更糟糕的是，该公司一直在向美国寻求生物制剂许可申请。美国食品药品监督管理局自6月起批准，这将需要很长时间，还需要额外的临床试验来支持该申请。如果这还不够，这家合资企业一半的利润将归巴拉特生物技术公司所有。</blockquote></p><p> The company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of&nbsp;approved alternatives&nbsp;available, it's best to be careful around Ocugen's stock.</p><p><blockquote>该公司的市值已飙升至15亿美元——尽管它只计划在美国销售1亿剂科瓦克辛。在有大量经批准的替代品可用的时候，最好小心Ocugen的股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Ocugen Is Skyrocketing On Monday<blockquote>这就是Ocugen周一飙升的原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Ocugen Is Skyrocketing On Monday<blockquote>这就是Ocugen周一飙升的原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-14 15:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p>There's both good and bad news for this troubled coronavirus vaccine biotech.</p><p><blockquote>对于这种陷入困境的冠状病毒疫苗生物技术公司来说，既有好消息也有坏消息。</blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> <b>Ocugen</b>(NASDAQ:OCGN)&nbsp;shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.</p><p><blockquote><b>奥库根</b>（纳斯达克：OCGN）周一股价放量飙升15.8%，至每股8.28美元，消息人士告诉印度通讯社亚洲新闻国际，世界卫生组织可能会在本周批准印度冠状病毒疫苗Covaxin的紧急使用上市。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> An EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.</p><p><blockquote>世卫组织的EUL将为世界各地更多监管机构批准科瓦克辛提供可信度。在临床试验中，该疫苗对有症状的新冠肺炎（包括由变异毒株引起的病例）表现出77.8%的有效性。总部位于印度的Bharat Biotech拥有科瓦克辛的全球商业化权利，但在美国和加拿大除外，该公司将其授权给了Ocugen。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/303e002c71ec48a633f9aeed23a7c925\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> While the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.</p><p><blockquote>虽然世卫组织的进展是个好消息，但请记住，Ocugen是一家处于研究阶段的生物技术公司，没有后期候选产品，甚至不拥有科瓦克辛。更糟糕的是，该公司一直在向美国寻求生物制剂许可申请。美国食品药品监督管理局自6月起批准，这将需要很长时间，还需要额外的临床试验来支持该申请。如果这还不够，这家合资企业一半的利润将归巴拉特生物技术公司所有。</blockquote></p><p> The company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of&nbsp;approved alternatives&nbsp;available, it's best to be careful around Ocugen's stock.</p><p><blockquote>该公司的市值已飙升至15亿美元——尽管它只计划在美国销售1亿剂科瓦克辛。在有大量经批准的替代品可用的时候，最好小心Ocugen的股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133790240","content_text":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.\nSo what\nAn EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.\nIMAGE SOURCE: GETTY IMAGES.\nNow what\nWhile the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.\nThe company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of approved alternatives available, it's best to be careful around Ocugen's stock.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888746229,"gmtCreate":1631533724561,"gmtModify":1631890460995,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/888746229","repostId":"2167630550","repostType":4,"isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881471232,"gmtCreate":1631399250926,"gmtModify":1631890461008,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881471232","repostId":"1147045390","repostType":4,"repost":{"id":"1147045390","kind":"news","pubTimestamp":1631321547,"share":"https://www.laohu8.com/m/news/1147045390?lang=zh_CN&edition=full","pubTime":"2021-09-11 08:52","market":"us","language":"en","title":"Why Apple’s Risk Is Limited<blockquote>为什么苹果的风险有限</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147045390","media":"Barrons","summary":"Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.In a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple  to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30%","content":"<p>Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.</p><p><blockquote>周五的裁决要求苹果允许开发者为通过苹果应用商店下载的应用程序中的购买提供替代支付方式，这给其收入和利润带来了真实但有限的风险。</blockquote></p><p> In a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple (ticker: AAPL) to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30% cut from large developers.</p><p><blockquote>在堡垒之夜发行商Epic Games提起的案件中，美国地区法官Yvonne Gonzalez Rogers发布了一项永久禁令，要求苹果（股票代码：AAPL）允许开发者选择在其应用程序中包含替代支付方式的链接。苹果自己的支付系统从大型开发商那里收取30%的提成。</blockquote></p><p> Data from the app tracker SensorTower shows that in calendar 2020, Apple had overall revenue from the App Store of $72.3 billion, generating an estimated $21.7 billion in fees, or about 7% of Apple’s overall revenues. That includes $21 billion in spending in the U.S., generating about $6.3 billion in fees, or about 2% of annualized revenues.</p><p><blockquote>应用追踪器SensorTower的数据显示，2020年，苹果从App Store获得的总收入为723亿美元，产生的费用估计为217亿美元，约占苹果总收入的7%。其中包括在美国的210亿美元支出，产生约63亿美元的费用，约占年收入的2%。</blockquote></p><p> SensorTower estimates that mobile-game spending in the App Store in calendar 2020 was $47.6 billion, generating $14.3 billion in fees, or a little under 5% of Apple’s total revenues.</p><p><blockquote>SensorTower估计，2020年App Store中的手机游戏支出为476亿美元，产生143亿美元的费用，略低于苹果总收入的5%。</blockquote></p><p> Gene Munster, managing director of the venture firm Loup Capital and a former sell-side analyst with a long history of tracking Apple, estimated that the App Store accounts for about 14% of the company’s profits. But he sees limited risk from Friday’s ruling.</p><p><blockquote>风险投资公司Loup Capital董事总经理、长期跟踪苹果的前卖方分析师吉恩·蒙斯特(Gene Munster)估计，App Store约占该公司利润的14%。但他认为周五裁决的风险有限。</blockquote></p><p> Munster thinks most app developers will stay inside of the Apple system. He sees “at most” a 2% headwind to overall revenue, and a potential 4% hit to profits.</p><p><blockquote>蒙斯特认为大多数应用程序开发人员将留在苹果系统内。他认为整体收入“最多”会受到2%的阻力，利润可能会受到4%的打击。</blockquote></p><p> “After the first year of these changes, app store growth rates will return to normal,” he said. “Bottom line, it’s at most a one-year headwind and does not change the big picture of where Apple is going over the next 5 years.”</p><p><blockquote>“在这些变化的第一年之后，app store的增长率将恢复正常，”他说。“最重要的是，这最多是一年的逆风，不会改变苹果未来5年的发展方向。”</blockquote></p><p> Evercore ISI analyst Amit Daryanani said in a research note that the ruling is a setback for Apple, but that the eventual impact is likely to be manageable, given Apple has alternative ways to generate revenue from the store, including its growing in-store ad business. And he noted that Apple actually got a win on a bigger issue in the case: The judge rejected Epic’s assertion that the App Store is an illegal monopoly. Daryanani estimated the risk to Apple’s per-share earnings at 2% to 4%.</p><p><blockquote>Evercore ISI分析师Amit Daryanani在一份研究报告中表示，这一裁决对苹果来说是一次挫折，但鉴于苹果有其他方式从商店创收，包括其不断增长的店内广告业务，最终的影响可能是可控的。他指出，苹果实际上在该案中的一个更大问题上取得了胜利：法官驳回了Epic关于App Store是非法垄断的主张。Daryanani估计苹果每股收益面临的风险为2%至4%。</blockquote></p><p> Wedbush analyst Dan Ives told&nbsp;<i>Barron’s</i>&nbsp;he thinks the worst-case scenario is a 3% to 4% hit to revenues, describing the risk as a “rounding error.” While Ives said the Street had expected an across-the-board win for Apple, the mixed decision removes an overhang on the stock and that investors are likely relieved to put the issue to rest.</p><p><blockquote>Wedbush分析师Dan Ives告诉<i>巴伦周刊</i>他认为最坏的情况是收入受到3%至4%的打击，并将这种风险描述为“舍入误差”。虽然Ives表示，华尔街原本预计苹果会全面获胜，但这一喜忧参半的决定消除了该股的悬念，投资者可能会因为解决这个问题而松一口气。</blockquote></p><p> The ruling is more a positive for companies like&nbsp;Spotify Technology&nbsp;and&nbsp;Match Group&nbsp;than it is a negative for Apple, he said. Apple stock fell 3.3% to $148.97&nbsp;on&nbsp;Friday, while Spotify and March gained 0.7% and&nbsp;4.2%, respectively.</p><p><blockquote>他表示，这一裁决对Spotify Technology和Match Group等公司来说更多的是积极的，而不是对苹果的负面影响。苹果股价周五下跌3.3%，至148.97美元，Spotify和March分别上涨0.7%和4.</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple’s Risk Is Limited<blockquote>为什么苹果的风险有限</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple’s Risk Is Limited<blockquote>为什么苹果的风险有限</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-09-11 08:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.</p><p><blockquote>周五的裁决要求苹果允许开发者为通过苹果应用商店下载的应用程序中的购买提供替代支付方式，这给其收入和利润带来了真实但有限的风险。</blockquote></p><p> In a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple (ticker: AAPL) to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30% cut from large developers.</p><p><blockquote>在堡垒之夜发行商Epic Games提起的案件中，美国地区法官Yvonne Gonzalez Rogers发布了一项永久禁令，要求苹果（股票代码：AAPL）允许开发者选择在其应用程序中包含替代支付方式的链接。苹果自己的支付系统从大型开发商那里收取30%的提成。</blockquote></p><p> Data from the app tracker SensorTower shows that in calendar 2020, Apple had overall revenue from the App Store of $72.3 billion, generating an estimated $21.7 billion in fees, or about 7% of Apple’s overall revenues. That includes $21 billion in spending in the U.S., generating about $6.3 billion in fees, or about 2% of annualized revenues.</p><p><blockquote>应用追踪器SensorTower的数据显示，2020年，苹果从App Store获得的总收入为723亿美元，产生的费用估计为217亿美元，约占苹果总收入的7%。其中包括在美国的210亿美元支出，产生约63亿美元的费用，约占年收入的2%。</blockquote></p><p> SensorTower estimates that mobile-game spending in the App Store in calendar 2020 was $47.6 billion, generating $14.3 billion in fees, or a little under 5% of Apple’s total revenues.</p><p><blockquote>SensorTower估计，2020年App Store中的手机游戏支出为476亿美元，产生143亿美元的费用，略低于苹果总收入的5%。</blockquote></p><p> Gene Munster, managing director of the venture firm Loup Capital and a former sell-side analyst with a long history of tracking Apple, estimated that the App Store accounts for about 14% of the company’s profits. But he sees limited risk from Friday’s ruling.</p><p><blockquote>风险投资公司Loup Capital董事总经理、长期跟踪苹果的前卖方分析师吉恩·蒙斯特(Gene Munster)估计，App Store约占该公司利润的14%。但他认为周五裁决的风险有限。</blockquote></p><p> Munster thinks most app developers will stay inside of the Apple system. He sees “at most” a 2% headwind to overall revenue, and a potential 4% hit to profits.</p><p><blockquote>蒙斯特认为大多数应用程序开发人员将留在苹果系统内。他认为整体收入“最多”会受到2%的阻力，利润可能会受到4%的打击。</blockquote></p><p> “After the first year of these changes, app store growth rates will return to normal,” he said. “Bottom line, it’s at most a one-year headwind and does not change the big picture of where Apple is going over the next 5 years.”</p><p><blockquote>“在这些变化的第一年之后，app store的增长率将恢复正常，”他说。“最重要的是，这最多是一年的逆风，不会改变苹果未来5年的发展方向。”</blockquote></p><p> Evercore ISI analyst Amit Daryanani said in a research note that the ruling is a setback for Apple, but that the eventual impact is likely to be manageable, given Apple has alternative ways to generate revenue from the store, including its growing in-store ad business. And he noted that Apple actually got a win on a bigger issue in the case: The judge rejected Epic’s assertion that the App Store is an illegal monopoly. Daryanani estimated the risk to Apple’s per-share earnings at 2% to 4%.</p><p><blockquote>Evercore ISI分析师Amit Daryanani在一份研究报告中表示，这一裁决对苹果来说是一次挫折，但鉴于苹果有其他方式从商店创收，包括其不断增长的店内广告业务，最终的影响可能是可控的。他指出，苹果实际上在该案中的一个更大问题上取得了胜利：法官驳回了Epic关于App Store是非法垄断的主张。Daryanani估计苹果每股收益面临的风险为2%至4%。</blockquote></p><p> Wedbush analyst Dan Ives told&nbsp;<i>Barron’s</i>&nbsp;he thinks the worst-case scenario is a 3% to 4% hit to revenues, describing the risk as a “rounding error.” While Ives said the Street had expected an across-the-board win for Apple, the mixed decision removes an overhang on the stock and that investors are likely relieved to put the issue to rest.</p><p><blockquote>Wedbush分析师Dan Ives告诉<i>巴伦周刊</i>他认为最坏的情况是收入受到3%至4%的打击，并将这种风险描述为“舍入误差”。虽然Ives表示，华尔街原本预计苹果会全面获胜，但这一喜忧参半的决定消除了该股的悬念，投资者可能会因为解决这个问题而松一口气。</blockquote></p><p> The ruling is more a positive for companies like&nbsp;Spotify Technology&nbsp;and&nbsp;Match Group&nbsp;than it is a negative for Apple, he said. Apple stock fell 3.3% to $148.97&nbsp;on&nbsp;Friday, while Spotify and March gained 0.7% and&nbsp;4.2%, respectively.</p><p><blockquote>他表示，这一裁决对Spotify Technology和Match Group等公司来说更多的是积极的，而不是对苹果的负面影响。苹果股价周五下跌3.3%，至148.97美元，Spotify和March分别上涨0.7%和4.</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/apple-app-store-epic-51631304007?mod=hp_LEAD_1_B_2\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.barrons.com/articles/apple-app-store-epic-51631304007?mod=hp_LEAD_1_B_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147045390","content_text":"Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.\nIn a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple (ticker: AAPL) to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30% cut from large developers.\nData from the app tracker SensorTower shows that in calendar 2020, Apple had overall revenue from the App Store of $72.3 billion, generating an estimated $21.7 billion in fees, or about 7% of Apple’s overall revenues. That includes $21 billion in spending in the U.S., generating about $6.3 billion in fees, or about 2% of annualized revenues.\nSensorTower estimates that mobile-game spending in the App Store in calendar 2020 was $47.6 billion, generating $14.3 billion in fees, or a little under 5% of Apple’s total revenues.\nGene Munster, managing director of the venture firm Loup Capital and a former sell-side analyst with a long history of tracking Apple, estimated that the App Store accounts for about 14% of the company’s profits. But he sees limited risk from Friday’s ruling.\nMunster thinks most app developers will stay inside of the Apple system. He sees “at most” a 2% headwind to overall revenue, and a potential 4% hit to profits.\n“After the first year of these changes, app store growth rates will return to normal,” he said. “Bottom line, it’s at most a one-year headwind and does not change the big picture of where Apple is going over the next 5 years.”\nEvercore ISI analyst Amit Daryanani said in a research note that the ruling is a setback for Apple, but that the eventual impact is likely to be manageable, given Apple has alternative ways to generate revenue from the store, including its growing in-store ad business. And he noted that Apple actually got a win on a bigger issue in the case: The judge rejected Epic’s assertion that the App Store is an illegal monopoly. Daryanani estimated the risk to Apple’s per-share earnings at 2% to 4%.\nWedbush analyst Dan Ives told Barron’s he thinks the worst-case scenario is a 3% to 4% hit to revenues, describing the risk as a “rounding error.” While Ives said the Street had expected an across-the-board win for Apple, the mixed decision removes an overhang on the stock and that investors are likely relieved to put the issue to rest.\nThe ruling is more a positive for companies like Spotify Technology and Match Group than it is a negative for Apple, he said. Apple stock fell 3.3% to $148.97 on Friday, while Spotify and March gained 0.7% and 4.2%, respectively.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881419491,"gmtCreate":1631375282313,"gmtModify":1631890461026,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881419491","repostId":"2166372458","repostType":4,"isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881542474,"gmtCreate":1631370484598,"gmtModify":1631890461035,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881542474","repostId":"1147045390","repostType":4,"repost":{"id":"1147045390","kind":"news","pubTimestamp":1631321547,"share":"https://www.laohu8.com/m/news/1147045390?lang=zh_CN&edition=full","pubTime":"2021-09-11 08:52","market":"us","language":"en","title":"Why Apple’s Risk Is Limited<blockquote>为什么苹果的风险有限</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147045390","media":"Barrons","summary":"Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.In a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple  to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30%","content":"<p>Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.</p><p><blockquote>周五的裁决要求苹果允许开发者为通过苹果应用商店下载的应用程序中的购买提供替代支付方式，这给其收入和利润带来了真实但有限的风险。</blockquote></p><p> In a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple (ticker: AAPL) to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30% cut from large developers.</p><p><blockquote>在堡垒之夜发行商Epic Games提起的案件中，美国地区法官Yvonne Gonzalez Rogers发布了一项永久禁令，要求苹果（股票代码：AAPL）允许开发者选择在其应用程序中包含替代支付方式的链接。苹果自己的支付系统从大型开发商那里收取30%的提成。</blockquote></p><p> Data from the app tracker SensorTower shows that in calendar 2020, Apple had overall revenue from the App Store of $72.3 billion, generating an estimated $21.7 billion in fees, or about 7% of Apple’s overall revenues. That includes $21 billion in spending in the U.S., generating about $6.3 billion in fees, or about 2% of annualized revenues.</p><p><blockquote>应用追踪器SensorTower的数据显示，2020年，苹果从App Store获得的总收入为723亿美元，产生的费用估计为217亿美元，约占苹果总收入的7%。其中包括在美国的210亿美元支出，产生约63亿美元的费用，约占年收入的2%。</blockquote></p><p> SensorTower estimates that mobile-game spending in the App Store in calendar 2020 was $47.6 billion, generating $14.3 billion in fees, or a little under 5% of Apple’s total revenues.</p><p><blockquote>SensorTower估计，2020年App Store中的手机游戏支出为476亿美元，产生143亿美元的费用，略低于苹果总收入的5%。</blockquote></p><p> Gene Munster, managing director of the venture firm Loup Capital and a former sell-side analyst with a long history of tracking Apple, estimated that the App Store accounts for about 14% of the company’s profits. But he sees limited risk from Friday’s ruling.</p><p><blockquote>风险投资公司Loup Capital董事总经理、长期跟踪苹果的前卖方分析师吉恩·蒙斯特(Gene Munster)估计，App Store约占该公司利润的14%。但他认为周五裁决的风险有限。</blockquote></p><p> Munster thinks most app developers will stay inside of the Apple system. He sees “at most” a 2% headwind to overall revenue, and a potential 4% hit to profits.</p><p><blockquote>蒙斯特认为大多数应用程序开发人员将留在苹果系统内。他认为整体收入“最多”会受到2%的阻力，利润可能会受到4%的打击。</blockquote></p><p> “After the first year of these changes, app store growth rates will return to normal,” he said. “Bottom line, it’s at most a one-year headwind and does not change the big picture of where Apple is going over the next 5 years.”</p><p><blockquote>“在这些变化的第一年之后，app store的增长率将恢复正常，”他说。“最重要的是，这最多是一年的逆风，不会改变苹果未来5年的发展方向。”</blockquote></p><p> Evercore ISI analyst Amit Daryanani said in a research note that the ruling is a setback for Apple, but that the eventual impact is likely to be manageable, given Apple has alternative ways to generate revenue from the store, including its growing in-store ad business. And he noted that Apple actually got a win on a bigger issue in the case: The judge rejected Epic’s assertion that the App Store is an illegal monopoly. Daryanani estimated the risk to Apple’s per-share earnings at 2% to 4%.</p><p><blockquote>Evercore ISI分析师Amit Daryanani在一份研究报告中表示，这一裁决对苹果来说是一次挫折，但鉴于苹果有其他方式从商店创收，包括其不断增长的店内广告业务，最终的影响可能是可控的。他指出，苹果实际上在该案中的一个更大问题上取得了胜利：法官驳回了Epic关于App Store是非法垄断的主张。Daryanani估计苹果每股收益面临的风险为2%至4%。</blockquote></p><p> Wedbush analyst Dan Ives told&nbsp;<i>Barron’s</i>&nbsp;he thinks the worst-case scenario is a 3% to 4% hit to revenues, describing the risk as a “rounding error.” While Ives said the Street had expected an across-the-board win for Apple, the mixed decision removes an overhang on the stock and that investors are likely relieved to put the issue to rest.</p><p><blockquote>Wedbush分析师Dan Ives告诉<i>巴伦周刊</i>他认为最坏的情况是收入受到3%至4%的打击，并将这种风险描述为“舍入误差”。虽然Ives表示，华尔街原本预计苹果会全面获胜，但这一喜忧参半的决定消除了该股的悬念，投资者可能会因为解决这个问题而松一口气。</blockquote></p><p> The ruling is more a positive for companies like&nbsp;Spotify Technology&nbsp;and&nbsp;Match Group&nbsp;than it is a negative for Apple, he said. Apple stock fell 3.3% to $148.97&nbsp;on&nbsp;Friday, while Spotify and March gained 0.7% and&nbsp;4.2%, respectively.</p><p><blockquote>他表示，这一裁决对Spotify Technology和Match Group等公司来说更多的是积极的，而不是对苹果的负面影响。苹果股价周五下跌3.3%，至148.97美元，Spotify和March分别上涨0.7%和4.</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple’s Risk Is Limited<blockquote>为什么苹果的风险有限</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple’s Risk Is Limited<blockquote>为什么苹果的风险有限</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-09-11 08:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.</p><p><blockquote>周五的裁决要求苹果允许开发者为通过苹果应用商店下载的应用程序中的购买提供替代支付方式，这给其收入和利润带来了真实但有限的风险。</blockquote></p><p> In a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple (ticker: AAPL) to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30% cut from large developers.</p><p><blockquote>在堡垒之夜发行商Epic Games提起的案件中，美国地区法官Yvonne Gonzalez Rogers发布了一项永久禁令，要求苹果（股票代码：AAPL）允许开发者选择在其应用程序中包含替代支付方式的链接。苹果自己的支付系统从大型开发商那里收取30%的提成。</blockquote></p><p> Data from the app tracker SensorTower shows that in calendar 2020, Apple had overall revenue from the App Store of $72.3 billion, generating an estimated $21.7 billion in fees, or about 7% of Apple’s overall revenues. That includes $21 billion in spending in the U.S., generating about $6.3 billion in fees, or about 2% of annualized revenues.</p><p><blockquote>应用追踪器SensorTower的数据显示，2020年，苹果从App Store获得的总收入为723亿美元，产生的费用估计为217亿美元，约占苹果总收入的7%。其中包括在美国的210亿美元支出，产生约63亿美元的费用，约占年收入的2%。</blockquote></p><p> SensorTower estimates that mobile-game spending in the App Store in calendar 2020 was $47.6 billion, generating $14.3 billion in fees, or a little under 5% of Apple’s total revenues.</p><p><blockquote>SensorTower估计，2020年App Store中的手机游戏支出为476亿美元，产生143亿美元的费用，略低于苹果总收入的5%。</blockquote></p><p> Gene Munster, managing director of the venture firm Loup Capital and a former sell-side analyst with a long history of tracking Apple, estimated that the App Store accounts for about 14% of the company’s profits. But he sees limited risk from Friday’s ruling.</p><p><blockquote>风险投资公司Loup Capital董事总经理、长期跟踪苹果的前卖方分析师吉恩·蒙斯特(Gene Munster)估计，App Store约占该公司利润的14%。但他认为周五裁决的风险有限。</blockquote></p><p> Munster thinks most app developers will stay inside of the Apple system. He sees “at most” a 2% headwind to overall revenue, and a potential 4% hit to profits.</p><p><blockquote>蒙斯特认为大多数应用程序开发人员将留在苹果系统内。他认为整体收入“最多”会受到2%的阻力，利润可能会受到4%的打击。</blockquote></p><p> “After the first year of these changes, app store growth rates will return to normal,” he said. “Bottom line, it’s at most a one-year headwind and does not change the big picture of where Apple is going over the next 5 years.”</p><p><blockquote>“在这些变化的第一年之后，app store的增长率将恢复正常，”他说。“最重要的是，这最多是一年的逆风，不会改变苹果未来5年的发展方向。”</blockquote></p><p> Evercore ISI analyst Amit Daryanani said in a research note that the ruling is a setback for Apple, but that the eventual impact is likely to be manageable, given Apple has alternative ways to generate revenue from the store, including its growing in-store ad business. And he noted that Apple actually got a win on a bigger issue in the case: The judge rejected Epic’s assertion that the App Store is an illegal monopoly. Daryanani estimated the risk to Apple’s per-share earnings at 2% to 4%.</p><p><blockquote>Evercore ISI分析师Amit Daryanani在一份研究报告中表示，这一裁决对苹果来说是一次挫折，但鉴于苹果有其他方式从商店创收，包括其不断增长的店内广告业务，最终的影响可能是可控的。他指出，苹果实际上在该案中的一个更大问题上取得了胜利：法官驳回了Epic关于App Store是非法垄断的主张。Daryanani估计苹果每股收益面临的风险为2%至4%。</blockquote></p><p> Wedbush analyst Dan Ives told&nbsp;<i>Barron’s</i>&nbsp;he thinks the worst-case scenario is a 3% to 4% hit to revenues, describing the risk as a “rounding error.” While Ives said the Street had expected an across-the-board win for Apple, the mixed decision removes an overhang on the stock and that investors are likely relieved to put the issue to rest.</p><p><blockquote>Wedbush分析师Dan Ives告诉<i>巴伦周刊</i>他认为最坏的情况是收入受到3%至4%的打击，并将这种风险描述为“舍入误差”。虽然Ives表示，华尔街原本预计苹果会全面获胜，但这一喜忧参半的决定消除了该股的悬念，投资者可能会因为解决这个问题而松一口气。</blockquote></p><p> The ruling is more a positive for companies like&nbsp;Spotify Technology&nbsp;and&nbsp;Match Group&nbsp;than it is a negative for Apple, he said. Apple stock fell 3.3% to $148.97&nbsp;on&nbsp;Friday, while Spotify and March gained 0.7% and&nbsp;4.2%, respectively.</p><p><blockquote>他表示，这一裁决对Spotify Technology和Match Group等公司来说更多的是积极的，而不是对苹果的负面影响。苹果股价周五下跌3.3%，至148.97美元，Spotify和March分别上涨0.7%和4.</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/apple-app-store-epic-51631304007?mod=hp_LEAD_1_B_2\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.barrons.com/articles/apple-app-store-epic-51631304007?mod=hp_LEAD_1_B_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147045390","content_text":"Apple faces real, but limited, risk to its revenue and profits from Friday’s ruling that requires it to allow developers to offer alternative payment methods for purchases made in apps downloaded through the Apple app store.\nIn a case filed by Fortnite publisher Epic Games, U.S. District Judge Yvonne Gonzalez Rogers issued a permanent injunction that requires Apple (ticker: AAPL) to allow developers the option to include links to alternative payment methods in their apps. Apple’s own payment system takes a 30% cut from large developers.\nData from the app tracker SensorTower shows that in calendar 2020, Apple had overall revenue from the App Store of $72.3 billion, generating an estimated $21.7 billion in fees, or about 7% of Apple’s overall revenues. That includes $21 billion in spending in the U.S., generating about $6.3 billion in fees, or about 2% of annualized revenues.\nSensorTower estimates that mobile-game spending in the App Store in calendar 2020 was $47.6 billion, generating $14.3 billion in fees, or a little under 5% of Apple’s total revenues.\nGene Munster, managing director of the venture firm Loup Capital and a former sell-side analyst with a long history of tracking Apple, estimated that the App Store accounts for about 14% of the company’s profits. But he sees limited risk from Friday’s ruling.\nMunster thinks most app developers will stay inside of the Apple system. He sees “at most” a 2% headwind to overall revenue, and a potential 4% hit to profits.\n“After the first year of these changes, app store growth rates will return to normal,” he said. “Bottom line, it’s at most a one-year headwind and does not change the big picture of where Apple is going over the next 5 years.”\nEvercore ISI analyst Amit Daryanani said in a research note that the ruling is a setback for Apple, but that the eventual impact is likely to be manageable, given Apple has alternative ways to generate revenue from the store, including its growing in-store ad business. And he noted that Apple actually got a win on a bigger issue in the case: The judge rejected Epic’s assertion that the App Store is an illegal monopoly. Daryanani estimated the risk to Apple’s per-share earnings at 2% to 4%.\nWedbush analyst Dan Ives told Barron’s he thinks the worst-case scenario is a 3% to 4% hit to revenues, describing the risk as a “rounding error.” While Ives said the Street had expected an across-the-board win for Apple, the mixed decision removes an overhang on the stock and that investors are likely relieved to put the issue to rest.\nThe ruling is more a positive for companies like Spotify Technology and Match Group than it is a negative for Apple, he said. Apple stock fell 3.3% to $148.97 on Friday, while Spotify and March gained 0.7% and 4.2%, respectively.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883648858,"gmtCreate":1631239849774,"gmtModify":1631890461049,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883648858","repostId":"2166426123","repostType":4,"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889519567,"gmtCreate":1631157305959,"gmtModify":1631890461065,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889519567","repostId":"2166392072","repostType":4,"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889344089,"gmtCreate":1631111608941,"gmtModify":1631892389015,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889344089","repostId":"1154837170","repostType":4,"repost":{"id":"1154837170","kind":"news","pubTimestamp":1631090918,"share":"https://www.laohu8.com/m/news/1154837170?lang=zh_CN&edition=full","pubTime":"2021-09-08 16:48","market":"us","language":"en","title":"Bitcoin Endured a Rocky Day. What's Behind the Selloff<blockquote>比特币经历了艰难的一天。抛售背后是什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1154837170","media":"Barron's","summary":"It should have been a happy day for Bitcoin, but it’s turned into a rout.Bitcoin  was trading was around $47,000 on Tuesday afternoon, down 9% in the last 24 hours, after dipping down to $42,900 this morning. Bitcoin had been above $52,800 before the selloff.Other cryptos were also ailing, including Ethereum , down 12% to $3,460.The selloff may reflect profit-taking after prices started rising in late July. Bitcoin had gained more than 50% since late July when it traded around $34,000. Ethereum ","content":"<p>It should have been a happy day for Bitcoin, but it’s turned into a rout.</p><p><blockquote>对比特币来说，这应该是快乐的一天，但它变成了一场溃败。</blockquote></p><p> Bitcoin (ticker: BTC) was trading was around $47,000 on Tuesday afternoon, down 9% in the last 24 hours, after dipping down to $42,900 this morning. Bitcoin had been above $52,800 before the selloff.</p><p><blockquote>比特币（股票代码：BTC）周二下午的交易价格约为47,000美元，在今天上午跌至42,900美元后，过去24小时内下跌9%。在抛售之前，比特币股价已高于52,800美元。</blockquote></p><p> Other cryptos were also ailing, including Ethereum (ETH), down 12% to $3,460.</p><p><blockquote>其他加密货币也表现不佳，包括以太币(ETH)，下跌12%至3,460美元。</blockquote></p><p> The selloff may reflect profit-taking after prices started rising in late July. Bitcoin had gained more than 50% since late July when it traded around $34,000. Ethereum has also been flying, following a technical upgrade in its underlying blockchain network.</p><p><blockquote>抛售可能反映了7月下旬价格开始上涨后的获利了结。自7月底交易价格约为34,000美元以来，比特币已上涨超过50%。在对其底层区块链网络进行技术升级后，以太币也一直在飞行。</blockquote></p><p> The down day may also reflect a “sell the news” dynamic after El Salvador became the first country to adopt Bitcoin as legal tender, alongside the dollar– the country’s other official currency.</p><p><blockquote>下跌的一天也可能反映了萨尔瓦多成为第一个采用比特币作为法定货币以及该国另一种官方货币美元的国家后的“抛售新闻”动态。</blockquote></p><p> Merchants in El Salvador are now supposed to accept Bitcoin for goods and services. Citizens have been promised $30 worth of Bitcoin in their digital wallets by the government. McDonald’s has started accepting Bitcoin in El Salvador, according to Reuters. And the government of president Nayib Bukele has been buying Bitcoin, including at least $20 million worth, ahead of the official launch.</p><p><blockquote>萨尔瓦多的商人现在应该接受商品和服务的比特币。政府向公民承诺在他们的数字钱包中提供价值30美元的比特币。据路透社报道，麦当劳已经开始在萨尔瓦多接受比特币。在正式启动之前，纳伊布·布克莱总统的政府一直在购买比特币，其中包括价值至少2000万美元的资金。</blockquote></p><p> But El Salvador’s crypto experiment isn’t sitting well with organizations like the International Monetary Fund and World Bank, which have warned El Salvador that its adoption as legal tender could imperil financial stability. Other countries are cracking down on crypto transactions, mining, and exchanges, indicating that El Salvador may be an outlier for now.</p><p><blockquote>但萨尔瓦多的加密货币实验并没有得到国际货币基金组织和世界银行等组织的认可，这些组织警告萨尔瓦多，将其作为法定货币可能会危及金融稳定。其他国家正在打击加密货币交易、采矿和交易所，这表明萨尔瓦多目前可能是一个例外。</blockquote></p><p> Crypto watchers are also blaming technical factors for the market downturn. Assuming prices don’t suddenly surge, Bitcoin is now in for “outside-down” day, says Katie Stockton, founder and managing partner of Fairlead Strategies, a crypto-trading research firm. The means Bitcoin is trading in a wider range and headed for a lower close than yesterday (assuming a 5 p.m. cutoff, though it trades 24 hours).</p><p><blockquote>加密货币观察人士也将市场低迷归咎于技术因素。加密货币交易研究公司Fairlead Strategies的创始人兼管理合伙人Katie Stockton表示，假设价格不会突然飙升，比特币现在将迎来“外部下跌”的一天。这意味着比特币的交易范围更广，收盘价将低于昨天（假设下午5点截止，尽管它24小时交易）。</blockquote></p><p> “The implications are for additional consolidation,” she says. So far, the selloff looks like a minor setback, she adds, since Bitcoin hasn’t breached its 50-day moving average around $44,000, which is its next support level.</p><p><blockquote>“这意味着进一步整合，”她说。她补充道，到目前为止，抛售看起来像是一个小挫折，因为比特币尚未突破44,000美元左右的50日移动平均线，这是下一个支撑位。</blockquote></p><p> “A breach of $44,000 isn’t a breakdown,” she says. “It’s a test of the 50-day moving average. “There is strong support for Bitcoin and most crytpos pretty close to their current lows.”</p><p><blockquote>“违反44,000美元并不是崩溃，”她说。“这是对50日移动平均线的测试。“比特币和大多数加密货币都非常接近当前低点，”</blockquote></p><p> Other factors that may have contributed to the selloff include reports of outages and “unscheduled maintenance” at Bitfinix, a leading crypto exchange. Coinbase Global (ticker: COIN) also experienced a spike in outages around noon, according to Downdetector.</p><p><blockquote>其他可能导致抛售的因素包括领先的加密货币交易所Bitfinix的停电和“计划外维护”报告。据Downdetector称，Coinbase Global（股票代码：COIN）中午左右也经历了停电高峰。</blockquote></p><p> Even if prices stabilize from here, it’s a reminder that Bitcoin and other cryptos remain vulnerable to rapid-fire declines. While you may be able to buy a Big Mac with a sliver of Bitcoin in San Salvador, you may be better off keeping it in your digital wallet–or not–depending on the time of day.</p><p><blockquote>即使价格从这里稳定下来，这也提醒人们比特币和其他加密货币仍然容易受到快速下跌的影响。虽然你可以在圣萨尔瓦多买到一个巨无霸和一片比特币，但你最好把它放在你的数字钱包里——或者不放在——这取决于一天中的不同时间。</blockquote></p><p></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin Endured a Rocky Day. What's Behind the Selloff<blockquote>比特币经历了艰难的一天。抛售背后是什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin Endured a Rocky Day. What's Behind the Selloff<blockquote>比特币经历了艰难的一天。抛售背后是什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barron's</strong><span class=\"h-time small\">2021-09-08 16:48</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It should have been a happy day for Bitcoin, but it’s turned into a rout.</p><p><blockquote>对比特币来说，这应该是快乐的一天，但它变成了一场溃败。</blockquote></p><p> Bitcoin (ticker: BTC) was trading was around $47,000 on Tuesday afternoon, down 9% in the last 24 hours, after dipping down to $42,900 this morning. Bitcoin had been above $52,800 before the selloff.</p><p><blockquote>比特币（股票代码：BTC）周二下午的交易价格约为47,000美元，在今天上午跌至42,900美元后，过去24小时内下跌9%。在抛售之前，比特币股价已高于52,800美元。</blockquote></p><p> Other cryptos were also ailing, including Ethereum (ETH), down 12% to $3,460.</p><p><blockquote>其他加密货币也表现不佳，包括以太币(ETH)，下跌12%至3,460美元。</blockquote></p><p> The selloff may reflect profit-taking after prices started rising in late July. Bitcoin had gained more than 50% since late July when it traded around $34,000. Ethereum has also been flying, following a technical upgrade in its underlying blockchain network.</p><p><blockquote>抛售可能反映了7月下旬价格开始上涨后的获利了结。自7月底交易价格约为34,000美元以来，比特币已上涨超过50%。在对其底层区块链网络进行技术升级后，以太币也一直在飞行。</blockquote></p><p> The down day may also reflect a “sell the news” dynamic after El Salvador became the first country to adopt Bitcoin as legal tender, alongside the dollar– the country’s other official currency.</p><p><blockquote>下跌的一天也可能反映了萨尔瓦多成为第一个采用比特币作为法定货币以及该国另一种官方货币美元的国家后的“抛售新闻”动态。</blockquote></p><p> Merchants in El Salvador are now supposed to accept Bitcoin for goods and services. Citizens have been promised $30 worth of Bitcoin in their digital wallets by the government. McDonald’s has started accepting Bitcoin in El Salvador, according to Reuters. And the government of president Nayib Bukele has been buying Bitcoin, including at least $20 million worth, ahead of the official launch.</p><p><blockquote>萨尔瓦多的商人现在应该接受商品和服务的比特币。政府向公民承诺在他们的数字钱包中提供价值30美元的比特币。据路透社报道，麦当劳已经开始在萨尔瓦多接受比特币。在正式启动之前，纳伊布·布克莱总统的政府一直在购买比特币，其中包括价值至少2000万美元的资金。</blockquote></p><p> But El Salvador’s crypto experiment isn’t sitting well with organizations like the International Monetary Fund and World Bank, which have warned El Salvador that its adoption as legal tender could imperil financial stability. Other countries are cracking down on crypto transactions, mining, and exchanges, indicating that El Salvador may be an outlier for now.</p><p><blockquote>但萨尔瓦多的加密货币实验并没有得到国际货币基金组织和世界银行等组织的认可，这些组织警告萨尔瓦多，将其作为法定货币可能会危及金融稳定。其他国家正在打击加密货币交易、采矿和交易所，这表明萨尔瓦多目前可能是一个例外。</blockquote></p><p> Crypto watchers are also blaming technical factors for the market downturn. Assuming prices don’t suddenly surge, Bitcoin is now in for “outside-down” day, says Katie Stockton, founder and managing partner of Fairlead Strategies, a crypto-trading research firm. The means Bitcoin is trading in a wider range and headed for a lower close than yesterday (assuming a 5 p.m. cutoff, though it trades 24 hours).</p><p><blockquote>加密货币观察人士也将市场低迷归咎于技术因素。加密货币交易研究公司Fairlead Strategies的创始人兼管理合伙人Katie Stockton表示，假设价格不会突然飙升，比特币现在将迎来“外部下跌”的一天。这意味着比特币的交易范围更广，收盘价将低于昨天（假设下午5点截止，尽管它24小时交易）。</blockquote></p><p> “The implications are for additional consolidation,” she says. So far, the selloff looks like a minor setback, she adds, since Bitcoin hasn’t breached its 50-day moving average around $44,000, which is its next support level.</p><p><blockquote>“这意味着进一步整合，”她说。她补充道，到目前为止，抛售看起来像是一个小挫折，因为比特币尚未突破44,000美元左右的50日移动平均线，这是下一个支撑位。</blockquote></p><p> “A breach of $44,000 isn’t a breakdown,” she says. “It’s a test of the 50-day moving average. “There is strong support for Bitcoin and most crytpos pretty close to their current lows.”</p><p><blockquote>“违反44,000美元并不是崩溃，”她说。“这是对50日移动平均线的测试。“比特币和大多数加密货币都非常接近当前低点，”</blockquote></p><p> Other factors that may have contributed to the selloff include reports of outages and “unscheduled maintenance” at Bitfinix, a leading crypto exchange. Coinbase Global (ticker: COIN) also experienced a spike in outages around noon, according to Downdetector.</p><p><blockquote>其他可能导致抛售的因素包括领先的加密货币交易所Bitfinix的停电和“计划外维护”报告。据Downdetector称，Coinbase Global（股票代码：COIN）中午左右也经历了停电高峰。</blockquote></p><p> Even if prices stabilize from here, it’s a reminder that Bitcoin and other cryptos remain vulnerable to rapid-fire declines. While you may be able to buy a Big Mac with a sliver of Bitcoin in San Salvador, you may be better off keeping it in your digital wallet–or not–depending on the time of day.</p><p><blockquote>即使价格从这里稳定下来，这也提醒人们比特币和其他加密货币仍然容易受到快速下跌的影响。虽然你可以在圣萨尔瓦多买到一个巨无霸和一片比特币，但你最好把它放在你的数字钱包里——或者不放在——这取决于一天中的不同时间。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/bitcoin-crypto-prices-drop-today-51631048243?mod=hp_LEAD_1\">Barron's</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"比特币ETF-Grayscale","COIN":"Coinbase Global, Inc."},"source_url":"https://www.barrons.com/articles/bitcoin-crypto-prices-drop-today-51631048243?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154837170","content_text":"It should have been a happy day for Bitcoin, but it’s turned into a rout.\nBitcoin (ticker: BTC) was trading was around $47,000 on Tuesday afternoon, down 9% in the last 24 hours, after dipping down to $42,900 this morning. Bitcoin had been above $52,800 before the selloff.\nOther cryptos were also ailing, including Ethereum (ETH), down 12% to $3,460.\nThe selloff may reflect profit-taking after prices started rising in late July. Bitcoin had gained more than 50% since late July when it traded around $34,000. Ethereum has also been flying, following a technical upgrade in its underlying blockchain network.\nThe down day may also reflect a “sell the news” dynamic after El Salvador became the first country to adopt Bitcoin as legal tender, alongside the dollar– the country’s other official currency.\nMerchants in El Salvador are now supposed to accept Bitcoin for goods and services. Citizens have been promised $30 worth of Bitcoin in their digital wallets by the government. McDonald’s has started accepting Bitcoin in El Salvador, according to Reuters. And the government of president Nayib Bukele has been buying Bitcoin, including at least $20 million worth, ahead of the official launch.\nBut El Salvador’s crypto experiment isn’t sitting well with organizations like the International Monetary Fund and World Bank, which have warned El Salvador that its adoption as legal tender could imperil financial stability. Other countries are cracking down on crypto transactions, mining, and exchanges, indicating that El Salvador may be an outlier for now.\nCrypto watchers are also blaming technical factors for the market downturn. Assuming prices don’t suddenly surge, Bitcoin is now in for “outside-down” day, says Katie Stockton, founder and managing partner of Fairlead Strategies, a crypto-trading research firm. The means Bitcoin is trading in a wider range and headed for a lower close than yesterday (assuming a 5 p.m. cutoff, though it trades 24 hours).\n“The implications are for additional consolidation,” she says. So far, the selloff looks like a minor setback, she adds, since Bitcoin hasn’t breached its 50-day moving average around $44,000, which is its next support level.\n“A breach of $44,000 isn’t a breakdown,” she says. “It’s a test of the 50-day moving average. “There is strong support for Bitcoin and most crytpos pretty close to their current lows.”\nOther factors that may have contributed to the selloff include reports of outages and “unscheduled maintenance” at Bitfinix, a leading crypto exchange. Coinbase Global (ticker: COIN) also experienced a spike in outages around noon, according to Downdetector.\nEven if prices stabilize from here, it’s a reminder that Bitcoin and other cryptos remain vulnerable to rapid-fire declines. While you may be able to buy a Big Mac with a sliver of Bitcoin in San Salvador, you may be better off keeping it in your digital wallet–or not–depending on the time of day.","news_type":1,"symbols_score_info":{"GBTC":0.9,"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":637,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":888746229,"gmtCreate":1631533724561,"gmtModify":1631890460995,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/888746229","repostId":"2167630550","repostType":4,"isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802192234,"gmtCreate":1627728794228,"gmtModify":1633756767350,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802192234","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":588,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819831232,"gmtCreate":1630052805426,"gmtModify":1704955216464,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/819831232","repostId":"2162847016","repostType":4,"isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":866995549,"gmtCreate":1632719027981,"gmtModify":1632798313176,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"F","listText":"F","text":"F","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/866995549","repostId":"2170488786","repostType":4,"repost":{"id":"2170488786","kind":"news","pubTimestamp":1632685409,"share":"https://www.laohu8.com/m/news/2170488786?lang=zh_CN&edition=full","pubTime":"2021-09-27 03:43","market":"other","language":"en","title":"Debt ceiling debates in Congress, consumer confidence: What to know this week<blockquote>国会债务上限辩论、消费者信心：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2170488786","media":"Yahoo Finance","summary":"Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race t","content":"<p><div> Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race to pass legislation to avoid a government shutdown by the end of the month and debate raising the ...</p><p><blockquote><div>投资者本周将密切关注华盛顿特区的事态发展，因为议员们竞相通过立法，以避免政府在本月底关闭，并就提高...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页连接</a></blockquote></p><p></p>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Debt ceiling debates in Congress, consumer confidence: What to know this week<blockquote>国会债务上限辩论、消费者信心：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDebt ceiling debates in Congress, consumer confidence: What to know this week<blockquote>国会债务上限辩论、消费者信心：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2021-09-27 03:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race to pass legislation to avoid a government shutdown by the end of the month and debate raising the ...</p><p><blockquote><div>投资者本周将密切关注华盛顿特区的事态发展，因为议员们竞相通过立法，以避免政府在本月底关闭，并就提高...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e7e749e88d2580d292ffc6ae18d03b65","relate_stocks":{"SPY.AU":"SPDR® S&P 500® ETF Trust"},"source_url":"https://finance.yahoo.com/news/debt-ceiling-debates-in-congress-consumer-confidence-what-to-know-this-week-194329712.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170488786","content_text":"Investors this week are set to closely monitor developments in Washington, D.C., as lawmakers race to pass legislation to avoid a government shutdown by the end of the month and debate raising the debt ceiling. Elsewhere, economic data on consumer confidence is also due for release.\nThe Senate is expected to vote Monday on a procedural motion over the legislation passed by the House of Representatives last week. That bill included a plan to temporarily fund the government through early December, and came alongside a measure to raise the government debt ceiling through December 2022.\nThe latter point has been an area of contention for Senate Republicans, who are only narrowly outnumbered by Democratic lawmakers in both chambers and who have threatened to block the bill in its current form.\nSenate Republicans including Minority Leader Mitch McConnell have suggested that Democratic lawmakers should use the budget reconciliation process to raise the debt ceiling without Republican support. McConnell has, however, supported a short-term government funding bill that excludes a debt ceiling suspension.\n\"If they [the Democrats] want to tax, borrow and spend historic sums of money without our input, they’ll have to raise the debt limit without our help. This is the reality,” McConnell said on the Senate floor last week.\nDemocratic lawmakers, for their part, have called for the move to raise the debt limit be bipartisan to prevent the government from defaulting on its obligations. The Treasury Department has warned that the U.S. could default on its debts as soon as October in absence of congressional action.\n\"The U.S. has always paid its bills on time, but the overwhelming consensus among economists and Treasury officials of both parties is that failing to raise the debt limit would produce widespread economic catastrophe,\" Treasury Secretary Janet Yellen wrote in an op-ed in the Wall Street Journal last week.\nFederal Reserve Chair Jerome Powell also warned of the consequences of a failure to raise the debt ceiling during his post-FOMC meeting press conference last week.\n\"It's just very important that the debt ceiling be raised in a timely fashion so that the United States can pay its bills when and as they come due. That's a critically important thing,\" he said. \"The failure to do that is something that could result in severe reactions, severe damage to the economy and to the financial markets ... no one should assume that the Fed or anyone else can protect the markets or the economy in the event of a failure.\"\nA dead Elm tree is removed on the West Front of the Capitol in Washington, Friday, Sept. 10, 2021. (AP Photo/J. Scott Applewhite)ASSOCIATED PRESS\nAmid the standoff, the Office of Management and Budget began warning federal agencies last week to prepare for a potential government shutdown. The reminder served as a standard warning one week out from Congress's deadline to reach an agreement to at least temporarily continue funding the government.\nThough leaders of both political parties have agreed that a continuing resolution to avoid the shutdown at the end of the month is needed, the ongoing tension over raising the debt limit has served as a potential roadblock in this effort.\n\"We still expect Congress to avert a partial government shutdown at the start of October. Republicans won’t vote for the current continuing resolution being touted by the Democratic leadership, which also includes a new debt ceiling suspension,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note Friday. \"But we expect a Plan B to emerge next week with the latter stripped out, which Republicans will support.\"\n\"The bigger issue is that there doesn’t appear to be an easy path to raising the debt ceiling by mid-October, which is when estimates suggest the Treasury’s will exhaust the 'extraordinary measures it is currently using to keep the lights on,\" he added.\nInvestors have also grown jittery as the debates wore on, with stocks posting their worst day since May last week amid a confluence of concerns that also included debt concerns with China Evergrande.\nMany strategists, however, have suggested market participants need not be overly concerned about the impacts of a potential government shutdown.\n\"Historically, we've seen that government shutdowns tend to be short-lived,\" Jordan Jackson, JPMorgan Asset Management global market strategist, told Yahoo Finance Live on Friday. \"We also know that for those non-essential federal employees, they do get furlough pay as well.\"\n\"If it lasts more than 30 days, it's certainly going to have a bigger impact on the economy. But generally speaking, these shutdowns tend to be short-lived and markets — while they may correct in the short-term — they do sort of continue to grind higher,\" he added. \"I think it's certainly a risk in terms of a short-term mini correction there. But again, with all the liquidity out there, I think any sort of blip in the markets will be short-lived.\"\nHistorical equity performance during and immediately following a government shutdown has also tended to point to a muted market impact.\n\"In the 14 government shutdowns since 1980, the S&P 500 generated median returns of -0.1% on the dates of budget authority expiration, 0.1% during the shutdown periods, and 0.3% on the dates of resolution,\" David Kostin, Goldman Sachs chief equity strategist, wrote in a note published on Sept. 21.\n\"One notable exception was the most recent federal shutdown in December 2018, when the S&P 500 fell 2% on the spending authority expiration date,\" he added. \"However, this decline was likely driven primarily by investor concerns about Fed tightening.\"\nKostin also noted that the typical government shutdown since 1980 has only lasted three days before ultimately being resolved. More recent shutdowns have lasted several times longer, however, with the duration of the four most recent federal shutdowns averaging 18 days, Kostin said.\nConsumer confidence\nOn the economic data front, one of the most closely watched new pieces of data will be on consumer confidence.\nThe Conference Board is set to release its September consumer confidence index Tuesday morning. Economists expect the index to tick up only slightly compared to August, with consumers' views on the coronavirus and rising prices stabilizing near the lowest level since February.\nSpecifically, consensus economists are looking for the index to rise to 115.0 in September after dropping to 113.8 in August. During the last monthly report, consumers' assessments of current business and labor market conditions both eased, and expectations for the next six months out also deteriorated.\n\"Consumer confidence fell to a six-month low in August, due to concerns around the Delta variant and inflation,\" wrote Bank of America economist Michelle Meyer in a note on Friday. \"We think these concerns largely remained in September.\"\nAt the time, Lynn Franco, senior director of economic indicators at the Conference Board, said it was still \"too soon to conclude\" whether decline in consumer confidence would \"result in consumers significantly curtailing their spending in the months ahead.\"\nThe latest spending data has also been equivocal. The Commerce Department's latest report showed retail sales rose 0.7% in August after declining in July. However, the categories posting the biggest declines were areas like e-commerce shops and grocery stores, suggesting consumer behavior was shifting back toward stay-in-place trends and away from in-person events like restaurant dining amid the latest wave of the coronavirus.\nEconomic calendar\n\nMonday: Durable goods orders, August preliminary (0.6% expected, -0.1% in July); Durable goods excluding transportation, August preliminary (0.5% expected, 0.8% in July); Non-defense capital goods orders excluding aircraft, August preliminary (0.3% expected, 0.1% in July); Non-defense capital goods orders excluding aircraft, August preliminary (0.9% in July); Dallas Fed Manufacturing Activity Index, September (11.0 expected, 9.0 in July)\nTuesday: Advance goods trade balance, August (-$87.0 billion expected, -$86.4 billion in July); Wholesale inventories, month-over-month, August preliminary (0.6% in July); Retail inventories, month-over-month, August (0.4% in July); FHFA House Price Index, month-over-month, July (1.5% expected, 1.6% in July); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, July (1.62% expected, 1.77% in June); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, July (20.1% expected, 19.08% in June); Conference Board Consumer Confidence Index, September (114.2 expected, 113.8 in August); Richmond Fed Manufacturing Index, September (9 in August)\nWednesday: MBA Mortgage Applications, week ended September 24 (4.9% during prior month); Pending home sales, month-over-month, August (1.0% expected, -1.8% in July)\nThursday: Initial jobless claims, week ended September 25 (320,000 expected, 351,000 during prior week); Continuing claims, week ended September 18 (2.845 million during prior week); GDP annualized, quarter-over-quarter, second-quarter third estimate (6.7% expected, 6.6% in prior estimate); Personal consumption, second-quarter third estimate (11.9% in prior estimate); Core personal consumption expenditures, second quarter third estimate (6.1% in prior estimate); MNI Chicago PMI, September (65.0 expected, 66.8 in August)\nFriday: Personal income, August (0.2% expected, 1.1% in July); Personal spending, August (0.7% expected, 0.3% in July); Personal consumption expenditures core deflator, month-over-over, August (0.2% expected, 0.3% in July); Personal consumption expenditures core deflator, year-over-year, August (3.6% expected, 3.6% in July); Markit manufacturing PMI, September final (60.5 in prior estimate); Construction spending, month-over-month, August (0.3% expected, 0.3% in July); University of Michigan sentiment, September final (71.0 expected, 71.0 in prior print); ISM Manufacturing, September (59.5 expected, 59.9 in August)\n\nEarnings calendar\n\nMonday: Aurora Cannabis (ACB) after market close\nTuesday: Micron Technology (MU) after market close.\nWednesday: No notable reports scheduled for release\nThursday: CarMax (KMX), Bed Bath & Beyond (BBBY) before market open; Jefferies (JEF) after market close\nFriday: No notable reports scheduled for releas","news_type":1,"symbols_score_info":{"SPY.AU":0.9}},"isVote":1,"tweetType":1,"viewCount":2139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861380860,"gmtCreate":1632457098750,"gmtModify":1632465444190,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/861380860","repostId":"2169240695","repostType":4,"isVote":1,"tweetType":1,"viewCount":2407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869578979,"gmtCreate":1632311053491,"gmtModify":1632801348195,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/869578979","repostId":"1146187405","repostType":4,"isVote":1,"tweetType":1,"viewCount":1734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885606281,"gmtCreate":1631781412643,"gmtModify":1631890460940,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/885606281","repostId":"1195990706","repostType":4,"repost":{"id":"1195990706","kind":"news","pubTimestamp":1631781148,"share":"https://www.laohu8.com/m/news/1195990706?lang=zh_CN&edition=full","pubTime":"2021-09-16 16:32","market":"us","language":"en","title":"3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195990706","media":"Motley Fool","summary":"Here are three healthcare stocks as nominees for a quick double in 2021.","content":"<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p><p><blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote></p><p> Read more to find out why we think&nbsp;<b>Novavax</b>(NASDAQ:NVAX),&nbsp;<b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and&nbsp;<b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p><p><blockquote>阅读更多内容，了解我们为什么认为<b>Novavax</b>（纳斯达克：NVAX），<b>索伦托治疗公司</b>（纳斯达克：SRNE），以及<b>InMode</b>（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p><p><blockquote><b>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</b></blockquote></p><p> <b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote></p><p> Right now,<b>Moderna</b>&nbsp;enjoys a $169 billion market cap, and&nbsp;<b>BioNTech</b>&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p><p><blockquote>现在，<b>现代</b>市值为1690亿美元，<b>BioNTech</b>估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote></p><p> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p><p><blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote></p><p> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.</p><p><blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote></p><p> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p><p><blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和初始疫苗受到世界上大多数未接种疫苗的人的欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote></p><p> <b>2. Sorrento Therapeutics: Don't sleep on this name</b></p><p><blockquote><b>2.Sorrento Therapeutics：别睡在这个名字上</b></blockquote></p><p> <b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.</p><p><blockquote><b>George Budwell（索伦托治疗公司）：</b>由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote></p><p> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p><p><blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote></p><p> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p><p><blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote></p><p> <b>3. InMode stock will spike as the world reopens</b></p><p><blockquote><b>3.随着世界重新开放，InMode股票将飙升</b></blockquote></p><p></p><p> <b>Patrick Bafuma</b>&nbsp;<b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p><p><blockquote><b>帕特里克·巴富马</b> <b>（在模式中）：</b>随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote></p><p> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p><p><blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote></p><p> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p><p><blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote></p><p> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p><p><blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote></p><p> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p><p><blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote></p><p> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p><p><blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Might Double Soon<blockquote>3只可能很快翻倍的新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-16 16:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p><p><blockquote>短期内任何事情都可能发生，所以说一只股票肯定会快速翻倍是愚蠢的。尽管如此，这些Fool.com撰稿人还是看好这三只医疗保健股，并且有理由保持短期乐观。</blockquote></p><p> Read more to find out why we think&nbsp;<b>Novavax</b>(NASDAQ:NVAX),&nbsp;<b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and&nbsp;<b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p><p><blockquote>阅读更多内容，了解我们为什么认为<b>Novavax</b>（纳斯达克：NVAX），<b>索伦托治疗公司</b>（纳斯达克：SRNE），以及<b>InMode</b>（纳斯达克：INMD）将轰轰烈烈地结束2021年。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p><p><blockquote><b>一、多重催化剂让诺瓦瓦克斯股价在2021年大涨</b></blockquote></p><p> <b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p><p><blockquote><b>泰勒·卡迈克尔（Novavax）：</b>Novavax股价今年已经翻了一番，从1月份的112美元上涨至本周的233美元。但是油箱里还有很多油，我预计到今年年底还会增加一倍。</blockquote></p><p> Right now,<b>Moderna</b>&nbsp;enjoys a $169 billion market cap, and&nbsp;<b>BioNTech</b>&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p><p><blockquote>现在，<b>现代</b>市值为1690亿美元，<b>BioNTech</b>估值为790亿美元。与此同时，Novavax的市值为170亿美元，非常便宜。当然，不同之处在于，mRNA生物技术公司的两种COVID-19疫苗现在都已上市，而Novavax仍在等待其首次紧急使用授权。但当政府机构开始允许Novavax分发其COVID-19疫苗时，该股将真正开始飙升。</blockquote></p><p> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p><p><blockquote>世界上大多数人口仍然没有接种疫苗。Novavax将在2022年准备分发20亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote></p><p> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.</p><p><blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。这相当于每剂13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将被打折。Novavax明年的收入完全有可能高于今天的市值。</blockquote></p><p> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p><p><blockquote>随着Novavax的疫苗在第四季度开始在全球获得授权，我预计Novavax的股价将飙升。Novavax的候选疫苗将作为加强注射和初始疫苗受到世界上大多数未接种疫苗的人的欢迎。Novavax在将COVID-19疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们通过一次注射接种了这两种疾病的疫苗。</blockquote></p><p> <b>2. Sorrento Therapeutics: Don't sleep on this name</b></p><p><blockquote><b>2.Sorrento Therapeutics：别睡在这个名字上</b></blockquote></p><p> <b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.</p><p><blockquote><b>George Budwell（索伦托治疗公司）：</b>由于其令人印象深刻的实验性COVID-19诊断和生物疗法阵容，临床阶段生物技术Sorrento Therapeutics去年声名鹊起。事实上，该生物技术公司的股票从2020年1月到2021年3月上涨了144%，主要是因为其广泛的COVID-19候选疫苗。然而，索伦托的股价在过去180天里已经下跌了近四分之一。鉴于该公司无法将其各种COVID-19候选疫苗中的一种推向美国市场，投资者显然已经转向了更好的领域。</blockquote></p><p> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p><p><blockquote>核心问题是，过去几个月，多家生物制药公司在美国和欧盟等主要市场成功开发并随后营销了COVID-19疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎极有可能演变成季节性呼吸道疾病。因此，投资者不一定应该注销索伦托等后来者。最终，该公司可以从COVID-19诊断和/或治疗中实现健康的收入流。</blockquote></p><p> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p><p><blockquote>Sorrento的COVID-19候选疫苗完全有可能在下一个日历年内在美国获得多项监管部门的批准，这对其股票来说将是一个重大利好。也就是说，在该公司在COVID-19领域获得美国食品和药物管理局的批准之前，这只中型生物技术股票肯定会保持波动。相应地投资。</blockquote></p><p> <b>3. InMode stock will spike as the world reopens</b></p><p><blockquote><b>3.随着世界重新开放，InMode股票将飙升</b></blockquote></p><p></p><p> <b>Patrick Bafuma</b>&nbsp;<b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p><p><blockquote><b>帕特里克·巴富马</b> <b>（在模式中）：</b>随着世界重新开放，人们聚在一起感觉更舒服，美学市场肯定会升温。这就是为什么我选择InMode作为COVID-19疫苗库存翻倍的公司，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，具有很强的品牌认知度。</blockquote></p><p> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p><p><blockquote>该公司采用剃须刀和刀片模式，销售医疗设备系统和相关消耗品，为身体塑形提供能源。InMode被多位医学专家使用，包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生，声称其程序比激光治疗更持久，比吸脂术等典型的塑身程序侵入性更小。</blockquote></p><p> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p><p><blockquote>这家价值52亿美元的美学公司正在全力以赴。在最近一个季度，InMode报告收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外的总销售额为3090万美元，是去年同期的三倍多。这种快速的国际增长占其总收入的35%，而2020年第二季度这一比例为22%。该公司目前在68个国家开展业务，拥有持续增长的巨大空间。</blockquote></p><p> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p><p><blockquote>随着世界慢慢恢复正常，消费者正在寻求因COVID-19而推迟的治疗方法。“我们的需求很强劲，”首席医疗官Spero Theodorou在上次电话会议上指出。“整个九月都很稳定。等待名单……大约还有一个月。”</blockquote></p><p> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p><p><blockquote>Theodorou接着说，“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了塑身市场，尽管有新冠肺炎疫情，该市场在2020年全球已达到62亿美元。预计到2026年，该市场将以7.2%的复合年增长率增长，因此InMode有很大的发展空间。</blockquote></p><p> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p><p><blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美容设备制造商将继续增长。尽管InMode自2021年初以来已上涨超过180%，但该公司拥有巨大的跑道，其剃须刀和刀片业务模式仍然是有效的定位策略。InMode已经实现盈利，第二季度调整后稀释每股收益为1.02美元，而2020年同季度稀释后每股收益为0.24美元。InMode的股价似乎将再次翻倍。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SRNE":"索伦托医疗","NVAX":"诺瓦瓦克斯医药","INMD":"InMode Ltd."},"source_url":"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195990706","content_text":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.\nRead more to find out why we think Novavax(NASDAQ:NVAX), Sorrento Therapeutics(NASDAQ:SRNE), and InMode(NASDAQ:INMD)will close out 2021 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\n1. Multiple catalysts will make Novavax shares jump in 2021\nTaylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.\nRight now,Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.\nThe majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.\nThe U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.\nI'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.\n2. Sorrento Therapeutics: Don't sleep on this name\nGeorge Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.\nThe core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.\nIt is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.\n3. InMode stock will spike as the world reopens\nPatrick Bafuma (InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.\nUsing a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.\nAnd this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.\nAs the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"\nTheodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.\nWith many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.","news_type":1,"symbols_score_info":{"NVAX":0.9,"SRNE":0.9,"INMD":0.9}},"isVote":1,"tweetType":1,"viewCount":1540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880975296,"gmtCreate":1631015771215,"gmtModify":1631892389018,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/880975296","repostId":"1130130857","repostType":4,"repost":{"id":"1130130857","kind":"news","pubTimestamp":1631007146,"share":"https://www.laohu8.com/m/news/1130130857?lang=zh_CN&edition=full","pubTime":"2021-09-07 17:32","market":"us","language":"en","title":"Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?<blockquote>策略师表示，今年秋天股市可能会陷入困境。现在买什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130130857","media":"Barron's","summary":"What a year this has been for the markets!Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and  a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnin","content":"<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&amp;P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.</p><p><blockquote>对于市场来说，这是多么美好的一年啊！在货币和财政刺激、经济和盈利增长以及（直到最近）疫情基本消退的推动下，标准普尔500股票指数已上涨20%，连续七个月上涨，并创下50多个高点。除此之外，去年市场从2020年3月的低点反弹了68%。</blockquote></p><p> Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.</p><p><blockquote>顺风依然存在，但逆风现在迫在眉睫，可能会减缓股市的上涨。刺激支出已经见顶，经济和企业盈利增长可能会在今年年底放缓。此外，美联储几乎承诺在未来几个月开始缩减债券购买规模，拜登政府也提议提高企业和个人税率。这些都不会让股价越来越贵的持有者满意。</blockquote></p><p> In other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”</p><p><blockquote>换句话说，要做好迎接波动性下跌的准备，这种冲突迫使巴菲特股票、债券和投资者。Nuveen全球股票首席投资官Saira Malik表示：“一切反弹都已经过去。”“这不会是一场急剧上升的经济浪潮，将所有船只从这里抬起。”</blockquote></p><p> That’s the general consensus among the six market strategists and chief investment officers whom<i>Barron’s</i>recently consulted. All see the S&amp;P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.</p><p><blockquote>这是六位市场策略师和首席投资官的普遍共识<i>巴伦周刊</i>最近咨询过。所有人都认为标普500将在周四收盘价4536点附近结束今年。他们的平均目标是：4585。</blockquote></p><p> Next year’s gains look muted, as well, relative to recent trends. The group expects the S&amp;P 500 to tack on another 6% in 2022, rising to about 4800.</p><p><blockquote>相对于最近的趋势，明年的涨幅看起来也很微弱。该集团预计2022年标普500将再增加6%，升至约4800。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/eb61c7b74b9b0f18a019afb4ac44ad59\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">With stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.</p><p><blockquote>由于股票交易价格约为来年预期收益的21倍，债券收益率很低，考虑通货膨胀后现金收益率低于零，投资者面临着艰难的资产配置决策。我们的市场观察人士建议关注“优质”投资，而不是提振快速增长的科技股、无增长的模因股和数字世界的狗狗币的“一切反弹”。在股票方面，这意味着拥有稳健的资产负债表、不断扩大的利润率以及充足且经常性的自由现金流的企业的股票。即使未来几个月平均指数表现不大，这些股票也可能会大放异彩。</blockquote></p><p> The stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.</p><p><blockquote>过去一年股市的大幅上涨是美联储的一份礼物，美联储向金融体系注入了大量资金，以避免新冠疫情造成的经济损失。自2020年3月以来，美联储每月购买总计1200亿美元的美国国债和抵押贷款支持证券，同时将基准联邦基金利率目标维持在0%至0.25%。这些举措压低了债券收益率，并推动投资者进入包括股票在内的风险较高的资产。</blockquote></p><p> Fed Chairman Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”</p><p><blockquote>美联储主席杰罗姆<a href=\"https://laohu8.com/S/POWL\">鲍威尔</a>曾表示，央行可能会在未来几个季度的某个时候开始逐步减少或缩减紧急资产购买，此举可能会扰乱各类风险资产。摩根士丹利(Morgan Stanley)首席投资官兼首席美国股票策略师威尔逊(Mike Wilson)表示：“对我们来说，缩减规模很简单：缩减规模就是紧缩。这是（美联储）距离最大限度宽松政策迈出的第一步。他们这次对此非常谨慎，但底线是，这应该会对股票估值产生负面影响。”</blockquote></p><p> The government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.</p><p><blockquote>策略师指出，政府的刺激支出也已见顶。每周300美元的补充联邦失业救济金将于9月6日到期。尽管国会似乎有可能在今年秋天通过一项两党基础设施法案，但与2020年3月以来推出的多轮刺激措施相比，近期的经济影响将相形见绌。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c2cb76c498c1c4c980139e3d0514c261\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">The bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.</p><p><blockquote>该法案包括约5500亿美元的新支出——只是之前法律授权的数万亿美元的一小部分——并且将分散在许多年内。基础设施刺激措施将给消费者支出带来的短期提振，占美国国内生产总值增长的近70%，但不会接近去年数百万美国人收到政府支票后的经济增长。</blockquote></p><p> A budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.</p><p><blockquote>仅由民主党批准的预算法案应该遵循基础设施法案，并包括支持医疗保险扩张、儿童保育资金、免费社区大学学费、公共住房和气候相关措施以及其他政党优先事项的支出。国会可能会投票提高企业和高收入个人的税收，以抵消这些支出——这是市场面临的另一个近期风险。</blockquote></p><p></p><p> <img src=\"https://static.tigerbbs.com/6693da658db16059fc99e08a7531675f\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">Other politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a <a href=\"https://laohu8.com/S/WASH\">Washington</a> shutdown in October.</p><p><blockquote>今年秋天，其他带有政治色彩的问题同样可能会让股市脱轨。国会需要通过提高债务上限来为政府提供资金，并在本月晚些时候通过一项权宜之计的支出法案来避免<a href=\"https://laohu8.com/S/WASH\">华盛顿州</a>10月停工。</blockquote></p><p> For now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.</p><p><blockquote>目前，我们的市场专家对Covid-19德尔塔变异毒株的经济影响相对乐观。他们说，只要疫苗在最大限度地减少导致住院和死亡的严重感染方面仍然有效，当前Covid浪潮的负面影响将主要限于旅游业和电影院。华尔街对市场的基本假设不包括会破坏经济增长的新一波封锁。</blockquote></p><p> Inflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.</p><p><blockquote>通胀一直是美联储和投资者的热门话题，部分原因是通胀最近非常火爆。6月和7月，美国消费者价格指数年化涨幅为5.4%，这是美联储评级暂时性的飙升，尽管其他人不太确定。策略师们站在鲍威尔一边。他们预计明年通胀将大幅下降。他们的预测在2.5%至3.5%之间，他们认为这对消费者和公司来说是可控的，也是经济快速增长的可接受的副作用。然而，通胀率高于2.5%，加上美联储缩减规模，意味着目前超低的债券收益率应该会上升。</blockquote></p><p> “We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”</p><p><blockquote>收益投资主管迈克尔·弗雷德里克斯(Michael Fredericks)表示：“我们认为通胀将继续比金融危机以来更高，但一旦许多与重新开放相关的压力开始消散，我们很难看到通胀率远高于2.5%。”贝莱德多资产策略集团。“因此债券收益率确实需要上升，但这将逐渐发生。”</blockquote></p><p> The strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for&nbsp;the bond market—and could be even more so for stocks.</p><p><blockquote>策略师预计，到年底，10年期美国国债收益率将攀升至1.65%左右。这比当前水平高出约35个基点（即百分之几个百分点），但低于2021年3月收益率高点时达到的1.75%。该组织表示，到明年，10年期国债收益率可能达到2%。从绝对值来看，这些举措并不是很大，但对债券市场来说意义重大，对股票来说可能更是如此。</blockquote></p><p> Rising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&amp;P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.</p><p><blockquote>收益率上升往往会打压股票估值，原因有二。高收益债券提供了与股票的竞争，当以更高的利率贴现时，公司的未来收益在目前毫无价值。尽管如此，2%左右的10年期国债收益率仍不足以将股票估值降至新冠疫情爆发前的水平。即使收益率攀升，市场策略师认为标普500的市盈率仍远高于预期市盈率16倍的30年平均水平。去年秋天，该指数的远期市盈率突破23。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e08d24cb421d7cc13debd76a9c6fea01\" tg-width=\"660\" tg-height=\"434\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> As long as 10-year Treasury yields stay in the 2% range, the S&amp;P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.</p><p><blockquote>策略师表示，只要10年期国债收益率保持在2%的范围内，标普500的远期市盈率就应该能够在十几岁左右。除非收益率高得多或其他导致股市下跌的因素带来更大压力，否则不可能回到16倍的长期平均水平。</blockquote></p><p> If yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says&nbsp;<a href=\"https://laohu8.com/S/STT\">State</a> Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”</p><p><blockquote>表示，如果收益率飙升超过2%或2.25%，投资者可能会开始更严重地质疑股票估值<a href=\"https://laohu8.com/S/STT\">国家</a>Street首席投资组合策略师Gaurav Mallik：“我们已经有一段时间没有看到（10年期国债收益率）超过2%了，因此这对投资者来说是一个重要的情绪水平。”</blockquote></p><p> <img src=\"https://static.tigerbbs.com/93ff6490069ab5dc1b4057f1ff7966f3\" tg-width=\"664\" tg-height=\"441\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Wilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says</p><p><blockquote>威尔逊更担心，他指出，股市的估值风险是不对称的：“市盈率不太可能上升，考虑到增长放缓和我们所处的位置，市盈率很有可能下降10%以上。在周期中，”他说</blockquote></p><p> If 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”</p><p><blockquote>他补充道，如果预期市盈率为16至23倍，“你已经处于这个范围的很高端。潜在风险大于回报。”</blockquote></p><p> Some P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&amp;P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.</p><p><blockquote>所有六位策略师的预测都包含了一些市盈率倍数的压缩，这对利润增长的路径变得更加重要。平均而言，策略师预计，继去年的盈利低迷之后，标普500今年的盈利将增长46%，至204美元左右。随后，2022年可能会上涨9%，达到约222.50美元。</blockquote></p><p></p><p> A potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.</p><p><blockquote>一个潜在的阻力是2022年联邦企业税率上升。民主党支出和税收计划的细节将在未来几周内制定出来，投资者可以期待听到更多有关潜在增税的消息。几位策略师认为，25%的联邦企业利润税率可能是一个妥协数字，高于2018年以来实施的21%，但低于拜登政府寻求的28%。</blockquote></p><p> An increase of that magnitude would shave about 5% off S&amp;P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time event for the market, some strategists predict.</p><p><blockquote>如此幅度的增长将使标普500明年的盈利减少约5%。随着今年秋天民主党和解法案的通过，该指数可能会下跌类似的幅度，但影响应该仅限于最初的调整。与2017年12月的减税一样，这一变化应该是<a href=\"https://laohu8.com/S/AONE.U\">一</a>——一些策略师预测，市场的时间事件。</blockquote></p><p> These concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.</p><p><blockquote>抛开这些担忧不谈，投资者不应错过更大的图景：美国经济状况良好，增长强劲。策略师预计今年国内生产总值将增长6.3%，2022年将增长约4%。Mallik表示：“周期性上涨和高于趋势的增长将至少持续到2022年，我们希望偏向于具有这种风险的资产。”</blockquote></p><p>   “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets  The State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.</p><p><blockquote>“今明两年我们的经济将会火爆。当GDP增长高于平均水平时，价值会战胜增长，周期性会战胜防御性。”—Lori Calvasina，加拿大皇家银行资本市场道富策略师建议在投资组合中增持材料、金融和科技股。这种方法既包括银行和矿业公司等对经济敏感的公司，也包括科技行业的稳定增长者。</blockquote></p><p> RBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.</p><p><blockquote>加拿大皇家银行资本市场(RBC Capital Markets)美国股票策略主管洛里·卡尔瓦西纳(Lori Calvasina)同样采取杠铃法，同时投资周期性和成长性。她最喜欢的行业是能源、金融和技术。</blockquote></p><p> “Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”</p><p><blockquote>卡尔瓦西纳表示：“金融和能源行业的估值仍然比增长行业（科技或非必需消费品等行业）更具吸引力。”“近期的催化剂是摆脱当前的新冠疫情浪潮……今年和明年我们将迎来经济火爆，传统上，当GDP增长高于平均水平时，价值会跑赢增长，周期性会跑赢防御性。”</blockquote></p><p> But the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.</p><p><blockquote>但对质量的关注将是关键，尤其是进入2022年下半年。届时美联储可能会在本周期内首次加息。到2023年，经济可能会恢复到新冠疫情前2%左右的增长。</blockquote></p><p> “The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”</p><p><blockquote>卡尔瓦西纳表示：“历史上的剧本是，走出衰退后，你往往会看到持续一年左右的低质量优异表现，然后领导力又会恢复到高质量。”“但从低质量回到高质量的转变往往非常坎坷。”</blockquote></p><p> <b>A Shopping List for Fall</b></p><p><blockquote><b>秋季购物清单</b></blockquote></p><p> Most strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.</p><p><blockquote>大多数策略师青睐对经济敏感的股票和稳定增长的股票（包括科技股）的组合。金融股应该会表现良好，特别是如果债券收益率上升的话。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a54c4bd114c1a5f7f700d1fc14d30d8e\" tg-width=\"970\" tg-height=\"230\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Although stocks with quality attributes have outperformed the market this summer, according to a <a href=\"https://laohu8.com/S/BLK\">BlackRock</a> analysis, the quality factor has lagged since positive vaccine news was first reported last November.</p><p><blockquote>尽管今年夏天具有质量属性的股票表现优于大盘，但根据一家<a href=\"https://laohu8.com/S/BLK\">贝莱德</a>分析，自去年11月首次报道疫苗正面消息以来，质量因素一直滞后。</blockquote></p><p> “We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”</p><p><blockquote>贝莱德的弗雷德里克斯表示：“我们正在进入周期中期环境，基本经济增长仍然强劲，但势头开始减速。”“我们的研究表明，优质股票在这样的时期表现尤其出色。”</blockquote></p><p> He recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.</p><p><blockquote>他建议增持盈利的科技公司；金融，包括银行，以及具有这些质量特征的消费品和工业。</blockquote></p><p> For <a href=\"https://laohu8.com/S/WFC\">Wells Fargo</a>’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.</p><p><blockquote>为了<a href=\"https://laohu8.com/S/WFC\">富国银行</a>股票策略主管克里斯托弗·哈维(Christopher Harvey)表示，大流行后受益者和防御性敞口的结合才是正确的选择。他构建了一篮子波动性低于平均水平的股票——在今年秋季市场不确定性或压力时期，这些股票应该会跑赢大盘——并且“新冠贝塔值”较高，即对有关大流行的好消息或坏消息的敏感性。一个要求；富国银行的股票分析师必须将这些股票评级为“买入”。</blockquote></p><p> “There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”</p><p><blockquote>哈维表示：“近期经济存在不确定性、利率不确定性和新冠病毒风险，一般来说，我们正处于9月份左右的季节性疲软时期。”“如果我们能够平衡低波动性和高新贝塔值，我们就可以减轻其中几种催化剂时机即将到来的不确定性和波动性。不过，从长远来看，我们仍然希望[重新开放风险。]”</blockquote></p><p></p><p> Harvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>(BAC),<a href=\"https://laohu8.com/S/NTRSP\">Northern</a> Trust(NTRS),Lowe’s(LOW),<a href=\"https://laohu8.com/S/IQV\">IQVIA</a> Holdings(IQV), andMasco(MAS).</p><p><blockquote>哈维列出的具有高新贝塔值的低波动性股票名单包括苹果(AAPL)、<a href=\"https://laohu8.com/S/BAC\">美国银行</a>（BAC），<a href=\"https://laohu8.com/S/NTRSP\">北方的</a>信托(NTRS)、劳氏(LOW)、<a href=\"https://laohu8.com/S/IQV\">IQVIA</a>控股公司（IQV）和马斯科公司（MAS）。</blockquote></p><p> Overall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.</p><p><blockquote>总体而言，银行是未来几个月最常被推荐的群体。Invesco KBW银行交易所交易基金(KBWB)提供对美国该行业的广泛投资。</blockquote></p><p> “We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.</p><p><blockquote>“我们喜欢估值和信用质量；他们现在被允许回购股票并增加股息，而且新冠贝塔值更高，”哈维说。</blockquote></p><p> Cheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.</p><p><blockquote>较低的估值意味着市场调整中潜在的下行空间较小。而且，与股市的其他大部分地区相反，更高的利率将成为银行的顺风车，银行可能会收取更高的贷款费用。</blockquote></p><p> <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> stocks also have some fans. “<a href=\"https://laohu8.com/S/HR\">Healthcare</a> has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> analysts and fitting his macro views.</p><p><blockquote><a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>股票也有一些粉丝。”<a href=\"https://laohu8.com/S/HR\">医疗保健</a>具有防御性和成长性，”威尔逊说。“如今，医疗保健行业每单位增长支付的费用比其他行业低得多。因此，我们认为，当我们担心估值时，它为这个市场提供了良好的平衡。”健康保险公司Humana(HUM)跻身威尔逊“新鲜资金买入名单”股票买入评级<a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>分析师并符合他的宏观观点。</blockquote></p><p> Nuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.</p><p><blockquote>Nuveen的Malik还将目光投向医疗保健领域，以获得相对低估的增长机会，即制药和生物技术领域。她指出了Seagen(SGEN)，该公司专注于肿瘤药物，可能成为制药巨头有吸引力的收购目标。</blockquote></p><p> Malik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.</p><p><blockquote>马利克还喜欢艾伯维(ABBV)，该公司的预期市盈率为8倍，股息收益率为4.7%。其重磅抗炎药修美乐(Humira)的专利即将到期，这让一些投资者望而却步，但马利克相信管理层能够限制损失，并看到这家价值2000亿美元的公司正在开发有前途的药物。</blockquote></p><p> Both stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of <a href=\"https://laohu8.com/S/ABBV\">AbbVie</a>’s most promising post-Humira products.</p><p><blockquote>这两只股票最近几天都过得很艰难。Seagen上周跌超8%，报152美元左右，因有消息称其联合创始人兼首席执行官近期大量抛售股票。在美国食品和药物管理局要求为JAK抑制剂贴上新的警告标签后，ABBVIE周三上涨7%，至112.27美元。JAK抑制剂是一种抗类风湿药物，其中包括一种<a href=\"https://laohu8.com/S/ABBV\">艾伯维</a>最有前途的后修美乐产品。</blockquote></p><p> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>(PFE),<a href=\"https://laohu8.com/S/AXP\">American Express</a>(AXP),Johnson &amp; Johnson(JNJ), andCisco Systems(CSCO) are other S&amp;P 500 members that pass a<i>Barron’s</i>screen for quality attributes.</p><p><blockquote><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>（PFE），<a href=\"https://laohu8.com/S/AXP\">美国运通</a>(AXP)、强生(JNJ)和思科系统(CSCO)是其他通过A的标普500成员<i>巴伦周刊</i>筛选质量属性。</blockquote></p><p> After a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. <a href=\"https://laohu8.com/S/JE\">Just</a> be more selective. And go with quality.</p><p><blockquote>经过一年的稳定上涨后，今年秋天投资者可能会被提醒，随着增长势头和政策支持开始消退，股市也可能下跌。但如果市场从高点下跌，潜在的经济实力支持逢低买入。<a href=\"https://laohu8.com/S/JE\">刚刚</a>更有选择性。追求质量。</blockquote></p><p></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?<blockquote>策略师表示，今年秋天股市可能会陷入困境。现在买什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStrategists Say the Stock Market Could Struggle This Fall. What to Buy Now?<blockquote>策略师表示，今年秋天股市可能会陷入困境。现在买什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barron's</strong><span class=\"h-time small\">2021-09-07 17:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&amp;P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.</p><p><blockquote>对于市场来说，这是多么美好的一年啊！在货币和财政刺激、经济和盈利增长以及（直到最近）疫情基本消退的推动下，标准普尔500股票指数已上涨20%，连续七个月上涨，并创下50多个高点。除此之外，去年市场从2020年3月的低点反弹了68%。</blockquote></p><p> Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.</p><p><blockquote>顺风依然存在，但逆风现在迫在眉睫，可能会减缓股市的上涨。刺激支出已经见顶，经济和企业盈利增长可能会在今年年底放缓。此外，美联储几乎承诺在未来几个月开始缩减债券购买规模，拜登政府也提议提高企业和个人税率。这些都不会让股价越来越贵的持有者满意。</blockquote></p><p> In other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”</p><p><blockquote>换句话说，要做好迎接波动性下跌的准备，这种冲突迫使巴菲特股票、债券和投资者。Nuveen全球股票首席投资官Saira Malik表示：“一切反弹都已经过去。”“这不会是一场急剧上升的经济浪潮，将所有船只从这里抬起。”</blockquote></p><p> That’s the general consensus among the six market strategists and chief investment officers whom<i>Barron’s</i>recently consulted. All see the S&amp;P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.</p><p><blockquote>这是六位市场策略师和首席投资官的普遍共识<i>巴伦周刊</i>最近咨询过。所有人都认为标普500将在周四收盘价4536点附近结束今年。他们的平均目标是：4585。</blockquote></p><p> Next year’s gains look muted, as well, relative to recent trends. The group expects the S&amp;P 500 to tack on another 6% in 2022, rising to about 4800.</p><p><blockquote>相对于最近的趋势，明年的涨幅看起来也很微弱。该集团预计2022年标普500将再增加6%，升至约4800。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/eb61c7b74b9b0f18a019afb4ac44ad59\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">With stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.</p><p><blockquote>由于股票交易价格约为来年预期收益的21倍，债券收益率很低，考虑通货膨胀后现金收益率低于零，投资者面临着艰难的资产配置决策。我们的市场观察人士建议关注“优质”投资，而不是提振快速增长的科技股、无增长的模因股和数字世界的狗狗币的“一切反弹”。在股票方面，这意味着拥有稳健的资产负债表、不断扩大的利润率以及充足且经常性的自由现金流的企业的股票。即使未来几个月平均指数表现不大，这些股票也可能会大放异彩。</blockquote></p><p> The stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.</p><p><blockquote>过去一年股市的大幅上涨是美联储的一份礼物，美联储向金融体系注入了大量资金，以避免新冠疫情造成的经济损失。自2020年3月以来，美联储每月购买总计1200亿美元的美国国债和抵押贷款支持证券，同时将基准联邦基金利率目标维持在0%至0.25%。这些举措压低了债券收益率，并推动投资者进入包括股票在内的风险较高的资产。</blockquote></p><p> Fed Chairman Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”</p><p><blockquote>美联储主席杰罗姆<a href=\"https://laohu8.com/S/POWL\">鲍威尔</a>曾表示，央行可能会在未来几个季度的某个时候开始逐步减少或缩减紧急资产购买，此举可能会扰乱各类风险资产。摩根士丹利(Morgan Stanley)首席投资官兼首席美国股票策略师威尔逊(Mike Wilson)表示：“对我们来说，缩减规模很简单：缩减规模就是紧缩。这是（美联储）距离最大限度宽松政策迈出的第一步。他们这次对此非常谨慎，但底线是，这应该会对股票估值产生负面影响。”</blockquote></p><p> The government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.</p><p><blockquote>策略师指出，政府的刺激支出也已见顶。每周300美元的补充联邦失业救济金将于9月6日到期。尽管国会似乎有可能在今年秋天通过一项两党基础设施法案，但与2020年3月以来推出的多轮刺激措施相比，近期的经济影响将相形见绌。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c2cb76c498c1c4c980139e3d0514c261\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">The bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.</p><p><blockquote>该法案包括约5500亿美元的新支出——只是之前法律授权的数万亿美元的一小部分——并且将分散在许多年内。基础设施刺激措施将给消费者支出带来的短期提振，占美国国内生产总值增长的近70%，但不会接近去年数百万美国人收到政府支票后的经济增长。</blockquote></p><p> A budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.</p><p><blockquote>仅由民主党批准的预算法案应该遵循基础设施法案，并包括支持医疗保险扩张、儿童保育资金、免费社区大学学费、公共住房和气候相关措施以及其他政党优先事项的支出。国会可能会投票提高企业和高收入个人的税收，以抵消这些支出——这是市场面临的另一个近期风险。</blockquote></p><p></p><p> <img src=\"https://static.tigerbbs.com/6693da658db16059fc99e08a7531675f\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">Other politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a <a href=\"https://laohu8.com/S/WASH\">Washington</a> shutdown in October.</p><p><blockquote>今年秋天，其他带有政治色彩的问题同样可能会让股市脱轨。国会需要通过提高债务上限来为政府提供资金，并在本月晚些时候通过一项权宜之计的支出法案来避免<a href=\"https://laohu8.com/S/WASH\">华盛顿州</a>10月停工。</blockquote></p><p> For now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.</p><p><blockquote>目前，我们的市场专家对Covid-19德尔塔变异毒株的经济影响相对乐观。他们说，只要疫苗在最大限度地减少导致住院和死亡的严重感染方面仍然有效，当前Covid浪潮的负面影响将主要限于旅游业和电影院。华尔街对市场的基本假设不包括会破坏经济增长的新一波封锁。</blockquote></p><p> Inflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.</p><p><blockquote>通胀一直是美联储和投资者的热门话题，部分原因是通胀最近非常火爆。6月和7月，美国消费者价格指数年化涨幅为5.4%，这是美联储评级暂时性的飙升，尽管其他人不太确定。策略师们站在鲍威尔一边。他们预计明年通胀将大幅下降。他们的预测在2.5%至3.5%之间，他们认为这对消费者和公司来说是可控的，也是经济快速增长的可接受的副作用。然而，通胀率高于2.5%，加上美联储缩减规模，意味着目前超低的债券收益率应该会上升。</blockquote></p><p> “We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”</p><p><blockquote>收益投资主管迈克尔·弗雷德里克斯(Michael Fredericks)表示：“我们认为通胀将继续比金融危机以来更高，但一旦许多与重新开放相关的压力开始消散，我们很难看到通胀率远高于2.5%。”贝莱德多资产策略集团。“因此债券收益率确实需要上升，但这将逐渐发生。”</blockquote></p><p> The strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for&nbsp;the bond market—and could be even more so for stocks.</p><p><blockquote>策略师预计，到年底，10年期美国国债收益率将攀升至1.65%左右。这比当前水平高出约35个基点（即百分之几个百分点），但低于2021年3月收益率高点时达到的1.75%。该组织表示，到明年，10年期国债收益率可能达到2%。从绝对值来看，这些举措并不是很大，但对债券市场来说意义重大，对股票来说可能更是如此。</blockquote></p><p> Rising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&amp;P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.</p><p><blockquote>收益率上升往往会打压股票估值，原因有二。高收益债券提供了与股票的竞争，当以更高的利率贴现时，公司的未来收益在目前毫无价值。尽管如此，2%左右的10年期国债收益率仍不足以将股票估值降至新冠疫情爆发前的水平。即使收益率攀升，市场策略师认为标普500的市盈率仍远高于预期市盈率16倍的30年平均水平。去年秋天，该指数的远期市盈率突破23。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e08d24cb421d7cc13debd76a9c6fea01\" tg-width=\"660\" tg-height=\"434\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> As long as 10-year Treasury yields stay in the 2% range, the S&amp;P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.</p><p><blockquote>策略师表示，只要10年期国债收益率保持在2%的范围内，标普500的远期市盈率就应该能够在十几岁左右。除非收益率高得多或其他导致股市下跌的因素带来更大压力，否则不可能回到16倍的长期平均水平。</blockquote></p><p> If yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says&nbsp;<a href=\"https://laohu8.com/S/STT\">State</a> Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”</p><p><blockquote>表示，如果收益率飙升超过2%或2.25%，投资者可能会开始更严重地质疑股票估值<a href=\"https://laohu8.com/S/STT\">国家</a>Street首席投资组合策略师Gaurav Mallik：“我们已经有一段时间没有看到（10年期国债收益率）超过2%了，因此这对投资者来说是一个重要的情绪水平。”</blockquote></p><p> <img src=\"https://static.tigerbbs.com/93ff6490069ab5dc1b4057f1ff7966f3\" tg-width=\"664\" tg-height=\"441\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Wilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says</p><p><blockquote>威尔逊更担心，他指出，股市的估值风险是不对称的：“市盈率不太可能上升，考虑到增长放缓和我们所处的位置，市盈率很有可能下降10%以上。在周期中，”他说</blockquote></p><p> If 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”</p><p><blockquote>他补充道，如果预期市盈率为16至23倍，“你已经处于这个范围的很高端。潜在风险大于回报。”</blockquote></p><p> Some P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&amp;P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.</p><p><blockquote>所有六位策略师的预测都包含了一些市盈率倍数的压缩，这对利润增长的路径变得更加重要。平均而言，策略师预计，继去年的盈利低迷之后，标普500今年的盈利将增长46%，至204美元左右。随后，2022年可能会上涨9%，达到约222.50美元。</blockquote></p><p></p><p> A potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.</p><p><blockquote>一个潜在的阻力是2022年联邦企业税率上升。民主党支出和税收计划的细节将在未来几周内制定出来，投资者可以期待听到更多有关潜在增税的消息。几位策略师认为，25%的联邦企业利润税率可能是一个妥协数字，高于2018年以来实施的21%，但低于拜登政府寻求的28%。</blockquote></p><p> An increase of that magnitude would shave about 5% off S&amp;P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time event for the market, some strategists predict.</p><p><blockquote>如此幅度的增长将使标普500明年的盈利减少约5%。随着今年秋天民主党和解法案的通过，该指数可能会下跌类似的幅度，但影响应该仅限于最初的调整。与2017年12月的减税一样，这一变化应该是<a href=\"https://laohu8.com/S/AONE.U\">一</a>——一些策略师预测，市场的时间事件。</blockquote></p><p> These concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.</p><p><blockquote>抛开这些担忧不谈，投资者不应错过更大的图景：美国经济状况良好，增长强劲。策略师预计今年国内生产总值将增长6.3%，2022年将增长约4%。Mallik表示：“周期性上涨和高于趋势的增长将至少持续到2022年，我们希望偏向于具有这种风险的资产。”</blockquote></p><p>   “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets  The State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.</p><p><blockquote>“今明两年我们的经济将会火爆。当GDP增长高于平均水平时，价值会战胜增长，周期性会战胜防御性。”—Lori Calvasina，加拿大皇家银行资本市场道富策略师建议在投资组合中增持材料、金融和科技股。这种方法既包括银行和矿业公司等对经济敏感的公司，也包括科技行业的稳定增长者。</blockquote></p><p> RBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.</p><p><blockquote>加拿大皇家银行资本市场(RBC Capital Markets)美国股票策略主管洛里·卡尔瓦西纳(Lori Calvasina)同样采取杠铃法，同时投资周期性和成长性。她最喜欢的行业是能源、金融和技术。</blockquote></p><p> “Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”</p><p><blockquote>卡尔瓦西纳表示：“金融和能源行业的估值仍然比增长行业（科技或非必需消费品等行业）更具吸引力。”“近期的催化剂是摆脱当前的新冠疫情浪潮……今年和明年我们将迎来经济火爆，传统上，当GDP增长高于平均水平时，价值会跑赢增长，周期性会跑赢防御性。”</blockquote></p><p> But the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.</p><p><blockquote>但对质量的关注将是关键，尤其是进入2022年下半年。届时美联储可能会在本周期内首次加息。到2023年，经济可能会恢复到新冠疫情前2%左右的增长。</blockquote></p><p> “The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”</p><p><blockquote>卡尔瓦西纳表示：“历史上的剧本是，走出衰退后，你往往会看到持续一年左右的低质量优异表现，然后领导力又会恢复到高质量。”“但从低质量回到高质量的转变往往非常坎坷。”</blockquote></p><p> <b>A Shopping List for Fall</b></p><p><blockquote><b>秋季购物清单</b></blockquote></p><p> Most strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.</p><p><blockquote>大多数策略师青睐对经济敏感的股票和稳定增长的股票（包括科技股）的组合。金融股应该会表现良好，特别是如果债券收益率上升的话。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a54c4bd114c1a5f7f700d1fc14d30d8e\" tg-width=\"970\" tg-height=\"230\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Although stocks with quality attributes have outperformed the market this summer, according to a <a href=\"https://laohu8.com/S/BLK\">BlackRock</a> analysis, the quality factor has lagged since positive vaccine news was first reported last November.</p><p><blockquote>尽管今年夏天具有质量属性的股票表现优于大盘，但根据一家<a href=\"https://laohu8.com/S/BLK\">贝莱德</a>分析，自去年11月首次报道疫苗正面消息以来，质量因素一直滞后。</blockquote></p><p> “We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”</p><p><blockquote>贝莱德的弗雷德里克斯表示：“我们正在进入周期中期环境，基本经济增长仍然强劲，但势头开始减速。”“我们的研究表明，优质股票在这样的时期表现尤其出色。”</blockquote></p><p> He recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.</p><p><blockquote>他建议增持盈利的科技公司；金融，包括银行，以及具有这些质量特征的消费品和工业。</blockquote></p><p> For <a href=\"https://laohu8.com/S/WFC\">Wells Fargo</a>’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.</p><p><blockquote>为了<a href=\"https://laohu8.com/S/WFC\">富国银行</a>股票策略主管克里斯托弗·哈维(Christopher Harvey)表示，大流行后受益者和防御性敞口的结合才是正确的选择。他构建了一篮子波动性低于平均水平的股票——在今年秋季市场不确定性或压力时期，这些股票应该会跑赢大盘——并且“新冠贝塔值”较高，即对有关大流行的好消息或坏消息的敏感性。一个要求；富国银行的股票分析师必须将这些股票评级为“买入”。</blockquote></p><p> “There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”</p><p><blockquote>哈维表示：“近期经济存在不确定性、利率不确定性和新冠病毒风险，一般来说，我们正处于9月份左右的季节性疲软时期。”“如果我们能够平衡低波动性和高新贝塔值，我们就可以减轻其中几种催化剂时机即将到来的不确定性和波动性。不过，从长远来看，我们仍然希望[重新开放风险。]”</blockquote></p><p></p><p> Harvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>(BAC),<a href=\"https://laohu8.com/S/NTRSP\">Northern</a> Trust(NTRS),Lowe’s(LOW),<a href=\"https://laohu8.com/S/IQV\">IQVIA</a> Holdings(IQV), andMasco(MAS).</p><p><blockquote>哈维列出的具有高新贝塔值的低波动性股票名单包括苹果(AAPL)、<a href=\"https://laohu8.com/S/BAC\">美国银行</a>（BAC），<a href=\"https://laohu8.com/S/NTRSP\">北方的</a>信托(NTRS)、劳氏(LOW)、<a href=\"https://laohu8.com/S/IQV\">IQVIA</a>控股公司（IQV）和马斯科公司（MAS）。</blockquote></p><p> Overall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.</p><p><blockquote>总体而言，银行是未来几个月最常被推荐的群体。Invesco KBW银行交易所交易基金(KBWB)提供对美国该行业的广泛投资。</blockquote></p><p> “We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.</p><p><blockquote>“我们喜欢估值和信用质量；他们现在被允许回购股票并增加股息，而且新冠贝塔值更高，”哈维说。</blockquote></p><p> Cheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.</p><p><blockquote>较低的估值意味着市场调整中潜在的下行空间较小。而且，与股市的其他大部分地区相反，更高的利率将成为银行的顺风车，银行可能会收取更高的贷款费用。</blockquote></p><p> <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> stocks also have some fans. “<a href=\"https://laohu8.com/S/HR\">Healthcare</a> has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> analysts and fitting his macro views.</p><p><blockquote><a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>股票也有一些粉丝。”<a href=\"https://laohu8.com/S/HR\">医疗保健</a>具有防御性和成长性，”威尔逊说。“如今，医疗保健行业每单位增长支付的费用比其他行业低得多。因此，我们认为，当我们担心估值时，它为这个市场提供了良好的平衡。”健康保险公司Humana(HUM)跻身威尔逊“新鲜资金买入名单”股票买入评级<a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>分析师并符合他的宏观观点。</blockquote></p><p> Nuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.</p><p><blockquote>Nuveen的Malik还将目光投向医疗保健领域，以获得相对低估的增长机会，即制药和生物技术领域。她指出了Seagen(SGEN)，该公司专注于肿瘤药物，可能成为制药巨头有吸引力的收购目标。</blockquote></p><p> Malik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.</p><p><blockquote>马利克还喜欢艾伯维(ABBV)，该公司的预期市盈率为8倍，股息收益率为4.7%。其重磅抗炎药修美乐(Humira)的专利即将到期，这让一些投资者望而却步，但马利克相信管理层能够限制损失，并看到这家价值2000亿美元的公司正在开发有前途的药物。</blockquote></p><p> Both stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of <a href=\"https://laohu8.com/S/ABBV\">AbbVie</a>’s most promising post-Humira products.</p><p><blockquote>这两只股票最近几天都过得很艰难。Seagen上周跌超8%，报152美元左右，因有消息称其联合创始人兼首席执行官近期大量抛售股票。在美国食品和药物管理局要求为JAK抑制剂贴上新的警告标签后，ABBVIE周三上涨7%，至112.27美元。JAK抑制剂是一种抗类风湿药物，其中包括一种<a href=\"https://laohu8.com/S/ABBV\">艾伯维</a>最有前途的后修美乐产品。</blockquote></p><p> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>(PFE),<a href=\"https://laohu8.com/S/AXP\">American Express</a>(AXP),Johnson &amp; Johnson(JNJ), andCisco Systems(CSCO) are other S&amp;P 500 members that pass a<i>Barron’s</i>screen for quality attributes.</p><p><blockquote><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>（PFE），<a href=\"https://laohu8.com/S/AXP\">美国运通</a>(AXP)、强生(JNJ)和思科系统(CSCO)是其他通过A的标普500成员<i>巴伦周刊</i>筛选质量属性。</blockquote></p><p> After a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. <a href=\"https://laohu8.com/S/JE\">Just</a> be more selective. And go with quality.</p><p><blockquote>经过一年的稳定上涨后，今年秋天投资者可能会被提醒，随着增长势头和政策支持开始消退，股市也可能下跌。但如果市场从高点下跌，潜在的经济实力支持逢低买入。<a href=\"https://laohu8.com/S/JE\">刚刚</a>更有选择性。追求质量。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2\">Barron's</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130130857","content_text":"What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.\nTailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.\nIn other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”\nThat’s the general consensus among the six market strategists and chief investment officers whomBarron’srecently consulted. All see the S&P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.\nNext year’s gains look muted, as well, relative to recent trends. The group expects the S&P 500 to tack on another 6% in 2022, rising to about 4800.\nWith stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.\nThe stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.\nFed Chairman Jerome Powell has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”\nThe government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.\nThe bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.\nA budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.\nOther politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a Washington shutdown in October.\nFor now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.\nInflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.\n“We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”\nThe strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for the bond market—and could be even more so for stocks.\nRising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.\n\nAs long as 10-year Treasury yields stay in the 2% range, the S&P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.\nIf yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says State Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”\n\nWilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says\nIf 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”\nSome P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.\nA potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.\nAn increase of that magnitude would shave about 5% off S&P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a one-time event for the market, some strategists predict.\nThese concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.\n\n “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets\n\nThe State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.\nRBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.\n“Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”\nBut the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.\n“The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”\nA Shopping List for Fall\nMost strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.\n\nAlthough stocks with quality attributes have outperformed the market this summer, according to a BlackRock analysis, the quality factor has lagged since positive vaccine news was first reported last November.\n“We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”\nHe recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.\nFor Wells Fargo’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.\n“There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”\nHarvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),Bank of America(BAC),Northern Trust(NTRS),Lowe’s(LOW),IQVIA Holdings(IQV), andMasco(MAS).\nOverall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.\n“We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.\nCheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.\nHealthcare stocks also have some fans. “Healthcare has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by Morgan Stanley analysts and fitting his macro views.\nNuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.\nMalik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.\nBoth stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of AbbVie’s most promising post-Humira products.\nPfizer(PFE),American Express(AXP),Johnson & Johnson(JNJ), andCisco Systems(CSCO) are other S&P 500 members that pass aBarron’sscreen for quality attributes.\nAfter a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. Just be more selective. And go with quality.","news_type":1,"symbols_score_info":{".IXIC":0.9,"SPY":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837333041,"gmtCreate":1629856239283,"gmtModify":1631892389038,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/837333041","repostId":"2162087564","repostType":4,"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881419491,"gmtCreate":1631375282313,"gmtModify":1631890461026,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881419491","repostId":"2166372458","repostType":4,"isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}